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ABSTRACT OF THE DISSERTATION
AN INVESTIGATION OF THE RELATIONSHIP BETWEEN ANTEMORTEM AND
POSTMORTEM DRUG CONCENTRATIONS IN BLOOD
by
Samantha Shirelle Tolliver
Florida International University, 2010
Miami, Florida
Professor Kenneth Furton, Major Professor
In the field of postmortem toxicology, principles from pharmacology and
toxicology are combined in order to determine if exogenous substances contributed to
ones death. In order to make this determination postmortem and (whenever available)
antemortem blood samples may be analyzed. This project focused on evaluating the
relationship between postmortem and antemortem blood drug levels, in order to better
define an interpretive framework for postmortem toxicology.

To do this, it was

imperative to evaluate the differences in antemortem and postmortem drug
concentrations, determine the role microbial activity and evaluate drug stability.
Microbial studies determined that the bacteria Escherichia coli and Pseudomonas
aeruginosa could use the carbon structures of drugs as a source of food. This would
suggest prior to sample collection, microbial activity could potentially affect drug levels.
This process however would stop before toxicologic evaluation, as at autopsy blood
samples are stored in tubes containing the antimicrobial agent sodium fluoride. Analysis
of preserved blood determined that under the current storage conditions sodium fluoride

vii

effectively inhibited microbial growth. Nonetheless, in many instances inconsistent drug
concentrations were identified.
When comparing antemortem to postmortem results, diphenhydramine, morphine,
codeine and methadone, all showed significantly increased postmortem drug levels. In
many instances, increased postmortem concentrations correlated with extended
postmortem intervals. Other drugs, such as alprazolam, were likely to have concentration
discrepancies when short antemortem to death intervals were coupled with extended
postmortem intervals. While still others, such as midazolam followed the expected
pattern of metabolism and elimination, which often resulted in decreased postmortem
concentrations. The importance of drug stability was displayed when reviewing the
clonazepam/ 7-aminoclonazepam data, as the parent drug commonly converted to its
metabolite even when stored in the presence of a preservative. In instances of decreasing
postmortem drug concentrations the effect of refrigerated storage could not be ruled out.
A stability experiment, which contained codeine, produced data that indicated
concentrations could continue to decline under the current storage conditions.

The

cumulative data gathered for this experiment was used to identify concentration trends,
which subsequently aided in the development of interpretive considerations for the
specific analytes examined in the study.
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1.0 Introductory Concepts of Postmortem Toxicology
1.1 Medical Examiner Department
The present study examined cases that fell under the jurisdiction of the MiamiDade County Medical Examiner’s (MDME) Department. The MDME is included within
the 11th District of the Florida State Judicial System (1). As described by the Florida
Department of Law Enforcement (FDLE) – Medical Examiners Commission, Chapter
406 section 11, cases fall within the Medical Examiners jurisdiction when a person dies
of violence, accident or suicide. Additional factors include persons of seemingly good
health who die suddenly, those in police custody or anyone dying under suspicious or
unusual circumstance (2).

As part of the medicolegal death investigative process,

pathologists conduct autopsies of the body, in order to identify any anatomic reason for
death.

During this process, biological fluids and tissues are collected and sent for

toxicological analyses. The cases utilized for this study were submitted for toxicologic
analysis to the MDME – Toxicology Laboratory.

1.2 Medical Examiner’s Toxicology Laboratory
Biological samples submitted to the laboratory are handled under a chain of
custody. The pathologist assigned to the case submits written documentation of each
sample (antemortem and postmortem) submitted per case. The collection site for each
postmortem blood specimen is specified on the tube and documented within the chain of
custody for a given case. Upon receipt of the specimens, laboratory staff members
review the submitted documentation, indicate the volume or mass of the specimen
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received and then initial the form. Postmortem blood specimens are received in gray-top
vacutainer tubes (total volume 10 mL) and in 50 mL screw cap polypropylene (red-top)
centrifuge tubes. Both tubes contain the anticoagulant potassium oxalate and the antimicrobial agent sodium fluoride. In addition to blood, urine, bile, vitreous humor and
gastric contents are routinely submitted. Brain and liver specimens are submitted at the
discretion of the pathologist.

These additional biological matrices are received in

vacutainer tubes or plastic containers without preservatives. Upon receipt, all samples
are stored in a walk-in refrigerator at 2 °C.
While the toxicology laboratory specializes in postmortem toxicological analyses,
antemortem samples from medical examiner cases are also analyzed. Area hospitals
provide antemortem (AM) samples to the Medical Examiner Department upon request.
Those AM samples collected close to the time of arrival at the hospital are analyzed as a
part of routine analysis within the toxicology laboratory. It is most important to analyze
arrival specimens as they are reflective of the substances affecting the person when the
terminal event was initiated. A specimen referred to as ‘delayed’, that is those specimens
collected during an extended stay in the hospital, can also be obtained upon request.
These specimens are analyzed on a case-by-case basis, as they typically only contain
medications administered by hospital staff.
Biological fluid and tissue samples, collected at autopsy and area hospitals, are
analyzed for the purpose of identifying and quantifying drugs/ toxins within the body.
The laboratory first conducts a presumptive screen analysis to identify the presence or
absence of drugs or drug classes within each sample.

Those substances that were

detected in the screen are then submitted for confirmatory testing. Drug confirmation
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conclusively identifies specific drugs (as opposed to classes) found in the screening stage
of analysis.

However, in keeping with good laboratory practices, the confirmatory

technique must be analytically different from that utilized in the screening process. Once
the presence of a drug has been confirmed, quantitation may be required.

Drug

quantitation is the determination of the amount of drug present within a sample. In some
instances, quantitation is done at the time of confirmation. In these situations, calibration
curves for specific analytes are run as part of the batch analyses. Sample concentrations
are then calculated by linear regression. When dual confirmation/ quantitation is not
possible, separate quantitative analyses must be prepared. Pathologists submit multiple
biological specimens for toxicological analysis. However a peripheral blood sample
(venous blood collected from the extremities (e.g. iliac vein)) as opposed to the central
cavity (e.g. heart blood) is often the desired specimen for quantitative analysis. The
reasons for this will be discussed in greater detail in section 1.6.
The information gathered from toxicological analyses is used in the death
investigative process to determine if the presence or absence of exogenous substances
contributed to ones death. The MDME- toxicology laboratory uses modern analytical
instrumentation including, but not limited to gas and liquid chromatographs, as well as
mass spectrometers, electron capture detectors and nitrogen phosphorus detectors (3) to
facilitate the identification process.
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1.3 Forensic Toxicology
In general terms, toxicology is the study of toxic (or adverse) effects of
compounds on biological systems. The field of forensic toxicology works to analyze
biological materials for the purpose of identifying toxic substances (including drugs and
alcohol) and interpret the results as described by law (4). Forensic toxicologists must
maintain objectivity to accurately and justly determine the truth (5).
The three main subsections of forensic toxicology are human-performance, urine
drug testing and postmortem. Human-performance forensic toxicology relies on analyses
of biological fluids or breath to determine the presence of performance or mood
modifying substances. Urine drug testing analyzes urine to determine if drugs and/ or
their major metabolites have been used recently. Post-mortem forensic toxicology is the
practice of analyzing biological fluid and tissues of deceased persons in order to
determine if drugs, chemicals or toxins caused or contributed to death. Since this project
focuses on postmortem forensic toxicology, the other subsets will no longer be
considered.

1.4 Pharmacology
Clinical pharmacology studies in living people have given researchers a strong
framework to interpret drug concentrations and their effects. By monitoring both doseresponse and pharmacologic processes, relationships between drug concentrations and
effects in humans have been better identified.
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Pharmacological response has two main components, pharmacodynamics and
pharmacokinetics. Pharmacodynamics is the study of what a drug does to the body once
the target site is reached. Conversely, pharmacokinetics examines how the body absorbs,
distributes, metabolizes and eliminates drugs from the system. Both pharmacodynamics
and pharmacokinetics are directly related to the dose – response relationship.

1.4.1 Dose-Response Studies
Dose-response studies monitor the response an individual or population has to
known doses (concentrations) of drugs. Typically, the magnitude of the response is
directly related to the given dose. Preliminary dosing experiments involve the use of
animals, most commonly mice and rats.

In these experiments, the animals are

administered known concentrations of drug. The data produced are used to determine the
median lethal dose (LD50). The LD50 is the dose required to kill 50% of the population.
Once the LD50 is established, animal studies are often extended for a period of years.
During this time, side-effects and identification of toxic ranges are determined. Those
concentrations determined to be toxic in animal trials can be applied to humans if
properly calculated. To do this, the dose per unit of body surface must be measured (6).
In order to expand a drug trial to human subjects, it must be determined if the benefits of
the drug outweigh the potential risk to human health and safety (e.g. allergic reactions or
carcinogenicity). If it can be determined that it does, the drug may be eligible for human
testing.
Clinical trials involve the use of human subjects. Since animal trials were used to
determine toxic and lethal doses, the primary goal of the human trials is to determine
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which concentrations effectively illicit the desired response.

Among other

considerations, the data collected from trial participants can be used to determine both
drug potency and efficacy. The data can be displayed in a logarithmic curve as seen in
Figure 1. In Figure 1 two drugs, A and B are displayed. The x-axis is a measurement of
drug concentration and is used to measure potency.

Drug A is effective at lower

concentrations than drug B, making A more potent than B. The y-axis is a measurement
of maximum effect. Drug A effects approximately 95% of the individuals in a trial,
while drug B effects only 60%. This makes drug A more effective than B.

Maximum Effect (%)

Figure 1: Dose-Response Curves for Drug A and Drug B
100

A

80
60

B

40
20
100

200

300

400

Dose (mg)

500

600

Drug A is both more potent and more effective than drug B
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1.4.2 Pharmacodynamics
Pharmacodynamic studies account for both physiological and biochemical effects
chemicals impose on a system. In order for a chemical or drug to impose an effect, it
must reach its target site and bind to a receptor. As the name suggests, receptors are

Figure 2: Drug and Receptor Relationship
Drug

Drug

Receptor
Unbound

Receptor
Bound

Upon drug and receptor binding, the drug can impose its effect

substances that are receptive to being bound to chemical agents (7). The combination of
drug and receptor binding (Figure 2) determines how a drug will affect the body. As a
result, chemical agents have been categorized as agonists, antagonists, partial agonists
and inverse agonists.
Agonists are chemicals that, when bound to their receptor sites illicit, a
biochemical or physiological response.

The given response mimics the effects of

endogenous substances. The intensity of the response however, can vary. If the resultant
effect does not reach its full intensity, the agonist is referred to as a partial agonist (8). An
inverse agonist (antagonist) imposes the opposite effect of the agonist in Figure 3. When
an antagonist is bound to a receptor, it inhibits the effects of the agonist by blocking its
action. Antagonists are important to the medical community because they can be given
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to counteract the deleterious effects of drugs. Agonists and antagonists can exist in the
system at the same time. In those situations, the chemical with the highest affinity to the
receptor will be bound. The resultant effect is dependent upon which compound is bound
to the receptor.

Figure 3: Cellular Response as a Result of Drug and Receptor Binding
Increasing Response

Full Agonist
Partial Agonist

Inverse Agonist
Decreasing Concentration

The partial agonist is imposing the same effect as the full agonist,
except with a diminished response. The antagonist (inverse
agonist) is exerting the opposite effect of the agonist.

1.4.3 Pharmacokinetics
Drugs and other chemical substances can be administered in a multitude of ways,
including but not limited to oral ingestion, parenteral injection, inhalation, transdermal
absorption or by insufflation. Upon administration, the first task of a chemical substance
is to cross the cellular membrane. The membrane is composed of a lipid bilayer, made of
hydrophilic heads and hydrophobic tails. In general, chemical compounds can traverse
the bilayer either by passive diffusion or active transport. Those chemicals that are small,
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unbound and nonionized have a greater possibility of passively diffusing across the
membrane. In passive diffusion, the chemical agent moves in response to a concentration
gradient (from high to low) without requiring an expenditure of energy (9). Those
molecules that are not amenable to diffusive mechanisms move via active transport. The
active translocation of chemicals across the cellular membrane requires energy, partly
because the chemicals are moving against the concentration gradient (from low to high)
(8). Whether by passive or active transport, once a chemical has crossed the lipid bilayer,
it has been absorbed into the system.
After absorption, a drug is able to distribute throughout the body. Typically,
highly vascularized tissues (e.g. liver, brain and kidneys) receive the drug first. Muscle,
fat and skin are secondary recipients for the drug (10).

Chemical compounds

preferentially distribute themselves either in the tissues or in the blood stream. The
solubility of the drug and the pH gradient established between the blood and tissues are
determining factors. In order to identify the extent to which a drug has distributed itself,
the apparent volume of distribution (Vd) can be determined. The apparent volume of
distribution is the volume of blood into which a drug appears to be distributed. It is not
based on the actual volume of fluid present within a person, but rather the volume needed
for a drug to be evenly distributed between tissues and organs. It has been argued that the
higher the Vd, the more likely a drug is to be sequestered in body tissues rather than
remain in circulation. Conversely, those drugs that remain in circulation are susceptible
for distribution, metabolism and elimination. During this time, a drug’s elimination halflife must be considered. Elimination half-life (t½) is the amount of time it takes to reduce
a drugs concentration by 50% (11). Some drugs, such as heroin, have a relatively short

9

half-life (2-6 minutes), while others like methadone have a more prolonged half-life (1555 hours). Knowing a drug’s half-life can be a useful tool in predicting the expected
concentration of a drug in blood circulation after a given amount of time.
During metabolism, the body converts foreign materials into polar, water soluble
compounds that are easier to eliminate. The liver, the primary organ of metabolism, has a
substantial number of enzymes used to aid in this process. Drug metabolism can occur in
one of two mechanisms (first pass or post distribution) and in one of two phases.
First pass metabolism primarily occurs in orally administered drugs.

After

ingestion, the drug can be metabolized in part by the intestines, but primarily by the liver
before systemic circulation begins. The metabolism and subsequent elimination of a drug
before distribution can significantly decrease its bioavailability. Bioavailability is a term
used to describe the remaining amount of drug available to affect the system post
ingestion. Bioavailability is an important factor to consider, because if a drug is highly
susceptible to first pass elimination, its bioavailability will be significantly reduced.
Drugs administered via intravenous injection, sublingual dissolution or insufflation are
not affected by first pass metabolism as they directly enter the blood stream and are
distributed upon absorption. As a result, they are eliminated post distribution. Whether a
drug is eliminated by first pass or post distribution mechanisms, all drugs will eventually
be metabolized.
Metabolism occurs in one of two phases. Phase I reactions increase chemical
polarity by either adding of modifying functional groups on the compound. Phase I
reactions can sufficiently rid the body of foreign materials on its own. However, if the
chemical elimination does not occur rapidly enough, a secondary reaction (Phase II) can
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occur.

Phase II reactions add endogenous substances (e.g. glucuronic acid, sulfate,

acetate or amino acid) to the exogenous chemical to form a conjugate (12). Conjugation
greatly increases polarity and water-solubility; thereby facilitating elimination.
Chemical elimination is regulated by the kidney.

The kidneys excrete non-

volatile, water soluble, polar compounds in urine. The rate of elimination depends on the
chemical properties of the drug as these properties directly affect the speed and efficiency
of the excretion process. The phase I and II reactions work to metabolize chemical
agents into a readily excretable form. However, there are situations where instead of
elimination a drug, is reabsorbed back into the system.
The pH of the fluid in the kidneys is vital to its ability to eliminate drugs.
Therefore, if the pH of the fluid is slightly basic, acidic compounds will become ionized
and eliminated through urine. However, any basic drugs present will remain nonionized
allowing them to potentially be reabsorbed back into the body. If reabsorption occurs,
the body can again be affected by the drug’s presence. However, the body will respond
once more by trying to eliminate it metabolically.
Pharmacological studies examine the relationship between physiological and
biochemical response, as well as concentration and time.

Dose-response analyses

measure concentration and response (13). The combination of the information gained
from both pharmacology and dose-response research has been used to develop the
interpretive framework of toxicology.

The data produced in clinical pharmacology

studies on living humans have aided in the development of analytical tools (e.g. tables
and charts) which can help assess the effects of drugs at known concentrations. This data
has been used as a guideline in determining physical, psychological and pharmacological
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effects of drugs. When applying this information to living subjects, these studies have
proven useful. However, attempting to apply the same information to postmortem drug
concentrations in deceased subjects has led to substantial errors.

1.5 Postmortem Processes
Just as living people have body processes, so do deceased persons. However,
these processes are significantly different. Upon death, the body no longer receives a
flow of blood carrying oxygen and nutrients and removing wastes. As a result, cells
begin to die and the process of decomposition has begun.
Human decomposition can begin within five minutes of death and is governed by
autolysis. Autolysis, otherwise known as self digestion, is the breakdown of cellular
materials by enzymes (14). This process begins within the intestines. The lack of
oxygen in the body allows for anaerobic bacteria and enzymes to take over and digest the
intestine. As the digestion continues, the enzymes will break out of the intestine and
begin digesting the surrounding organs and other body tissues. As the cells within the
body die, they release drugs, toxins and other substances.
While the cellular breakdown of the body is not immediately visible, with time it
does show itself on the outside of the body in the form of skin blisters and slippage (large
pieces of skin separating from the body) (15). In addition to the anaerobic and enzymatic
activity, internal changes including body temperature decrease, blood settling in the
direction of gravity (causing skin discoloration) and rigor mortis (body stiffening) occur.
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After these initial changes, the body will bloat as a result of the production and
build up of gas inside.

During bloat, insect activity flourishes, resulting in the

acceleration of organ and tissue breakdown. Eventually, the gas is expressed and the
body collapses (decay). In addition to gases, the liquefied tissues of the body are released
as well. The drainage of the liquids allows the body to dry out and depending on the
environmental conditions mummification or skeletonization ensues.
The rate of decomposition can vary from weeks to years, depending on the
environment surrounding the body. Climate, precipitation, trauma and insect activity can
all contribute to the rate of decomposition (16). In warmer, more humid environments
decomposition can be accelerated, compared to cool, dry environments. This is in part
the result of increased insect activity, as insects flourish in these types of environments.
Maggots are largely responsible for the digestion of body tissues (17).

Eggs are

deposited into body orifices (e.g.eyes and mouth) as well as areas of traumatic injury, as
these open areas are easily accessible. Conversely in situations where the body is buried,
encased, wrapped or located in a cold or dry climate, insect activity is diminished,
thereby retarding the rate of decomposition (16).
Cases analyzed for this study were obtained in Miami-Dade County in Miami,
Florida, USA between the years of 2004 through 2008.

Summers (June through

September) during those four years in Miami, FL had an average temperature of 82.6 °F
(Chart 1) with an average monthly rainfall of 0.29 inches (18). As a result, the relative
humidity in Miami can well exceed 85% during summer months (19).

Winters

(December through February) in Miami tend to be milder, with the average monthly
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Chart 1: Average Monthly Temperature in Miami, FL from January 2004 –
December 2008

Chart 2: Average Monthly Precipitation in Miami, FL from January 2004 –
December 2008
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winter temperature and precipitation (2004-2008) being 69.9 °F and 0.06 inches,
respectively (19). The average monthly precipitation for the years 2004 – 2008 are
displayed in Chart 2.
As a result of the climate, depending on the conditions of the body (e.g. indoors,
outdoors or wrapped) advanced decomposition can occur within 24 hours after death. In
terms of toxicology, decomposition fluid has very limited value as it is a mixture of
degraded tissues and organs. As a result, any quantifiable data obtained is a result of a
contaminated sampling pool. Therefore, samples containing decomposition fluid were
not used for this study.
The body processes in living people (as discussed in section 1.4 Pharmacology)
are vastly different from those processes occurring in deceased persons. Even in the
earliest stages of decomposition, the processes of the body are dissimilar to those
occurring in a living person. The effects these distinctively different processes have on
the body are what make it virtually impossible to apply the same interpretive parameters
to both living and deceased people. A thorough guide exists for clinical toxicologists;
however, one is still needed for postmortem toxicologists. The lack of an accurate and
reliable interpretive framework for PM toxicology has opened the field up to gross errors
and mis-steps.

1.6 Interpretive Considerations of Postmortem Toxicology
As was discussed in sections 1.4 and 1.5, there are unique considerations for
interpreting drug concentrations for both living and deceased persons. One of the goals
of this project was to gain a better understanding of postmortem drug interpretation. In
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doing so, some fundamental concepts must be understood. These include the effect of
specimen choice, postmortem interval, postmortem redistribution, and drug stability. All
of these factors influence a toxicologist’s ability to interpret postmortem drug
concentrations.

1.6.1 Specimen Choice (Whole blood) and Postmortem Phenomena
In postmortem toxicology, quantitative analysis is usually conducted on whole
blood. Those drugs identified in blood samples are believed to be reflective of the
substances potentially affecting a decedent at the time of death. This is an extremely
important detail when trying to determine if the presence or absence of drugs contributed
to ones death.
At autopsy, both central and peripheral blood samples are collected when
possible. Central sourced blood is collected from the trunk of the body (e.g. heart or
aorta). Blood collected from the body’s extremities is considered to be peripheral blood.
Common examples of peripheral blood include that from the femoral or iliac veins.
Since blood can be collected from any number of areas, the samples submitted for
analysis are labeled with the appropriate source. The correct designation of the source is
important because a phenomenon known as postmortem redistribution can cause
inconsistent quantitative results among blood and tissues collected within the same body.
Postmortem redistribution (PMR) is a term used to describe a complex array of
variables that can lead to the redistribution of drugs after death, which in turn can result
in quantitative concentration discrepancies. In general, postmortem blood concentrations
can vary depending on collection site and the time interval between death and autopsy.
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As a result, postmortem blood concentrations are not believed to be reflective of blood
concentrations present at, and around, the time of death.

The combination of

physiochemical drug characteristics, cellular and tissue breakdown during decomposition,
as well as the proximity of internal organs and vessels (20) all contribute to a drug’s
ability to redistribute itself in the postmortem. Since upon death, the body is no longer
able to produce energy, it is believed that passive diffusion of drugs (down the
concentration gradient) is responsible for their movement (21).
Postmortem redistribution occurs more extensively in areas of the body where
drug storage depots and vessels are in direct contact with each other. Not only are the
liver, lungs and gastrointestinal tract well known drug reservoirs (20), but their proximity
to each other (as well as vessels) can facilitate a more extensive redistribution effect (22).
In contrast, peripheral vessels have limited contact with adipose and skeletal muscle.
Both of which are susceptible to the decomposition processes at a much slower rate than
the central organs.

Therefore, peripheral blood sources, which are believed to be

protected from the initial putrefactive processes, are the preferred sampling sites for
postmortem quantitative work.
The extent to which a drug is able to redistribute itself is often governed by its
apparent volume of distribution (Vd), which is mathematically calculated in Equation 1
(23). The Vd value accounts for drug chemistry as some drugs remain in the vessels
(hydrophilic) while others preferentially store themselves within the tissue (lipophilic).
Higher values for the Vd reflect a greater preference of a drug to concentrate itself in the
tissues rather than in blood (24). Thus it is believed that drugs with higher volumes of
distribution can be released from their storage tissues and diffuse into the vessels and
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surrounding tissues during redistribution. For that reason, blood collected from the major
vessels in the central cavity of the body, is more likely to be contaminated by the drug
concentrations of the surrounding organs (e.g. liver and lungs).

Equation 1: Apparent Volume of Distribution Calculation

Vd =

Amount of drug in the body
Concentration of drug in the blood or plasma

The result reflects a theoretical volume needed for a drug
to evenly distribute between blood and tissue

The extent of PMR can also be influenced by the postmortem interval (PMI).
This is the time between death and sampling at autopsy. Greater time intervals result in
increased time for drug release and redistribution to occur. Although central blood is not
the preferred source for quantitative analysis it is not without value. Typically the
volume of the central blood available is far greater than that of peripheral blood.
Therefore, central blood can be utilized for initial qualitative analysis, followed by
peripheral blood when additional interpretive information is needed (25).
The quantitative differences between central and peripheral sources is known as
the central to peripheral (C:P) ratio (22). As previously mentioned, the central source
blood is more prone to redistribution and thus contamination. On the basis of the central
to peripheral theory, when redistribution occurs the central sourced blood will have a
higher concentration than the periphery, which leads to a C:P ratio greater than 1.
Another ratio used to measure the extent of PMR is the postmortem to antemortem

18

(PM:AM) ratio. Similar to the C:P ratio, when redistribution is believed to be present,
the PM to AM ratio should be greater than 1. The PM: AM ratio are believed to be more
susceptible to the PMI, meaning the greater the interval, the greater the chances of
redistribution. While the C:P ratios are believed to be more influenced by the anatomical
location of the blood sources. Regardless of which ratio is used, PMR in and of itself
does not always respond in a predictable manner (26); therefore, neither relationship will
always hold true.

1.6.2 Additional Biological Matrices
In addition to whole blood, urine, bile, vitreous humor and gastric contents are
also routinely collected at autopsy. Urine analysis provides qualitative information about
recent drug use. It is not used for quantitative work because the drug content present in
urine has already been metabolized and removed from blood circulation. As a result,
drugs identified in urine are not reflective of what was actually affecting a decedent
around the time of death. Bile typically is used for qualitative analysis but has proven
additionally useful as an alternate sample for quantitative ethanol testing (27). The eyes,
which are remotely located from the central cavity, work as a protective case for vitreous
humor. The location of the vitreous allows for both minimal contamination and bacterial
degradation (27) (28). The decreased bacterial fermentation makes vitreous a reliable
quantitative sample for ethanol analysis. Additionally, quantitative analysis of gastric
contents can identify drug overdoses and distinguish between accidental and intentional
overdose (29).
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When interpreting postmortem drug concentrations the information gained from
the above biological matrices aids in developing the full toxicological spectrum of each
case. However, the scope of this project focuses solely on the direct comparison between
antemortem (AM) and postmortem (PM) blood samples. Additionally, bile, vitreous
humor and gastric contents are not potential specimens for collection from living patients.

1.6.3 Drug Stability
Upon consumption, some drugs are more unstable than others.

Heroin, a

synthetic opiate, is rapidly sequentially hydrolyzed to 6-monoacetylmorphine, then to
morphine.

Both heroin (3,6-diacetylmorphine) and 6-monoacetylmorphine are very

unstable in blood with half lives of 2 – 6 minutes and 6 – 25 minutes, respectively (30).
One study, conducted on all male subjects, found that regardless of ingestion route
(intranasal, parenteral or insufflation), heroin concentrations peaked within 5 minutes of
ingestion and then fell below 1 ng/mL detection limits thirty minutes post ingestion (31).
Because of the rapid hydrolysis of heroin and 6-monoacteylmorphine, in cases where a
fatal heroin overdose is suspected, factors such as the postmortem interval (PMI) and the
time between ingestion and death usually preclude an analyst’s ability to detect heroin.
In such situations, metabolite detection is far more likely.

1.6.4 Drug Interactions
When interpreting toxicological data, it is important to consider the total effect of
all drugs present (29). While some drugs may not contribute to death, others may impose
additive or synergistic effects resulting in a deadly outcome (24). When two or more
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substances additively interact, they produce a total effect that would be equal to the sum
of the effects of each drug if given separately. Synergistic interactions have enhanced
toxicity as their cumulative effect is greater than would be expected of either substance if
given separately. Synergism is often displayed when substances imposing the same
effect are taken in combination.

For example, narcotic analgesics (e.g. fentanyl),

benzodiazepines (e.g. alprazolam) and ethanol can all cause respiratory depression.
When taken in combination, fatal results can occur at concentrations both within and
below therapeutic levels (24) (32).

1.6.5 Donor Cases
Donor cases are those in which the decedent’s body was used for organ donation.
In these situations, a hospitalized patient must first be pronounced dead. The term
‘death’ refers to brain death. Up until the time of brain death, a patient may be receiving
medications and treatment by the hospital staff to help maintain life. Medications, such
as corticosteroids, are given to help reduce the swelling of the brain in order to preserve
its integrity and function. A side effect of this treatment is that the organs of the body
will dehydrate, thereby compromising their function. However, at the time of brain death
the use of such medications are ceased. Organ functions (including the beating of the
heart, kidney filtration and liver metabolism) are maintained artificially with the aid of
medical equipment. As a result, body processes such as metabolism and urine production
are still active. In addition, in preparation for organ procurement, the body is infused
with fluids to rehydrate the organs. A donor may receive fluids and be maintained on life
support for a matter of hours or even days after brain death.
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Organ harvesting is a surgical procedure that occurs in a sterile, surgical
environment. Just prior to the surgery, blood and urine samples are collected. These
samples are often obtained by the MDME’s toxicology laboratory. However, infusions
of hospital fluids severely dilute the concentration of drugs of toxicological importance.
Additionally, those drugs that are identified and/ or quantified in donor cases are typically
those administered by the hospital. Therefore, their presence may render little insight
into the cause of death. As a result, donor samples are obtained and stored, but often not
tested as a part of routine analysis.

1.7 Drug and Drug Classes of Interest
1.7.1 Benzodiazepines
Benzodiazepines are a class of drugs which fall under the category of central
nervous system (CNS) depressants.

Chlordiazepoxide (Librium®), the first

benzodiazepine, was introduced to the world in the 1960’s; diazepam (Valium®) soon
followed. Benzodiazepines were first used as a replacement for barbiturates (a class of
sedative hypnotic drugs). Barbiturates, while effective, required higher doses, had more
severe withdrawal symptoms and had higher incidence of unintentional overdose than
benzodiazepines. The perceived increased safety offered by benzodiazepines along with
their wide array of uses (e.g. anti-anxiety, antidepressant and anticonvulsant), has now
made them among the most frequently prescribed medications in the United States.
Structurally, all benzodiazepines have the same heterocyclic ring structure,
consisting of a benzene ring fused to a 7-member diazepine ring. However, they have
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variations

which

include

1,4

–benzodiazepines

(e.g.

diazepam),

7-nitro-1,4

benzodiazepines (e.g. clonazepam) and –azolo benzodiazepines (e.g. midazolam and
alprazolam) (33). While the actual effectiveness of benzodiazepines has been questioned
in recent years (34), they are still widely prescribed for their sedative, hypnotic and
antiepileptic properties. However, studies have suggested that their long-term use can
result in cognitive dysfunction, psychomotor impairment and physical dependency (35)
(36).

Table 1: Benzodiazepines of Interest
Chemical Name
7-aminoclonazepam*

Trade Name
N/A

Usage
Duration
N/A
N/A
Sedation,
Midazolam
Versed®
amnesiac
short-acting
properties
Nitrazepam ISTD
Mogadon®
Sedative
long-acting
®
Clonazepam
Klonopin
Anticonvulsant
long-acting
®
Xanax
Antidepressant
Alprazolam
short-acting
& Anxiolytic
Nordiazepam
Stilny®
Anxiolytic
long-acting
Diazepam
Valium®
Anxiolytic
long-acting
®
Bromazepam ISTD
Lectopam
Anxiolytic
short-acting
* 7-aminoclonazepam is the major metabolite of clonazepam and cannot
be obtained by a separate prescription

Dosing amounts of benzodiazepines are largely reflective of their intended
treatment. Generally, high doses are used as hypnotics, moderate doses as anxiolytics
and low doses are employed for their sedative properties (37). When taken as prescribed,
benzodiazepines rarely cause toxicity. However, it has been well documented that when
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taken in conjunction with other central nervous system depressants, they can be highly
toxic (24) (32).

Additionally, while some benzodiazepines are metabolites, they may

still be pharmacologically active. For example the parent drug diazepam (Valium®) can
metabolize to nordiazepam (Chlorazepate®), temazepam (Restoril®) and oxazepam
(Serax®). All four drugs are available by prescription as they all effectively treat anxiety.
As a result, blood analysis for this class of drugs can be rather extensive. Table 1
outlines the benzodiazepines analyzed for this study.

1.7.2 Opiates
Opiates are a class of drugs derived (either naturally or synthetically) from opium
poppy. Opiates are often referred to as narcotic analgesics as these highly addictive
medications are a potent remedy for severe pain. While opiates are the most effective
pain management medication available, they offer many undesirable effects including
stupor, nausea, vomiting and respiratory depression. Opiate users (both licit and illicit)
often build a tolerance to the medication, which can lead to abuse.

In terms of

toxicology, tolerance makes it difficult to properly interpret the significance of opiate
concentrations in blood (21).

For this study, hydrocodone, codeine, oxycodone,

morphine, 6-monoacetylmorphine (6-MAM), hydromorphone and oxymorphone were
monitored. However, a sufficient amount of case data was only collected for morphine,
codeine and 6-MAM. Their results are discussed in the 6.1 Opiates section. As a result
of the lack of data, oxycodone and oxymorphone were no longer considered. However,
hydrocodone and hydromorphone are still included in the results section as they were
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monitored in the stability experiment (refer to section 6.5). Additionally, hydrocodone
(in addition to codeine) was used in the microbial study (refer to section 6.4) as well.
Codeine and morphine each have their own analgesic properties; however, 6monoacetylmorphine is a major metabolite of heroin (3,6-diacetylmorphine) degradation.
Heroin is not a naturally occurring opiate; rather it is synthesized from opium poppy.
The poppy seeds, which are harvested from an opium plant, are sliced in order to allow
their fluid to drain. Contained within this fluid mixture are the naturally occurring
opiates, codeine and morphine. A non-specific extraction process is used to isolate both
codeine and morphine from the fluid. The compounds are treated with an acetylating
agent, which when reacting with morphine produces heroin (3,6-diacetlymorphine).
Codeine will react as well, resulting in the formation of the impurity acetylcodeine (38)
(39). Upon ingestion, heroin is rapidly converted to 6-MAM, then to morphine, while
acetylcodeine is converted to codeine. As a result, heroin usage often results in the
detection of 6-MAM, morphine and codeine. While heroin is currently a Schedule I drug
(meaning it has no medicinal use in the United States (40)), it was once used to treat
tuberculosis and cure morphine addiction (38). However, its addictive nature caused the
drug to be banned in the United States in 1956 (38). Heroin screening is typically not
part of routine analytical analyses as it is highly unstable in blood (refer to Drug Stability
1.6.3).
While codeine and morphine can be used as markers of heroin abuse, they are
also medications in their own right. Codeine can be found in numerous formulations,
including prescription cold remedies and antihistamines. Morphine is the primary active
ingredient in opium. It is commonly used for pain management and in combination for
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preoperative sedation. Its pain relieving ability is the standard used to measure the
effectiveness of newer analgesics (41). Table 2 lists the opiates evaluated in this study.

Table 2: Opiates Evaluated for Research
Chemical Name

Trade Name

Usage

Treatment

Heroin1,2

N/A

Illicit

N/A

Codeine

Codeine

Antitussive

Morphine

Kadian®

Analgesic

Moderate to
severe pain

6-Monoacetylmorphine2

N/A

N/A

Hydrocodone

Vicodin®,
Narco®

Hydromorphone

Diluadid®

Antitussive
&
Analgesic
Antitussive
&
Analgesic

1
2

Heroin detection was qualitative only
Not approved for medicinal usage
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Origin
Semisynthetic
Natural
Natural

N/A

Semisynthetic

Moderate
pain

Semisynthetic

Moderate to
severe pain

Semisynthetic

Figure 4: Acetylation Reaction of Morphine and Codeine

Morphine

6-Monoacetylmorphine

opium
poppy

Codeine

Acetylcodeine
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Heroin

1.7.3 Additional Drugs of Interest
Diphenhydramine and methadone were of additional interest for this project.
Diphenhydramine is a common over the counter medication. Its properties relieve itchy
and watery eyes as well as other allergy related symptoms (Benadryl®). In addition, it
imposes sedation and therefore has been used as a sleep aid in a number of formulations.
Methadone (Dolophine®) has analgesic properties equal to that of morphine. While it is a
central nervous system depressant and works on the same receptors as the opiates,
structurally it is not related to them. Continued use of methadone can result in drug
accumulation in the system, which can lead to severe sedation (42).

Therefore,

methadone usage is controlled and almost exclusively used to treat narcotic addiction.

2.0 History of Postmortem Interpretation
Clinical toxicology is a broad field that encompasses the pharmacokinetic,
pharmacodynamic and dose-response relationship that occurs between people and
exogenous substances. As a result of understanding these relationships, individualized
interpretive guidelines have been developed to identify both physiological and
psychological effects of a given drug at a known dosage. The guidelines evolved into a
clinical therapeutic index, which is used to identify therapeutic, toxic and lethal dosages
(1). For many years, it was these clinical models that were used as the basis of drug
interpretation in the field of postmortem toxicology.
A postmortem toxicologist, just as a clinician, would compare drug levels to a
clinical model and make a determination about how said drug(s) influenced a person at
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the time of one’s death. While clinical models have been invaluable tools for clinicians,
they proved to be horribly inaccurate in postmortem work (2) (3) (4) (5). Deceased
persons do not undergo the same biological processes as living persons. Consequently,
the comparison of postmortem concentrations to clinical models resulted in large errors.
However, in the early stages of postmortem interpretation this was not known. Sporadic
reports of drug concentration discrepancies began to emerge in the 1970’s. Nevertheless,
it was not until the late 1980’s when the concept of postmortem concentration change
came to the forefront of many discussions.
One of the most popular prescription medications in the 1970’s was digoxin.
Digoxin replaced digitoxin as the primary treatment of heart failure related conditions.
With the use of digoxin came several peer reviewed publications detailing analytical
techniques for the appropriate extraction and identification of the drug (6) (7).

In

addition some authors encouraged postmortem interpretation to be conducted on heart
serum.

As it was believed by them, that heart serum most accurately reflected

antemortem concentrations at the time of death (8) (9) (10). Factors that could contribute
to PM concentration changes (e.g. the apparent volume of distribution, antemortem to
death interval and postmortem interval) were not thoroughly investigated at that time.
However, in 1977 Vorpahl and Coe (11) published a study where they aimed to
determine if discrepancies existed between antemortem and postmortem digoxin samples.
In addition they considered both the influence of the postmortem interval as well as the
role of the postmortem collection site on digoxin levels. Ultimately, they determined that
significant variations can exist between AM and PM digoxin concentrations. However
the length of the PMI could not be correlated to the magnitude of change within the PM
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sample. While Vorpahl and Coe published a fairly comprehensive study on digoxin, this
type of evaluation of other drugs was still lacking.
From the late 1970’s into the 1980’s scientific conferences became the forum in
which postmortem toxicologists could discuss their interpretive issues.

Many early

published articles detailing challenges stemming from postmortem change, by then
referred to as postmortem redistribution, referenced talks presented at scientific
conferences (12) (13) (14) (15) (16), rather than published sources. With time and
concurrence among the postmortem toxicology community, more articles emerged
addressing

the

concentration

inconsistencies

among

drugs

such

as

tricyclic

antidepressants (e.g. amitriptyline), ethyl alcohol, propoxyphene and methadone (17) (18)
(19). The reporting mechanism however was varied by author. For instance a single case
was published by Jones and Pounder (20), in which they analyzed a number of tissues, as
well as cerebral spinal fluid, vitreous humor, arterial and venous blood concentrations of
6 analytes. Other authors chose to do compilation studies, where they presented data that
had been collected over a period of years (18) (17) (21). Compilation studies typically
had an extensive amount of data presented in the form of tables. Some studies presented
both antemortem and postmortem results, while others focused solely on various
postmortem specimens. During that time ratio calculations, including PM:AM, C:P as
well as liver: blood (11) (22) were conducted as a means to identify the source of the
discrepancy.
By the 1990’s a substantial amount of meetings and publications resulted in a
shift in the interpretive process for postmortem work. Toxicologists were now clearly
aware of concentration discrepancies that could exist between postmortem and
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antemortem samples. The community strongly advised against using clinical models for
interpretation. The only exception to the elimination of the clinical models was the role
of drug interaction and how those interactions could have affected someone around the
time of their death. Postmortem studies were indicating that certain drugs, particularly
those with a high apparent volume of distribution, could disproportionately increase in
concentration after death. Factors such as the antemortem to death interval, postmortem
interval and ratio calculations were being reported more frequently.

However,

comprehensive articles about how all of these (and other) factors contributed to
postmortem changes were still infrequent. The goal of this project was not to interpret
postmortem results, but rather to gain a better understanding for which factors can, and
frequently do, influence postmortem results. This comprehensive study was the first of
its kind in which the role of microbial activity, drug stability in storage, antemortem
intervals, postmortem intervals, postmortem specimen choice, apparent volume of
distribution, postmortem to antemortem, as well as central to peripheral ratios were
considered for seven commonly encountered medications in postmortem work. The end
result both refuted and confirmed some ideals that are currently still in practice. This
study also identified the specific variables that have the highest likelihood of influencing
each of the seven drugs of interest. While understanding the dynamics of postmortem
work may never be as simple as comparing a result to an individualized model, this study
has certainly contributed to the understanding of postmortem change and by extension,
the interpretation of postmortem results.
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3.0 Research Objectives
Cases included in this project were submitted with both antemortem (AM) and
postmortem (PM) blood specimens. The ideal case had an AM to death interval that did
not exceed 24 hours, a postmortem interval within 48 hours and tested positive for at least
one drug of interest (refer to section 1.7 Drug and Drug Classes of Interest). Cases that
both met and exceeded the time frame requirements were analyzed and the importance of
time intervals was evaluated on a drug-by-drug basis in section 6.0 Results and
Discussion.
The first objective was to evaluate the differences in drug concentrations between
antemortem and postmortem blood. In order to achieve this, data comparisons between
intra-case antemortem and postmortem quantitative results were conducted. Whenever
available, both postmortem central and peripheral bloods were tested and the impact of
postmortem specimen choice was examined. The cumulative data collected for each drug
was used to identify concentration trends and ultimately make determinations about drug
relationships.
The second objective was to determine how sample preservation impacts drug
stability. While the postmortem samples analyzed were preserved in tubes containing the
anti-microbial agent sodium fluoride, it was important to assess the effectiveness of the
preservative.

To that end, a two-part microbial experiment was conducted.

One

experiment evaluated the ability of microbes to use drugs as a food source, in the absence
of a preservative. The other tested the effectiveness of sodium fluoride under both
aerobic and anaerobic conditions.
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Thirdly, it was necessary to assess the stability of drugs after two months of
refrigerated storage. The samples analyzed for this study often had a two month (or
greater) lapse between collection and analysis. As a result, it was necessary to determine
if storage conditions could contribute to concentration discrepancies between antemortem
and postmortem samples.
The final objective was to combine the information gained from the first three
objectives and develop an interpretive framework for postmortem concentrations.
Unfortunately, a set guidelines aiding in the postmortem interpretive process do not exist.
The creation of one could be an extremely valuable tool, which could ultimately lead to
the reduction of erroneous interpretive errors.

4.0 Materials, Methods and Instrumentation
4.1 Introduction:
All of the cases used in this project were initially screened and confirmed, as part
of the routine analysis by the toxicology staff at the Miami-Dade County Medical
Examiner (MDME) Department. The laboratory adheres to strict standard operating
procedures (SOPs). All methods were validated prior to their use for case work. In some
instances, the initial quantitative data was also collected by the lab staff as part of the
death investigative process. This will be discussed in more detail in the results section.
The following quantitative methods are those used within the MDME toxicology
laboratory and in this project.
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4.2 Benzodiazepines: Quantitative Blood Analysis by GC/ECD, HPLC/DAD and
HPLC/MS
Benzodiazepine quantitation was conducted

on three instruments, gas

chromatography/ electron capture detector (GC/ECD), high performance liquid
chromatography/ diode-array detection (HPLC/DAD) and high performance liquid
chromatography/ mass spectroscopy (HPLC/MS). All data collected as part of routine
laboratory analyses were obtained from both the GC/ECD and HPLC/DAD.

The

GC/ECD was utilized by the researcher for benzodiazepine quantitation until March
2008.

After which, quantitative research testing was conducted solely on Thermo

Finnigan’s LCQ Advantage HPLC/MS system.
The HPLC/DAD system was used to quantitate diazepam and nordiazepam
(among other benzodiazepines) with a linear range of 0.1 – 10 mg/L. The GC/ECD
system had a quantitation method for alprazolam, clonazepam and 7-aminoclonazepam
with a linear range of 0.01 – 0.2 mg/L. In an effort to combine the two methods, the
HPLC/MS was used to analyze the most frequently encountered benzodiazepines seen in
this research project.

Those included midazolam, lorazepam, clonazepam, 7-

aminoclonazepam, diazepam, nordiazepam and alprazolam (linear range: 0.01 – 1.0
mg/L). The combination of the extended linear range and the four additional analytes
made the HPLC/MS method a convenient alternative, which offered the same level of
sensitivity and accuracy as the GC/ECD and HPLC/DAD.

Liquid-liquid extraction

procedure was used for both the GC/ECD and HPLC/MS systems (Section 4.2.1 (a)),
while solid-phase extraction (4.2.1 (b)) was utilized for the benzodiazepines analyzed by
HPLC/DAD.
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4.2.1(a) Standards and Extraction Procedure for GC/ECD and HPLC/MS
Stock standards, obtained from Cerilliant Corporation (Round Rock, TX), were
used to prepare working standards. The working standards were serially diluted to
comprise a five point calibration curve, ranging from 0.01 mg/L to 0.2 mg/L by GC/ECD
and a six-point curve ranging from 0.01 mg/L to 1.0 mg/L by HPLC/MS.

After

preparation, the standards were spiked in drug-free whole blood. Whenever necessary,
samples that exceeded the limits of quantitation were diluted, to bring their
concentrations within range, and reanalyzed on the appropriate instrument. Additional
stock standards were purchased from Alltech Associates (State College, PA) to prepare
controls.

A 0.05 mg/L working control was prepared for GC/ECD analysis, while

0.1mg/L control was prepared for HPLC/MS analysis.

All standard and sample

concentrations were calculated using linear regression.
To each 1 mL blood sample, 100 µL of internal standard (GC/ECD = 0.4 mg/L of
bromazepam; HPLC/MS = 4 mg/L of nitrazepam) followed by 1 mL of pH 9 saturated
sodium borate buffer were added. The samples were vortex-mixed and 10 mL of n-butyl
chloride was added. The mixture was capped and rotated for 15 minutes followed by
centrifugation (3000 RPM) for 5 minutes. The organic fraction was transferred to a clean
tube and the solvent was evaporated at 40 ºC under a stream of nitrogen. The dried
extracts were reconstituted with 50 µL of toluene (GC/ECD) or 50 µL of mobile phase
(HPLC/MS) and aliquoted into autosampler vials.
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4.2.1 (b) Standards and Extraction Procedure for HPLC/DAD
Stock standards, obtained from Cerilliant Corporation (Round Rock, TX), were
used to prepare the calibration standards. The calibration standards were serially diluted
to comprise a four point calibration curve, ranging from 0.1 mg/L to 10 mg/L. After
preparation, 100 µL of each standard was spiked into drug-free whole blood. Whenever
necessary, samples that exceeded the limits of quantitation were diluted to bring their
concentrations within range, and reanalyzed. Additional stock standards were purchased
from Alltech Associates (State College, PA) to prepare a 1.0 mg/L working control,
containing both diazepam and nordiazepam. All standard and sample concentrations
were calculated using linear regression.
To each 1 mL blood sample, 100 µL of nitrazepam internal standard
(concentration = 0.1 mg/L) was added, followed by 4 mL of pH 6 sodium phosphate
buffer (0.1M). The samples were vortex-mixed and allowed to stand for 15 minutes. The
mixture was then centrifuged (3500 RPM) for 10 minutes.

The supernatant was

transferred to a clean tube and submitted for automated solid-phase extraction preparation
on Caliper Life Sciences (Hopkinton, PA) RapidTraceTM system.
All solvents used for the rapid trace system were high purity grade.

Clean

ScreenTM extraction columns (Worldwide Monitoring, Inc.) were first conditioned with
an ethyl acetate: ammonia (98:2) elution solvent. Additional conditioning was conducted
by the sequential rinsing of the extraction columns with methanol, water and finally pH 6
sodium phosphate buffer (0.1 M). The blood samples were then loaded onto the columns
(2 mL/min) and then rinsed with water and a 20% acetonitrile solution. The columns
were dried with ultra zero grade air. Three milliliters of elution solvent was passed
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through the column at 1 mL/min and the extract collected in a clean screw cap culture
tube. In an effort to clean up the extracts, three milliliters of deionized water was added
to the eluent. The mixture was rotated for 3 minutes, then centrifuged for 1 minute
(speed = 3000 RPM). The organic fraction was transferred to a 16 x 100 culture tube and
evaporated to dryness at 40 ºC under a stream of nitrogen. The dried extracts were
reconstituted with 75 µL of mobile phase and aliquoted into autosampler vials.

4.2.2 (a) Instrumentation: GC/ECD
Agilent technologies HP 6890N network GC model, equipped with dual electron
capture detectors and a 7683B series injector was used for quantitative analysis. Two
columns (DB-5 and DB-17 both with the following dimensions: 30m X 0.32 mm ID X
0.25 µm film thickness, Agilent technologies, Palo Alto, CA) were joined at the injection
port through the use of a silica “Y” connector. After sample injection, the columns were
independent of each other and the flow was carried into their respective detectors. The
initial oven temperature of 120 °C was held for 2 minutes, then ramped at 20 °C/ minute
to 290 °C and held for one minute using nitrogen (60 cc/min) as the makeup gas. Both
detectors remained constant at 325 °C. Analyte identification was based on relative
retention time identification in both columns.
4.2.2 (b) Instrumentation: HPLC/MS
The samples were analyzed in electrospray ionization (ESI) mode on a Thermo
Finnigan LCQ Advantage HPLC/MS system. The narrow-bore Agilent Eclipse – XDB
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C18 column was held constant at 40 ºC. Mobile phase, comprised of a mixture of 45%
methanol to 55% formic acid (0.1%) in water, had a flow rate of 400 µL/ minute. The

Table 3: Benzodiazepines monitored by HPLC/MS/MS
Segment
1
2
3
4
5

Compound Name
7-aminoclonazepam
Midazolam
Nitrazepam ISTD
Clonazepam

Molecular ion
286
326
282
316

Qualifying Ions
250 BP, 222
291 BP, 244
236 BP, 254
270 BP, 288, 251

Alprazolam

309

281 BP, 274, 251

Nordiazepam
271
Diazepam
285
BP = Base Peak

243 BP, 208, 165
257 BP, 227, 182

method searched for the seven analytes previously mentioned, including the internal
standard, and was divided into five segments (Table 3). Identification was based on mass
spectral and retention time matches.

4.2.2 (c) Instrumentation: HPLC/DAD
The samples were analyzed on a Perkin Elmer (PE) 200 series HPLC system,
equipped with a PE 235 C diode-array detector, 200 series pump and a 101 LC oven.
The C-8 column was held constant at 30 ºC and the detector had a fixed wavelength of
245 nm. Mobile phase was comprised of a mixture of 16.5% acetonitrile to 57% pH 6,
0.1 M sodium acetate buffer to 26.5% methanol and had a flow rate of 2.0 mL/ minute.
The total run time of the method was 20 minutes.
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4.3 Basic Drugs: Quantitative Blood Analysis by GC/NPD
The basic drug method was used to quantitate diphenhydramine, and methadone.
Cerilliant Corporation (Round Rock, TX), stock standards were used to prepare working
standards.

The working standards were serially diluted to comprise a four point

calibration curve ranging from 0.1 mg/L to 2.0 mg/L. If necessary, samples were diluted
to bring their concentrations within the established limits of the curve.

Alltech

Associates (State College, PA) stock standards were used to prepare a 0.5 mg/L working
control. Linear regression was used to calculate sample concentrations.
Each 1 mL blood sample was fortified with 1 mL of mepivacaine internal
standard (0.5 mg/L) and 1 mL of pH 9 saturated sodium borate buffer. The samples were
vortex-mixed, then 10 mL of n-butyl chloride was added. The mixture was capped and
rotated for 15 minutes followed by centrifugation (3000 RPM) for 5 minutes. The
organic fraction was then back extracted into 1.5 mL of 0.1 N HCl. The solution rotated
for 15 minutes, followed by centrifugation (3000 RPM) for 5 minutes. The organic layer
was aspirated to waste, after which, the aqueous layer was alkalinized with 2 mL of
sodium carbonate/ sodium bicarbonate (pH 9.8) buffer and re-extracted into 10 mL of nbutyl chloride. The organic layer was transferred into a clean tube and evaporated down
to approximately 3 mL at 40 ºC under a stream of nitrogen. A 100 µL aliquot of
concentrated HCl in methanol was added to each sample before drying to completion.
The extracts were reconstituted with 50 µL of ethanol and aliquoted into autosampler
vials for analysis.
Hewlett-Packard’s 5890 Series II GC model, equipped with an NPD and a 7673
autosampler was used for quantitative analysis. A DB-1 (100% Methylpolysiloxane)
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megabore column (15m X 0.53mm ID X 1.5µm film thickness, Agilent Technologies,
Palo Alto, CA) was used for chromatographic separation. The initial oven temperature
was 120 °C for 1 minute then ramped at 10 °C/minute to 290 °C and held at for one
minute.

Identification was based on relative retention times and previous GC/MS

confirmation.

4.4 Opiates
Three opiate methods have been used by the MDME- Toxicology laboratory since
2006. Originally the opiate method was divided into two separate assays. Opiate I
included morphine, codeine and 6-monoacetylmorphine (6-MAM). Opiate II method
included hydrocodone, hydromorphone and oxycodone. As of January 2009, the opiate
assay was combined into one comprehensive method to include all six of the previously
mentioned opiates as well as the addition of oxymorphone. Both Opiate I and Opiate II
methods were analyzed by GC/MS utilizing single ion monitoring (SIM), each with a
linear range of 10 – 1,000 ng/mL.

The comprehensive method was analyzed by

GC/MS/MS and had a linear range of 5 – 500 ng/mL for hydrocodone and 5–1,000ng/mL
for the remaining six opiate compounds.

4.4.1 Preparation of Standards for Opiates by GC/MS (SIM)
Stock standards, obtained from Cerilliant Corporation (Round Rock, TX), were
used to prepare working standards. The working standards were serially diluted to
comprise a four point calibration curve for the Opiate I method and a five point
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calibration curve for the Opiate II method. Both methods had a linear range of 10–1,000
ng/mL.

After preparation, the standards were spiked in drug-free whole blood.

Whenever necessary, samples that exceeded the limits of quantitation were diluted, to
bring their concentrations within range, and reanalyzed on the appropriate instrument.
Additional stock standards were purchased from Alltech Associates (State College, PA)
to prepare controls. Both a high and a low working control (50 ng/mL and 500 ng/mL)
were prepared for Opiate I, while a single 25 ng/mL working control was prepared for
Opiate II.

All standard and sample concentrations were calculated using linear

regression.

4.4.2 Extraction Procedure for Opiates by GC/MS (SIM)
4.4.2 (a) Extraction: Opiate I by GC/MS (SIM)
To each 1 mL blood sample, 100 µL of internal standard (morphine- D3, codeineD3 and 6-MAM – D3; final concentration equaled 50 ng/mL) was added followed by
4mL of pH 6, 0.1 M sodium phosphate buffer. The samples were then vortex-mixed,
followed by a 15 minute equilibration. Afterwards, the samples were centrifuged (3500
RPM) for 10 minutes. The supernatant was transferred to a clean tube and submitted for
automated solid-phase extraction preparation on Caliper Life Sciences (Hopkinton, PA)
RapidTraceTM system.

4.4.2 (b) Extraction: Opiate II by GC/MS (SIM)
To each 1 mL blood sample, 100 µL of internal standard (hydrocodone- D3,
hydromorphone- D3 and oxycodone – D3; final concentration equaled 25 ng/mL) was
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added followed by 50 µL of methoxamine (MOX) reagent. The samples were then
vortex-mixed, followed by a 10 minute equilibration. Afterwards, the samples were
heated at 56 ºC for 15 minutes and allowed to cool. Then 4 mL of 0.1 M, pH 6 sodium
phosphate buffer was added. The samples were vortex-mixed and centrifuged at 3500
RPM for 10 minutes. The organic fraction was transferred to a clean tube and submitted
for automated solid-phase extraction preparation on Caliper Life Sciences (Hopkinton,
PA) RapidTraceTM system.

4.4.2 (c) Automated Extraction: Opiates I and II by GC/MS (SIM)
All solvents used for the rapid trace system were high purity grade.

Clean

ScreenTM extraction columns (Worldwide Monitoring, Inc.) were conditioned with the
elution solvent. Opiate I elution solvent consisted of methylene chloride: IPA: NH4OH;
80:20:2.

Opiate II elution solvent was comprised of ethyl acetate: NH4OH; 98:2.

Afterwards, the columns were additionally conditioned with methanol, followed by water
and finally pH 6 sodium phosphate buffer (0.1 M). The blood samples were then loaded
onto the columns (2 mL/min) and sequentially rinsed with water, HCl and methanol. The
columns were dried with ultra zero grade air. Three milliliters of elution solvent was
passed through the column at 1 mL/min and the extract collected in a clean screw cap
culture tube. The eluent was evaporated to dryness at 40 ºC under a stream of nitrogen.

4.4.3 Derivatization: Opiates I and II by GC/MS (SIM)
Opiate I dried extracts were derivatized with 100 µL of 1,1,1,3,3,3- Hexafluoro-2propanol (HFIP) followed by 100 µL of pentafluoropropionic acid anhydride (PFAA).
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Opiate II extracts were derivatized using 100 µL of acetic anhydride and 15 µL of
pyridine. The samples containing derivatizing reagent were then heated at 65 ºC and
75ºC, for Opiate I and Opiate II, respectively. Afterwards, all samples were cooled to
room temperature, then dried to completion at 40 ºC under a stream of nitrogen. All
extracts were reconstituted with 50 µL of ethyl acetate and aliquoted into autosampler
vials.

4.4.4 Instrumentation: Opiates by GC/SIM-MS
The Hewlett Packard 6890 series gas chromatograph coupled with a 5973 mass
selective detector was utilized for quantitative analysis. A deactivated capillary guard
column (5m X 0.250mm) was connected to a DB-5 (5% phenyl methyl polysiloxane)
analytical column (15m X 0.25mm ID X 0.25µm film thickness; Agilent Technologies,
Palo Alto, CA) to achieve chromatographic separation. The initial oven temperature was
set for 65 °C and held for 1 minute, then ramped 15 °C/ minute to 300 °C. The collection
methods were divided into segments based on retention time of each analyte (Table 4).
Identification was made on the basis of mass spectral matches of the appropriate ion
ratios (± 20%).

4.4.5 Opiates: Quantitative Blood Analysis by GC/MS/MS
This method was utilized to quantify hydrocodone, oxycodone, codeine,
hydromorphone, morphine, 6-monoacetylmorphine (6-MAM) and oxymorphone. Stock
standards obtained from Cerilliant Corporation (Round Rock, TX) were used to prepare
working standards. The working standards were serially diluted to comprise a six point
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calibration curve ranging from 5 ng/mL to 1,000 ng/mL. If necessary, samples were
diluted to bring their concentrations within the established limits of the curve. Alltech
Associates (State College, PA) stock standards were used to prepare two working
controls, 50 ng/mL and 500 ng/mL, respectively. Linear regression was used to calculate
sample concentrations.
To each 1 mL blood sample, 100 µL of deuterated internal standard mix (Table 5)
and 4 mL of 0.1 M, pH 6 sodium phosphate buffer were added. The samples were
vortex-mixed and centrifuged at 3500 RPM for 10 minutes. The samples were then
submitted for automated solid-phase extraction (SPE) on Caliper Life Sciences
(Hopkinton, PA) RapidTraceTM system. All solvents used were high purity grade. Clean
ScreenTM extraction columns (Worldwide Monitoring, Inc.) were conditioned with the
elution solvent (methylene chloride: IPA: NH4OH; 80:20:2), followed by methanol, then
water and, finally, pH 6 sodium phosphate buffer (0.1 M). The blood samples were then
loaded onto the columns (2 mL/min) and sequentially rinsed with water, HCl and
methanol. The columns were dried with ultra zero grade air. Three milliliters of elution
solvent was passed through the column at 1 mL/min and the extract collected in a clean
screw cap culture tube. The eluent was evaporated to dryness at 40 ºC under a stream of
nitrogen. The dried extracts were derivatized with 100 µL of propionic anhydride,
catalyzed with 25 µL of pyridine, and heated at 60 ºC for 30 minutes. The samples were
then dried to completion at 40 ºC under a stream of nitrogen.

The extracts were

reconstituted with 50 µL of ethyl acetate and aliquoted into autosampler vials.
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Table 4: Opiate Compounds Quantitated Using GC/ SIM- MS
Method

Segment
1

Opiate I

2
3
1

Opiate II

2
3

1

Analytes
Morphine
Morphine- D31
Codeine
Codeine – D31
6-MAM
6-MAM – D31
Hydrocodone
Hydrocodone – D31
Oxycodone
Oxycodone– D31
Hydromorphone
Hydromorphone –D31

Molecular Ion
577
446
473
329
386
356
-

Only quantifying ions were collected for internal standards
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Quantifying Ion
414
417
282
285
414
417
328
331
386
389
356
359

Qualifying Ions
430
445
430
297
230
343
283
314
-

A Varian CP-3800 gas chromatograph coupled with a 1200L Triple Quadrupole
Mass Spectrometer and CP-8400 autosampler system was utilized for quantitative
analysis. A deactivated capillary guard column (5m X 0.250mm) was connected to a
DB-5 (5% phenyl methyl polysiloxane) analytical column (15m X 0.25mm ID X 0.25µm
film thickness; Agilent Technologies, Palo Alto, CA). The initial oven temperature was
set for 65 °C and held for 1 minute, then ramped 15 °C/ minute to 315 °C (total run time
= 17.67 minutes). The collection method was divided into four segments based on
retention time for each of the seven analytes and their respective deuterated internal
standards (Table 5). Identification was made on the basis of mass spectral matches of the
appropriate ion ratios (± 30%).

Table 5: Opiate Compounds Quantitated Using GC/MS/MS
Segment
1
2

3

4

1

Molecular Quantifying
Qualifying
Ion
Ion
Ions
Hydrocodone
299
242BP
270
299
1
Hydrocodone – D3
302
245
Codeine
355
282BP
298
355
Codeine - D31
358
285
Oxycodone
371
314BP
212
371
Oxycodone – D31
374
215
Hydromorphone
341
285BP
229
341
1
Hydromorphone – D3
344
288
6-Acetylmorphine
383
327BP
204
383
6-Acetylmorphine – D31
386
207
Morphine
397
341BP
218
397
Morphine – D31
400
221
Oxymorphone
413
357BP
284
413
Oxymorphone – D31
416
360
- Deuterated internal standards did not require qualifying ions
Analytes

Qualifying ions were not collected for the internal standards
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4.5 Microbial Study
4.5.1 Preparation of Nutrient Agar plates
Five-hundred milliliters of double-distilled water was added to 11.5 grams of
Becton, Dickinson and Company brand (Sparks, MD) nutrient agar. The mixture was
heated until the agar went into solution, then autoclaved for 15 minutes at 121 ºC. After
which, the solution cooled to approximately 50 ºC and was poured into 100 x 15mm petri
dishes (Medegen Medical Products, Gallaway, TN). The agar plates were stored at room
temperature (25 ºC) for 24 hours, followed by refrigeration until use.

4.5.2 Phosphate Buffered Saline Standards
For the stability and microbial studies, drug standards made in phosphate buffered
saline (PBS) solution were needed. Drug standards at the MDME- toxicology laboratory
are often prepared in organic solvents (e.g. methanol or acetonitrile). However, for the
purpose of these experiments, it was disadvantageous to use standards that introduced
additional carbon sources into the matrices. As a result, powdered standards were mixed
with 1X PBS solution and used as needed.
The procedure was conducted as follows: 25 mL volumetric flasks, individual
1mg/ mL stock standards of diazepam, codeine and hydrocodone were prepared.
Twenty-five milligrams of hydrocodone bitartrate (Endo Laboratiories, Inc., Garden City,
NY), 24.9 mg of codeine sulfate (Lilly, Inc., Indianapolis, IN) and 25.2 mg of diazepam
(La Roche, Inc, Nutley, NJ) were added to their respective volumetric flasks containing
PBS solution. The solutions were vortex mixed.
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Codeine and hydrocodone stock

standards were transferred into individual amber vials fitted with screw cap lids. The
diazepam standard however, would not dissolve. Therefore, that mixture (in its flask)
was sonicated for 45 minutes in a water bath. The standard remained a heterogeneous
mixture. A review of the original container that held the powdered standard was only
marked diazepam and did not give any additional information about its formulation.
However, the diazepam powder was visibly different from that of the codeine and
hydrocodone standards. The diazepam powder was tan in color and had a consistency
similar to a starch-based powder (e.g. baby powder), as opposed to the white, salt based
opiate powders used. Therefore, it was determined that the properties of the diazepam
standard would not allow for the preparation of a homogenous solution. A subsequent
review of the literature revealed that diazepam (along with other benzodiazepines) is not
soluble in water (43), therefore explaining its resistance to the water based PBS solution.
Consequently, diazepam could no longer be used for this portion of the study.
One hundred micro-liters of codeine and hydrocodone stocks were added to
individual 10 mL volumetric flasks and mixed with 9,900 µL of PBS solution to make
0.01 mg/mL (10,000 ng/mL) working stock solutions.

The solutions were then

transferred into amber vials fitted with screw caps and stored under refrigeration (2 ºC).

4.5.3 Aerobic and Anaerobic Microbial Experiments
All of the postmortem blood used for this experiment was stored in tubes
containing the anti-microbial agent sodium fluoride (NaF).

In an effort to test the

effectiveness of the NaF, blood samples needed to be inoculated in a nutrient-rich
environment to determine if any microbial activity would exist. The PM blood used for
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this part of the experiment was collected from the chest of a decomposing cadaver.
Based on the odor and discoloration of the body, it was evident that microbial activity
was flourishing. The blood (green in color) was collected in 2 BD vacutainer gray-top
tubes (10 mL each) and 1 red-top polypropylene tube (50 mL total).

The red-top

contained NaF that was added by the MDME staff upon receipt of the tubes, while the
gray-top was commercially prepared. Upon sample collection, all of the tubes were
inverted multiple times to ensure proper mixing of the NaF with the blood.
Nutrient agar plates were inoculated in duplicate, each with 75 µL of chest blood
from the red-top and gray-top tubes. Additionally 75 µL of antemortem blood, stored in
a gray-top tube was also inoculated. Disposable sterile loops (Thermo Fisher Scientific,
Waltham, MA) were used to streak the plates. For the aerobic experiment, a set of
duplicate plates were stored in the dark for 11 days at 17 °C.

For the anaerobic

experiment, an additional set of duplicate plates were stored in a vented BBL® anaerobic
system jar (Becton Dickinson Microbiology Systems, Cockeysville, MD). In order to
provide the anaerobic environment, BD GasPakTM EZ Anaerobe Gas Generating Pouch
system with indicator (Becton, Dickinson and Company, Sparks, MD) was used. Once
the plates were properly positioned in the jar, the foil wrapping was removed from the EZ
gas pouch.

The release of carbon monoxide (thereby providing an anaerobic

environment) was activated when the pouch was open and exposed to air.
activation, the lid was sealed and the jar was stored in the dark for 11 days at 17 °C.
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Upon

4.5.4 Assessing the Usefulness of Codeine and Hydrocodone as a Food Source for
Bacteria
Since a major part of this project was to determine the reason for drug
concentration changes among antemortem and postmortem samples, it was imperative to
evaluate the role of microbial activity. In an effort to determine if drug compounds could
themselves be used as a food source for bacteria, the following procedure was employed.
A DH5α strain of Eschericia coli (E. coli) and a PAO1 strain of Pseudomonas
aeruginosa (Pseudomonas) was plated onto LB agar plates and allowed to grow for 48
hours at 37 ºC. Individual colonies were transferred into two 50 mL polypropylene tubes
(one for each bacteria) containing 8 mL of nutrient broth. The suspension was rocked for
24 hours, followed by 24 hour incubation (37 ºC). The suspension was then centrifuged
and the supernatant disposed.
buffered saline (PBS) solution.
supernatant was disposed.

The cellular precipitate was rinsed with phosphate
That suspension was centrifuged and again the

This step was repeated twice.

The cells were then re-

suspended in 5 mL of nutrient broth. A 1 mL aliquot of both suspensions was reserved
for photometric reading.
A 96 well MT plate (9x12), manufactured by Biolog (Haywood, CA), was
arranged as shown in Figure 5. Columns 3, 7, 11 and 12 were not used. Negative and
positive controls were setup in the first two columns.

One-hundred micro-liters of

codeine and hydrocodone (prepared in 1X PBS solution) at concentrations of 100, 200
and 600 ng/mL each were aliquoted into columns 4-6 and 8–10. Afterwards, a baseline
reading of the plate was taken using a Modulus Microplate reader (Turner Biosystems,
Sunnyvale, CA) at a wavelength of 600 nm. The plate was then refrigerated for 48 hours
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Figure 5: Arrangement of the 96 Well MT Plate
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while the bacteria (E. coli and P. aeruginosa) were prepared. Upon which time, 50 µL of
E. coli was inoculated in columns 4–6, with 50 µL Pseudomonas in columns 8–10. After
which, another density reading was taken. Microplate readings continued daily for a total
of 8 readings.
The 1 mL aliquot reserved for photometric reading was analyzed using a
BioPhotometer (Eppendorf AG, Germany) at a 600 nm wavelength. This reading was
taken to ensure the density of the bacteria population would be sufficient for use in this
study.

4.6 Drug Stability Study
The purpose of this experiment was to assess the stability of hydrocodone and
codeine in whole blood when stored in refrigeration (2 ºC) for three months. In the Peters
article (44), four main types of drug stability were identified. They include long-term
stability (examination of drug stability in storage), freeze/thaw stability (examines the
effect of re-analysis of samples that have been frozen), in-process or bench top stability
(assesses the stability of a drug during the sample preparation procedure) and finally
processed sample stability, which addresses the stability of a drug while awaiting
instrument injection. This experiment was solely focused on long-term stability. While
some of the cases analyzed for this project were obtained a year or more before the
inception of this research, many were analyzed within three months of the sample
acquisition. The three month lapse typically accounted for the time required for routine
laboratory analyses to be completed. At the completion of routine testing, research
analysis could begin. An extended stability study (≥ 3 mon ths) was not conducted by the
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researcher as several articles (21)(44)(45)(46)(47) have been published addressing the
stability of drugs and drug classes used in this study (e.g. benzodiazepines, opioids and
methadone).
One milliliter each of codeine and hydrocodone working stocks (prepared as
described in section 4.5.2 Phosphate Buffered Saline Standards) were spiked into 48 mL
of chest blood to give a final concentration of 200 ng/mL each. The mixture was rocked
for 10 minutes to ensure equilibrium.

Twenty milliliters of the spiked blood was

separated into two gray-top vacutainer tubes (each tube held 10 mL). The remaining
30mL of spiked blood was stored in a red-top polypropylene tube (50 mL capacity).
Stock, working stock and spiked blood tubes were kept in refrigeration (2 °C) until
further use. Additionally, in an effort to correlate drug stability with microbial activity,
the chest blood spiked for this experiment was the same blood inoculated (without the
drug spike) on the nutrient agar plates in section 4.5.3 Aerobic and Anaerobic Microbial
Experiments. Similarly the hydrocodone and codeine standards were the same ones used
in the MT plate experiment described in section 4.5.4.

5.0 Calculations
In order to better interpret the significance of the data, statistical analyses were
conducted. Statistical testing was applied to the control data collected for each drug of
interest. The controls, as opposed to the actual case blood samples, were analyzed
because they had enough data points generated to produce relevant population sizes.
Conversely, the cases used for this study had a finite amount of blood available for
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testing. Therefore, analyzing multiple replicates over a period of days was not feasible.
The controls, however, were extracted and analyzed with every batch, thereby allowing
for more replicates over a period of months to years depending on the assay.
As the testing for this project was conducted over a three year period, control lot
numbers, and, at times, instrumentation were changed. The data that were produced for
drugs analyzed on one instrument, but with multiple lot numbers, underwent one-way
Analysis of Variance (ANOVA) testing, to test the hypothesis that the lot numbers were
not different.
As an example, the diphenhydramine control (0.50 mg/L) was run forty-one times
by GC/NPD and had three different lot numbers. The population sizes for lots 1, 2 and 3
were 15, 19 and 7, respectively. To determine if each lot produced similar results a oneway ANOVA with a 95 percent confidence interval, was calculated using Microsoft
Excel’s Data Analysis Toolpak software. The results given in Table 6 show both the
summary and ANOVA analysis output. Listed within the summary is a breakdown of
each lot number, indicating its population size and average (Table 6) control
concentration. The ANOVA analysis results gave such parameters as the sum of squares
(SS), degrees of freedom (df) and mean square (MS) values. Of particular interest were
the calculated values for F and F crit. The F value is the F-test (Equation 3) result that
was calculated by the ANOVA.

If F > Fcrit, it was determined that a significant

difference between the populations existed.

The F value for the diphenhydramine

calculation was 2.839, while Fcrit equaled 3.244. Therefore, in this example, F was less
than Fcrit, indicating that the populations were not statistically different. As a result, the
data produced by all 3 lot numbers were treated as one population.
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The control data for each drug was evaluated as described above. Once it was
determined that the data could be combined, the population standard deviation (Equation
4) was calculated. After which, the coefficient of variation (CV), that is the percent
relative error, was determined for each drug by using Equation 5. In keeping with the
diphenhydramine example, the population mean and standard deviation values were 0.55
and 0.08, respectively. Therefore the CV, for this drug was approximately 15%. The CV
was used as a way to measure ‘significance’ among the intra-case data. In order to make
a determination as to whether or not the concentration differences observed (within any
given case) was statistically significant, the CV value was applied. If the differences in
sample concentrations fell within the established CV (for example ± 15%), then no
significant difference was observed, however if the concentrations were not within the
limits of the relative error as described by the CV, then the concentrations were deemed
statistically different.
Additionally, as methodology in the MDME – toxicology laboratory changed, so
did the methodology for this project. As a result, some of the quantitative drug results
were collected on two instruments. A two-way Analysis of Variance (ANOVA) with a
95% confidence interval was conducted to determine if the control values obtained on
different instruments were statistically similar. If the F-test results generated by the
ANOVA determined the control results were similar, then the data were treated as an
entire population, regardless of instrumentation. If however, there was a significant
difference between instruments, then Tukey’s honestly significant difference (HSD) test
(Equation 6) was employed on a post hoc basis. This was the case for clonazepam.
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Clonazepam data for this project were originally collected by GC/ECD.
Eventually the method was modified and analyzed by LC/MS/MS. The F-test result
(generated by the two-way ANOVA) equaled 26.84, while the Fcrit equaled 4.35. Since F
was greater than Fcrit, the results indicated that the data produced on the two instruments
differed. Therefore, the data were evaluated as two separate populations (one population
per instrument), as opposed to being treated as a single population. In an attempt to
check the validity of the ANOVA results, Tukey’s HSD post hoc analysis was conducted.
Post hoc analysis is only used on data that has indicated a statistical difference.
Tukey’s HSD test compares the difference between mean values of sample populations to
a newly calculated critical value (HSDcrit). In the case of clonazepam, the control values
generated by GC/ECD had a mean of 0.10 mg/L and the LC/MS mean control data
equaled 0.13 mg/L. The calculated mean difference between the two equaled 0.03.
When solving for HSDcrit, the critical value equaled 0.01. When the mean difference is
greater than HSDcrit (as was the case with clonazepam) a significant difference exists.
Consequently, there was a difference in the clonazepam data collected by GC/ECD when
compared to that of the data collected by LC/MS/MS. As a result, the data were treated
as two separate populations, with each having its own amount of relative error (CV).
Not only was it important to identify an acceptable amount of variance within an
entire population, it was also imperative to determine which PM results were reasonable
and which were not. Since each case had its own unique set of circumstances, it would
not have been appropriate to implement a static scale in which to determine significance.
Instead, dynamic calculations, which could be tailored to each case, were used.
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Equation 2: Average of n measurements (48)

Σxi = sum of all the measurements
n = number of measurements

Equation 3: F-test for Comparison of Standard Deviations (48)

s = standard deviation

Equation 4: Standard deviation of n measurements (48)

s= sample
xi= sum of all measurements
= mean
n = number of measurements
n - 1 = degrees of freedom
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Table 6: Example of One-WAY ANOVA Data Output by Microsoft Exel® Generated
when Comparing the Three Diphenhydramine Control Lots
Anova: Single Factor
SUMMARY
Groups
lot 1
lot 2
lot 3

Count
15
19
7

Sum
8.624
10.5
3.46

Average Variance
0.574933 0.013845
0.552632 0.00242
0.494286 0.001762

ANOVA
Source of
Variation

Sum of Squares

Between lots
Within lots

0.031157
0.247973

degrees
Mean
of
F
F crit
Square
freedom
2
0.015579 2.387292 3.244818
38
0.006526

If F > F crit: Significant difference exists
If F < F crit: no significant difference exists
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Equation 5: Coefficient of Variation (48)

Equation 6: Tukey’s Honestly Significant Difference Equation

(70)

HSDcrit = newly calculated critical value
q = reference value obtained from a studentized range table
MSwithin = Mean Square within value obtained from the ANOVA data output
n= population size
*if mean difference > HSDcrit, a significant difference exists
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Ratio calculations are common tools used in postmortem casework to determine if
postmortem redistribution could have influenced the results. Whenever both postmortem
and antemortem samples (for the same case) have been tested and rendered quantitative
results a PM to AM ratio can be calculated. This comparison allows the interpreter to
determine the true extent of the concentration disparity, as any time the ratio is≥ 1.0 it is
said that postmortem redistribution was likely a factor. Similarly, when comparing two
postmortem sources (central and peripheral) if the resultant ratio≥is1.0, postmortem
redistribution is believed to be the cause. When interpreting the results of both ratios, the
higher the value is above 1.0, the more likely that redistribution has occurred. While both
ratios are useful, only about 33% of the cases submitted at the MDME Department are
sent with AM specimens. In contrast, greater than 75% are submitted with both central
and peripheral PM sources. Therefore, if a question about the occurrence of PMR arises,
it is the central to peripheral that will most likely be available. For the purposes of this
study, however, both central to peripheral as well as postmortem to antemortem
calculations were applied whenever possible to better assess the intra-case relationships.
Finally, it was imperative to determine what drug concentrations would be expected at
the time of death. The pharmacodynamic process (section 1.4.2), which governs the
body’s ability to remove substances from its system, had to be taken into account when
attempting to identify any concentration expectations. As indicated in Equation 7, when
substituting the antemortem concentration for Nt, the antemortem to death (AMD)
interval for T and separately inputting the minimum and maximum elimination half-life
values for t1/2, an expected drug concentration range at the time of death could be
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calculated. The PM concentrations that fell within their expected ranges were believed to
demonstrate drug metabolism (and elimination) occurring in a predicted fashion.

Equation 7: Calculated Expected Drug Concentration Range at the Time of Death(22)

= Estimated concentration at the time of death
= AM concentration of the sample
T= Time between AM and death
t ½= elimination half-life of the drug

The use of both the minimum and maximum elimination half-life values, resulted
in a concentration range that could likely account for the majority of people (both fast
and slow metabolizers).

The range was critical in determining whether or not

postmortem concentrations were significantly different than expected. The expected
ranges vary by case and are addressed on a case-by-case basis in Chapter 6: Results and
Discussion.

6.0 Results and Discussion
The data discussed in the following sections were from cases obtained by the
Miami-Dade County Medical Examiner’s Department. At the time of the sample testing
for this project, the cases were no longer being actively analyzed in the toxicology
laboratory. However, initial analyses were conducted by laboratory staffers to identify,
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and in most instances, quantify the drugs of interest, as part of the death investigative
process.

Any sample whose volume was not sufficient for repeat analyses by the

researcher was still included in the study if a quantitative value was obtained as a part of
routine laboratory analyses. Since it is of the utmost importance that the identities of the
subjects remain private, each case has been assigned an alpha-numeric combination, not
related to their actual case numbers.
6.1 Opiates
As discussed in section 1.7.2, opiates are drug class characterized by their
analgesic properties. Users often establish a tolerance, which can make it difficult to
interpret the true meaning of a given concentration determined in blood. The following
sections will cover both prescription and illicit opiates. Through December 2008, the
MDME- toxicology laboratory divided opiates into two analytical methods of analysis.
The Opiate I method included morphine, codeine and 6- monoacetylmorphine (6-MAM),
while the Opiate II method included hydrocodone, hydromorphone and oxycodone. Both
methods were analyzed on an Agilent GC/MSD instrument (SIM-mode) and had a linear
range of 10 – 1,000 ng/mL. As of January 2009, the opiate methods were combined and
analyzed by GC/MS/MS using Varian’s 1200L system. The six previously mentioned
analytes, plus the addition of oxymorphone were included in this comprehensive method.
Hydrocodone had a linear range of 5 – 500 ng/mL, all other opiates had a linear range of
5 – 1,000 ng/mL by GC/MS/MS. All three opiate methods were validated according to
the procedures implemented by MDME- toxicology laboratory.

62

6.1.1 Heroin, Morphine and Codeine
While, heroin, morphine and codeine are all separate drugs in their own right,
they are being discussed collectively because they are often detected together.

As

described in Section 1.7.2, heroin synthesis also produces the byproduct acetylcodeine.
As a result, when heroin is metabolized, codeine, 6-monoacetylmorphine (6-MAM) and
morphine may also be produced. Additionally, even in the absence of heroin usage,
morphine and codeine can still be detected together, as morphine is also the demethylated
metabolite of codeine. Therefore, in cases where codeine has been identified, morphine
is also commonly found.

The cases investigated here have been divided into two

sections. The first includes those morphine/ codeine (MOC) cases whose antemortem
was collected within two elimination half-lives before death. Those cases are listed in
Table 9 in order of increasing antemortem to death interval. Codeine has an elimination
half-life ranging from 1.9 – 3.9 hours with morphine ranging from 1.4 – 6.7 hours and
volumes of distribution of 3.5 L/ kg and 2- 5 L/kg, respectively (50)(51). The second
section covers the MOC cases whose AM was collected beyond two elimination halflives.
Because two instruments were used to obtain the data for this chapter, atwo-way
ANOVA (α = 0.05) was conducted to determine if there were any statistical differences
between the two methods (Table 7). The ANOVA F-test values for morphine, codeine
and 6-MAM were 48.8, 3.7 and 17.6, respectively. While the Fcrit values were 6.0, 7.7
and 7.7 for morphine, codeine and 6-MAM, respectively. When the F-test value is
greater than the Fcrit, a significant difference exists. Therefore, analysis of variance
concluded that the F-test values for both morphine and 6-MAM resulted in statistically
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different results between the two instruments, while codeine detection did not differ as a
function of analytical methods. Subsequently, the morphine and 6-MAM intra-sampling
data could not be evaluated as one population. Tukey’s honestly significant difference
(HSD) post hoc test was applied to both morphine and 6-MAM to determine how the data
sets differed. The calculated critical values for Tukey’s HSD were less than the mean
differences calculated for morphine and 6-MAM (Table 7). When the mean difference >
HSDcrit, a significant difference does in fact exist. Therefore, the post hoc analysis
supported the ANOVA results, which indicated that the populations were different.
Consequently, the coefficient of variation for morphine and 6-MAM differed depending
on the instrumentation used (Table 8).

Conversely, since there was no significant

difference among the codeine data, the populations (GC/SIM-MS and GC/MS/MS data)
were combined and evaluated as one.
The morphine/ codeine (MOC) cases discussed were separated into two sections.
The first being those cases whose antemortem blood was collected within two elimination
half-lives before death (Table 9). The second section is comprised of the remaining
MOC cases whose antemortem blood collection time exceeded two elimination half-lives
(Table 10). All of the cases are presented in order of increasing antemortem to death
(AMD) interval, as opposed to numerical order.
The antemortem sample for morphine/ codeine case 14 was collected 9 minutes
before death. Analysis of the sample detected 48 ng/mL of morphine present. Aorta and
iliac vein bloods were submitted for postmortem analyses. Aorta blood contained 339
ng/mL of morphine, 18 ng/mL of codeine and 6.5 ng/mL of 6-MAM. Similarly, iliac
vein blood was positive for morphine, codeine and 6-MAM as well, with concentrations
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Table 7: Two-Way Analysis of Variation Results for Morphine, Codeine and 6-MAM by Comparing Control Data for
GC/SIM-MS to GC/MS/MS
Drug

Source of Variation

Sum of
Squares

df

Mean
Square

F-test
result

F critical
value

Morphine
Codeine
6-MAM

GC/MS vs. GC/MS2
GC/MS vs. GC/MS2
GC/MS vs. GC/MS2

666.80
70.66
240.97

5
3
3

666.80
70.66
240.97

48.80
3.69
17.60

5.99
7.71
7.71

Tukey’s
critical
value
4.27
N/A
5.21

 If F > F critical, then results are significantly different
 If F < F critical, then results are similar
 If mean difference > Tukey’s crit, then the results are
significantly different

Table 8: Coefficient of Variation Results for Morphine, Codeine and 6-MAM
Drug
Morphine
Codeine
6-MAM

Method
GC/SIM-MS
GC/MS2
GC/SIM-MS and GC/MS2
GC/SIM-MS
GC/MS2
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CV
10.0%
9.1%
9.8%
8.8%
5.1%

Mean
Difference
14.14
N/A
13.50

of 139 ng/mL, 7 ng/mL and 5 ng/mL, respectively. Statistical analyses determined that
the PM aorta blood concentrations were different from the iliac vein blood
concentrations. Additionally, both PM morphine concentrations were dis-similar to the
antemortem concentration. Antemortem blood analysis was negative for codeine and 6MAM; however, urine screen results identified the presence of all three drugs. The
detection of codeine and 6-MAM in the urine, but their absence in the AM blood
suggested that during the time of AM blood collection the drugs were no longer being
distributed. Instead they had been eliminated into liquid waste. The detection of both
codeine and 6-MAM in the PM blood samples indicated storage of the drugs in tissues (at
the time of the AM collection) and then their release upon death. During the 26 hour
PMI, all three drugs were able to redistribute themselves. Aorta blood: AM, as well as
ILBL:AM ratios equaled 6.8 and 2.8 for morphine and codeine, respectively.
Additionally, C:P ratios equaled 2.4, 2.6 and 1.3 for morphine, codeine and 6-MAM,
respectively. All the ratio data in this case were consistent with PMR.
At 23 minutes before death the AM blood for MOC 12 was collected. Upon
analysis it was determined that 1,544 ng/mL morphine and 40 ng/mL of codeine were
present. The presence of both morphine and codeine were the result of heroin usage.
Heroin has an elimination half-life of 2-6 minutes (30).

Because of this rapid

metabolism, heroin is quickly eliminated from blood and metabolized into urine. Heroin
has an elimination half-life of 2-6 minutes (30). Because of this rapid metabolism, heroin
is quickly eliminated from blood and metabolized into urine. Heroin was detected only
in the urine. However since urine is not a suitable sample for quantitative analyses
(section 1.6.2) and heroin is rarely detected in blood, many laboratories (including
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Table 9: Morphine, Codeine and Heroin Antemortem samples collected within 2 elimination half-lives
Heroin t1/2 = 2-6 minutes
6-MAM t1/2 = 2- 25 minutes
Morphine t1/2 = 1.4 – 6.7 hours; Vd = 2-5 L/ kg
Codeine t1/2 = 1.9 – 3.9 hours; Vd = 3.5 L/kg

AMDeath

9 min

23 min

Case #

MOC
142

MOC
122

Source
(whole blood)

Aorta
Iliac
Mixed
IVC

Concentration
(ng/mL)

morphine 339
codeine 18
6MAM 6.5
morphine 139
codeine 7
6MAM 5
morphine 2,945
codeine 76
6MAM 858
morphine 2,539
codeine 83
6MAM 1,255

AM
concentration
(ng/mL)

morphine 48

morphine 1,544
codeine 40
6-MAM 90

Analyte

PM:AM

MO
CO
6MAM
MO
CO
6MAM
MO
CO
6MAM
MO
CO
6MAM

7.1
2.9
1.9
1.9
9.5
1.6
2.1
13.9

PMI
(hours)

Race/Sex

Age

26.5

WM

49

N/A

18

WM

49

C:P

2.4
2.6
1.3

45 min

MOC
132

CHBL*

morphine 259
codeine 9.75

morphine 104
codeine 20

MO
CO

2.5
0.49

N/A

48

BM

40

1 hour

MOC
051

Aorta

morphine 48
codeine 25

morphine 65

MO

0.7

N/A

13.5

WM

57

2 hours

MOC
031

morphine 52
codeine 698
morphine 71
codeine 1,397

morphine 17
codeine 65

MO
CO
MO
CO

3.0
10.7
4.2
21.5

N/A

47

BF

31

Aorta
Chest
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AMDeath

Case #

2 hours

MOC
081

5 hours

MOC
021

Source
(whole blood)

HTBL
ILBL
Mixed*

Concentration
(ng/mL)

AM
concentration
(ng/mL)

Analyte

PM:AM

C:P

PMI
(hours)

Race/Sex

Age

0.5
0.4
-

1.4
1.0

23

BM

37

N/A

N/A

19

WF

81

morphine 105
codeine 10
morphine 76
codeine 10

morphine 205

MO
CO
MO
CO

morphine 30

morphine <LOQ
codeine 25

MO

1

GC/MS linear range: 10-1,000 ng/mL
GC/MS2 linear range: 5-1,000 ng/mL
*Average concentration
Morphine = MO
Codeine = CO
6-Monoacetylmorphone = 6-MAM

2

Table 9, continued

68

MDME-toxicology lab) do not have a blood quantitative method for heroin. Instead 6monoacetlymorphine (t1/2= 6-25 minutes), the major metabolite of heroin, is more often
encountered and quantitated, as it is more likely to be identified in whole blood (section
1.6.3).
Postmortem mixed blood (MXBL) and inferior vena cava blood (IVC BL) were
submitted for analysis following autopsy. Mixed blood had a morphine concentration of
2,945 ng/mL with a codeine concentration of 76 ng/mL. Inferior vena cava blood had
concentrations of 2,539 ng/mL and 83 ng/mL for morphine and codeine, respectively.
All samples (PM and AM) were diluted to bring their concentrations within the linear
range (ULOQ = 1,000 ng/mL) of the assay.

The PM results for morphine were

determined to be statistically similar to each other. This was also true for the PM results
of codeine.

However, both morphine and codeine results were determined to be

statistically different from the AM concentrations (morphine CV ± 9.1%, codeine ±
9.8%). On the basis of the AM results the expected concentration range for morphine
was 1,277 – 1,484 ng/mL. Codeine had an expected range of 34.8 – 37.4 ng/mL. The
PM results for both drugs exceeded their linear range. The MXBL:AM ratio equaled 2.0
for both morphine and codeine, while IVC BL:AM ratio equaled 1.7 and 2.0 for
morphine and codeine, respectively. When comparing the PM to AM data, one could
conclude that PMR occurred during the 18 hour PMI. While PMR may have contributed
to the elevated postmortem concentrations, it is more likely that the drug was still being
absorbed at the time of death. The oversaturation of the body’s system, due to an
overdose of heroin, can significantly hinder the pharmacokinetic process.
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Morphine/codeine case 13 had AM blood drawn 45 minutes before death.
Analysis of this sample detected the presence of both morphine and codeine at
concentrations of 104 ng/mL and 20 ng/mL, respectively. Chest blood (CHBL) samples
in both red-top (RT) and gray-top (GT) tubes were submitted for postmortem analyses.
The red-top chest blood sample had 228 ng/ml of morphine and 8.5 ng/mL of codeine.
Gray-top chest blood had 290 ng/mL of morphine and 11 ng/ml of codeine. Since the
PM samples were from the same source, their drug concentrations were averaged to give
259 ng/mL and 9.75 ng/mL for morphine and codeine, respectively. Chest blood to AM
ratios for morphine and codeine equaled 2.6 and 0.49, respectively. The ratio values
suggested that PMR occurred for morphine, but not for codeine.

The expected

concentration ranges were in agreement with the ratio data, as PM morphine
concentrations exceeded its expected range (71.7 – 96.2 ng/mL), while codeine was
below its range of 15.2 – 17.5 ng/mL. The decrease in codeine concentration from AM
to PM sample, may appear to be due to metabolism. However, the 45 minute antemortem
to death (AMD) interval would not have been enough time for that amount of
metabolism. Conversely, the PMI lasted 48 hours. In that amount of time, anaerobic
conversion could be a possibility. This could account for the decrease of codeine’s
concentration and the increase of morphine, as morphine is the demethylated metabolite
of codeine.

So while PMR may have caused the concentration changes, anaerobic

activity cannot be ruled out. In which case, the process of chemical conversion was
ceased once the samples were aliquoted into RT and GT tubes which contain the
antimicrobial agent sodium fluoride.
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The antemortem blood for MOC 05 was collected within one hour of death and
had a postmortem interval of 13.5 hours. The AM blood had a morphine concentration of
65 ng/mL and was negative for codeine. Postmortem aorta blood was collected at
autopsy and submitted for testing. Quantitative analysis determined that morphine was
present at a concentration of 48 ng/mL and codeine at 25 ng/mL. The concentration
differences for AM and PM morphine values were statistically different (CV ± 10%).
The PM:AM ratio of morphine was 0.8, which indicated a lack of PMR. Based on the
data, it would appear as though before the collection of the AM sample, the body
metabolized codeine to the extent to which it was undetectable. The presence of codeine
in the PM does seem to indicate the sequestering of codeine in or around the heart tissue
and released upon death. This equates to PMR of codeine, but not morphine. Morphine
had an expected concentration range of 36.6 – 54.1 ng/mL. The AOBL concentration fell
within this range, reiterating that PMR did not occur for morphine.
Antemortem blood for MOC 03 was collected 2 hours before death. The AM
results determined that morphine and codeine were present at concentrations of 17 ng/mL
and 65 ng/mL, respectively. The decedent in this case was prescribed Tylenol 3®, a
mixture of codeine and acetaminophen. Therefore, the presence of morphine in the AM
was likely the result of drug metabolism. The expected calculated concentration range
for morphine was 7.4 – 16.3 ng/mL, while the range for codeine was 28.9 – 42.0 ng/mL.
Postmortem aorta (AOBL) and chest (CHBL) blood samples were also submitted for
analysis (PMI = 47 hours). Quantitative analysis of the aorta blood had a morphine
concentration of 52 ng/ml and codeine of 698 ng/mL.

The chest blood had

concentrations of 71 ng/mL and 1,397 ng/mL for morphine and codeine, respectively.
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The PM results were not only statistically different from the antemortem concentration,
but they were also different from each other.

Additionally, the actual postmortem

concentrations for both morphine and codeine well exceeded their expected concentration
ranges.

The AOBL:AM ratios equaled 2.6 and 11.6 for morphine and codeine,

respectively. The CHBL:AM ratio for morphine was calculated at 3.55, while codeine
was 23.3. Both of the PM:AM ratios indicated PMR of morphine and codeine.
In MOC 03, both AOBL and CHBL samples were collected from the central
region of the body. However, the data indicated a more extensive redistribution present
in the chest blood. The term ‘chest blood’ is a generic designation for pooled blood
collected from inside the chest cavity. Therefore, a chest blood sample is often a mixture
of blood that has been released from the lungs, liver, stomach and/ or various chambers
of the heart. Further review of the medical records determined that the decedent vomited
prior to the arrival of the ambulance. Therefore, it is possible that some of the stomach
contents were aspirated into the lungs, thereby contaminating the chest blood sample.
This in turn could account for chest blood codeine concentrations that were significantly
higher than both the aorta and antemortem bloods (50% and 96%, respectively).
Morphine/ codeine (MOC) 08 was submitted with AM blood that was collected 2
hours before death.

The AM sample had 205 ng/mL of morphine but no codeine

detected. Upon autopsy, both postmortem heart and iliac vein bloods were submitted.
Heart blood (HTBL) had a morphine concentration of 105 ng/mL and codeine of
10ng/mL. Iliac vein blood (ILBL) analyses determined concentrations of 76 ng/mL and
10 ng/mL of morphine and codeine, respectively. While the PM codeine concentrations
were equal, the PM morphine concentrations were statistically different. Additionally,
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both PM morphine concentrations were also different from the AM concentrations. The
central to peripheral ratios equaled 1.4 and 1.0 for morphine and codeine, respectively.
The HTBL:AM ratio of morphine equaled 0.5, while the ILBL:AM morphine ratio
equaled 0.4.
For MOC 08, the central to peripheral ratios indicated that PMR was present for
both morphine and codeine. However, the PM:AM ratios did not support this finding for
morphine. A codeine ratio could not be calculated, as codeine was not detected in the
AM sample. Therefore, upon examining the data, the researcher determined that PMR of
codeine was present. The lack of codeine in the AM, but its presence in both PM
samples indicated that codeine had both metabolized (to the point of non-detection in the
AM) and sequestered itself during life. The 23 hour PMI was enough time to allow
codeine to be released in both the central and peripheral regions of the body, thereby
facilitating its PM detection. However, the same conclusion could not be drawn for
morphine.
Morphine’s elimination half-life varies from 1.3 to 6.7 hours. Based on this, the
expected PM morphine concentrations would have been between 76.2 – 166.7 ng/mL.
Both HTBL and ILBL concentrations fell within this range, suggesting that metabolism
occurred as expected. Therefore, based on this information it would appear as though
PMR was not present. However, the value calculated for the central to peripheral blood
ratio did exceed 1.0, thereby suggesting the presence of PMR. In a situation when
calculated values used to indicate PMR disagree, it can be difficult to determine if it
actually occurred or not. However, in this case, the PM concentrations were within their
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expected concentration range; therefore, the researcher determined that PMR was not a
factor in this case.
Antemortem blood for MOC 02 was collected 5 hours before death. Antemortem
codeine concentration equaled 25 ng/mL, while morphine was detected below the LOQ
(10 ng/mL by Agilent 5890 GC/MS system). Postmortem mixed blood samples (PMI =
19 hours) were submitted for analysis in both red-top and gray-top tubes. Both tubes
were analyzed (on the same day as the antemortem) and both detected 30 ng/mL of
morphine. Codeine was not detected in either PM tube. Since the PM results were
identical and of the same source, the results were combined into one averaged value. The
elimination half-life for codeine ranges between 1.9 - 3.9 hours. As a result, the expected
codeine concentration after five hours of metabolism would have between 4.010.3ng/mL. The upper limit of the expected range would have just been equal to the
LOD and the LOQ for the GC-SIM/MS method. When interpreting the PM data, it
appears as though codeine was extensively metabolized into morphine during the AMD
interval. This resulted in both the lack of codeine detection and the increase of morphine
in the PM sample (relative to the AMBL sample).
Those cases whose antemortem samples were collected within one elimination
half-life illustrated many different considerations when trying to interpret toxicological
data. For example, when AM blood is collected more than a few minutes before death,
drug metabolism can change both the content of the drugs detected as well as their
concentrations. This was illustrated in MOC 02 when the AM sample (collected 5 hours
before death) had a quantifiable amount of codeine. However, PM analysis was negative
for codeine and had increased levels of morphine.
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Similarly, during the metabolic

process some drugs sequester themselves in organs. In these situations, AM blood results
can be negative, but PM analysis can give a positive result. Morphine/ codeine case 05
and 08 were examples of this.

In both cases, only morphine was present in the

antemortem samples. However, upon PM analysis, both morphine and codeine were
detected in quantifiable amounts. Additionally, in both of these cases, the PM morphine
concentrations fell within their expected concentration ranges, indicating a lack of PMR.
This illustrates that, while under the same conditions two drugs can respond differently.
While codeine was sequestered and released after death, morphine was eliminated at a
predictable rate.
In MOC 03, both morphine and codeine were quantified in the AM blood.
Postmortem submission included aorta and chest blood samples. Both PM samples
contained morphine with concentrations at least three times greater than that of the AM,
as well as codeine, which had 10 times greater than the AM sample. Since two hours
elapsed between AM collection and death, it would be expected that the concentrations of
morphine and codeine would have decreased. Instead the increased amount of drugs led
to PM:AM ratios of 3.0 and 10.7 for morphine and codeine, respectively in the aorta
blood. While, the chest blood sample had PM:AM ratios of 4.2 and 21.5 for morphine
and codeine, respectively. Chest blood concentrations of morphine and codeine exceeded
those of the other two specimens (morphine by > 25% and codeine by > 98%). This was
probably due to the contamination present in a pooled blood sample taken from the chest
cavity. Such a sample is predisposed to redistribution of drugs being released from any
of the organs present within the chest cavity. In this case, there was a 47 hour PMI which
would be ample time for the process of PM release and redistribution to occur.
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In cases where it has been determined that postmortem redistribution was a factor,
two important considerations are needed.

First, the length of the PMI should be

considered. Secondly, identification of the major source of contamination that led to the
redistribution. Morphine/ codeine 03 was a case where PMR was present in both the
aorta and chest blood samples. The collection of the PM samples was 47 hours after
death. During this time, the codeine concentration from the chest blood sample was
almost twice that of the aorta blood. The significantly increased amount of codeine in the
chest may suggest that the main source of contamination for this sample came from the
stomach. The stomach holds un-metabolized drugs and is anatomically positioned within
close proximity to the chest cavity. Additionally, the concentration of codeine in the
aorta blood was more than 11 times greater than was detected in the AM blood sample.
While the aorta blood also had a significant amount of PMR, it is not located close
enough to the stomach to have been contaminated by it directly. Instead, the aorta was
likely contaminated by the lungs, as well as the pooled chest blood. Based on the data,
the chest blood had a more significant contamination than the lungs.
Finally, testing more than one sample matrix can give additional information to
aid in the interpretive process. In the case of MOC 12, for example, blood as well as
urine samples were tested. While urine is only used for qualitative purposes, it was the
only sample in which heroin was detected. Although the extremely high morphine
concentration would be indicative of heroin usage, actually identifying heroin in the urine
eliminated the need to infer its role in this case. Morphine/ codeine case 12 is a good
example of how gathering as much data as possible (toxicological, as well as social and
medical history) can aid in the interpretative process.
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The following cases had antemortem blood collected greater than or equal to 2
elimination half-lives before death (Table 10). While their AM sample collection times
are not the most ideal, they still offer quantitative information of value. The AM blood
for MOC 09 was collected 6.5 hours before death.

The sample had a codeine

concentration of 48 ng/mL, however morphine was not detected. Postmortem aorta and
iliac vein bloods were also submitted for analyses.

Codeine concentrations were

determined to be 34 ng/mL and 27 ng/mL for aorta blood and iliac vein blood,
respectively. Statistical analyses determined that the CV range for codeine in the AOBL
was 30.6 – 37.4 ng/mL. The range for the ILBL sample was between 24.3 – 29.7 ng/mL.
Therefore, although the range values were close, ultimately the AOBL and ILBL
concentrations are dis-similar to each other. Additionally, as with the AM sample neither
postmortem sample detected the presence of morphine.
equaled 1.2, suggesting PMR.

The C:P ratio for codeine

However, both PM:AM ratios were less than 1.0

(AOBL:AM = 0.68; ILBL:AM = 0.54), which would indicate a lack of PMR. The
expected concentration range of codeine would have been between 4.5 – 15.1 ng/mL.
The concentrations of both PM samples exceeded this range.

Therefore, it can be

determined that while the drug continued to metabolize and decrease in concentration
during the 6.5 hours between AM collection and death, during the 33.5 hour PMI drug
redistribution did occur. This, thereby, resulted in elevated PM sample concentrations.
Morphine/ codeine case 11 had antemortem concentrations of 92 ng/mL and
17ng/mL for morphine and codeine, respectively. The AM sample was collected 10
hours prior to death. As a result, the expected PM morphine concentrations would range
between 0.65 – 32.7 ng/mL, with codeine ranging from 0.4 – 2.9 ng/mL. Mixed heart as
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well as inferior vena cava bloods was submitted for PM analyses. Nine and a half
nanograms per milliliter of morphine were detected in the mixed heart sample, while
8ng/mL was detected in the IVC blood. These concentrations were determined to be
statistically similar. Codeine was not detected in either PM sample. The lack of codeine
was consistent with the expected concentration range, as the values obtained there were
below both the LOD (3 ng/mL) and LOQ (5 ng/mL) of the GC/MS/MS analysis.
However, the morphine concentration detected fell within its expected range. Therefore,
there is no reason to believe that PMR affected this case.
The antemortem blood submitted for MOC 06 was negative for morphine and
codeine. However, the antemortem urine sample was positive for morphine. As a result,
the PM blood was analyzed by the researcher to determine if morphine or codeine could
be detected. The postmortem blood submission consisted of both aorta and iliac vein
blood samples. Morphine concentrations of 17 ng/mL for both AOBL and ILBL samples
were detected. Codeine had concentrations of 25 ng/mL and 27 ng/mL in aorta and iliac
vein bloods, respectively. These samples were analyzed by SIM GC/MS and had a LOD/
LOQ of 10 ng/mL. Therefore, if morphine and codeine were present in the AM sample,
their concentrations would have been below 10 ng/mL. As a result, the detection of
morphine and codeine in both PM samples was indicative of increased concentrations for
both drugs. This would suggest that during the 48 hour PMI, PMR occurred.
Morphine/ codeine case 15 had an AM blood sample collected 12 hours before
death.

The AMBL had a morphine concentration of 98 ng/mL.

Based on this

information the expected morphine concentration would be between 0.3 – 28.9 ng/mL.
Heart blood was submitted for PM analysis in both red-top and gray-top tubes. Red-top
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Table 10: Morphine, Codeine and Heroin Antemortem samples collected after 2 elimination half-lives
Heroin t1/2 = 2-6 minutes
6-MAM t1/2 = 2- 25 minutes
Morphine t1/2 = 1.4 – 6.7 hours; Vd = 2-5 L/ kg
Codeine t1/2 = 1.9 – 3.9 hours; Vd = 3.5 L/kg

AM –Death
(hours)

Case#

6.5

Source
(whole blood)

Concentration
(ng/mL)

MOC
091

Aorta

codeine 34

Iliac

codeine 27

10

MOC
112

Mix heart

morphine 9.5

IVC

morphine 8

< 10

MOC
061

Aorta

morphine 17
codeine 25

Iliac

morphine 17
codeine 27

12

MOC
152

Heart*

morphine 156

≤ 20

MOC
041

Mix heart

24

MOC
101

Heart

< 24

MOC
011

IVC

Heart
Aorta
Iliac

morphine 1,170
codeine 10
morphine 111
codeine 9.5
morphine 20.5
codeine 14
morphine 17
codeine 14
morphine 403
codeine 35
morphine 2,185
codeine 72

AM
concentration
(ng/mL)
48 codeine
92 morphine
17 codeine

NDD3

98 morphine
298 morphine

Detected4

226 morphine
32 codeine
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Analyte

PM:AM

C:P

PMI
(hours)

Sex

Age

CO
CO

0.7
0.6

1.2

33.5

BM

38

MO

0.1

MO
MO
CO
MO
CO
MO
MO

0.1
1.5
1.7

-

19.5

WF

34

1.0
0.9

48

WM

41

-

23

WF

62

MO

3.9

MO

0.4

-

34

BF

65

MO/CO

-

MO/CO

-

-

31.5

WM

39

MO
CO
MO
CO

1.8
1.1
9.7
2.2

0.2
0.5

20

BM

40

AM –Death
(hours)

Case#

unknown

MOC
071

Source
(whole blood)
Iliac
Iliac

Concentration
(ng/mL)
morphine 33.5
codeine 81
morphine 30.5
codeine 42.5

AM
concentration
(ng/mL)
10 codeine

Analyte

PM:AM

CO

8.1

CO

4.2

Morphine = MO
Codeine = CO
1
GC/MS linear range 10-1,000 ng/mL
2
GC/MS2 linear range 5-1,000 ng/mL

AM blood was negative, but qualitative screen of urine was positive for morphine
Sample quantity only sufficient for blood drug screen, not quantitation

3

4

* Average concentration

Table10, continued
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C:P

PMI
(hours)

Sex

Age

-

46.5

WF

43

morphine concentration was 149 ng/mL, while the gray-top equaled 164 ng/mL.
Statistical analysis determined the PM morphine concentrations were similar. Since these
samples were statistically similar and of the same source their morphine concentrations
were averaged to equal 156 ng/mL. The PM results not only exceed their expected range,
they also surpassed the AM concentration, resulting in a HTBL:AM ratio of 1.6. The
data supports the idea that PMR occurred during the 23 hour postmortem interval.
Antemortem blood for MOC 04 had 298 ng/mL of morphine present. Codeine
was not detected in the sample. The AM tube did not indicate the time of collection;
therefore, the exact time between the AM collection and death was not known. However,
based on the hospital records the decedent was in the hospital for 20 hours before death,
therefore the AM sample would have been collected within the same time frame. When
using 20 hours as the time between AM collection and death, the expected morphine
concentration at the time of death would have been between 0.15 – 37.7 ng/mL.
Postmortem mixed heart (MXHT) and IVC bloods were submitted for analyses. The
MXHT blood sample had 1,170 ng/mL of morphine and 10 ng/mL of codeine. One
hundred - eleven nanograms per milliliter of morphine and 9.5 ng/mL of codeine were
detected in the IVC blood sample. Both PM morphine concentrations exceeded their
expected ranges. Morphine PM:AM ratios were calculated to be 3.9 and 0.37 for mixed
heart and IVC bloods, respectively. Codeine, which was not detected in the AM sample,
was present in both PM samples, near the LOQ of 10 ng/mL (GC- SIM/MS) detection.
The increased codeine concentration did suggest PMR of codeine. While the ratio data
for morphine in the MXHT sample was indicative of PMR, it’s concentration in the IVC
BL sample did not. However, both PM morphine concentrations exceeded the calculated
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concentration at the time of death. Therefore, the researcher determined that both PM
morphine values were a result of PMR.
The volume of AM blood submitted for MOC 10 was only sufficient for
morphine identification (codeine was not detected) in a routine blood screen. Before
quantitative analysis could be conducted, the sample was depleted. Heart blood was
submitted in both gray-top and red-top tubes.

Analysis of the RT tube detected

20.5ng/mL of morphine and 14 ng/mL of codeine. Gray-top tube analysis detected 17
ng/mL of morphine and 14 ng/mL of codeine. Since morphine was not quantitated in the
AM sample, it is not known how the 31.5 hour PMI affected the sample concentration, if
at all.

The emergence of codeine in the PM does suggest PMR for that drug.

Additionally, the consistent drug concentrations between the two tubes shows how
similar results can be obtained when a sample is properly homogenized with the
antimicrobial agent present within the tubes.
Morphine/codeine 01 had antemortem concentrations of 226 ng/mL and 32 ng/mL
for morphine and codeine, respectively. As a result, the expected concentration range for
morphine was 0.001 – 18.9 ng/mL, while codeine was 0.005 – 0.45 ng/mL by GC/MS
(LOD and LOQ = 10 ng/mL). Postmortem analysis was conducted on aorta and iliac
vein blood samples. The aorta blood had concentrations of 403 ng/mL of morphine and
35 ng/mL of codeine. The iliac vein blood sample had a morphine concentration of
2,185ng/mL and codeine of 72 ng/mL. The PM concentrations of both morphine and
codeine exceeded the antemortem concentrations and calculated concentration ranges at
the time of death. Aorta blood to AM ratio equaled 1.8 and 1.1 for morphine and
codeine, respectively. The iliac blood to AM ratio equaled 9.7 and 2.25 for morphine and
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codeine, respectively. All of the PM:AM ratios were consistent with PMR being a factor
in this case. However, since the iliac vein blood had higher concentrations than the aorta
blood, the C:P ratios for both morphine and codeine were below 1.0. Regardless, the
increased PM concentrations were enough evidence to support the possibility of PMR
being present within this case.
Alternatively, while heroin was not detected in MOC 01’s biological samples, the
significant difference between morphine and codeine blood concentrations for MOC 01
suggested the possibility of heroin usage. A review of the circumstances surrounding the
decedent’s death indicated that his body was found with a syringe in close proximity. If
heroin was injected in the leg or foot area, this would account for the elevated morphine
concentration in the iliac vein blood as compared to the aorta blood. Under those
circumstances, heroin would have metabolized out of the blood stream, but morphine and
codeine remained. If this were true, then incomplete drug distribution, not PMR, was the
reason for the concentration differences.
Ten nanograms per milliliter of codeine were detected in the AM sample
collected for MOC 07. In this case, the exact time of the AM sample before death was
unknown.

Based on the medical records obtained by the MDME Department, the

decedent was hospitalized for three days before her death. Postmortem iliac vein blood
was submitted in both gray-top and red-top tubes for analyses. The RT sample had
morphine and codeine concentrations of 35.5 and 81 ng/mL, respectively. The GT
sample had 30.5 ng/mL of morphine and 42.5 ng/mL of codeine detected.

Since

morphine is a metabolite of codeine, its presence in the PM samples and absence in the
AM sample, may suggest that metabolism continued between the time of AM sample
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collection and death. However, since both morphine and codeine concentrations were
elevated in the PM samples, it is also likely the PMR occurred for both drugs. The
inconsistent codeine concentration within the RT and GT iliac vein blood samples could
be indicative of two separate blood draws. In instances such as this, one draw will be
used to fill the red-top tube (which can hold up to 50 mL of blood), while a second draw
can be used to fill the gray-top tube (10 mL total volume). If two draws occurred, then it
is possible that the blood was drawn from two different regions of the iliac vein, which
resulted in the significant codeine concentration discrepancy between the two tubes.
Those cases whose antemortem collection were greater than or equal to two
elimination half-lives add value to this section by highlighting the importance of time. In
the time between antemortem blood draw and death, drug concentration and
identification can be altered. In morphine/codeine case 09, the 6.5 hour interval between
AM and death was sufficient time for codeine (which was detected in both the AM and
PM samples) to metabolize, resulting in a lower concentration.

While the PM

concentration did decrease, it still exceeded its expected concentration range, which was
believed to be due the PMR that occurred during the 33.5 hour PMI.
In comparison, morphine/codeine case 11 had AM samples collected 10 hours
before death, but had a PMI of 19.5 hours. Therefore, the time difference between AM to
death increased, but the PMI decreased when comparing it to MOC 09. In MOC 11, both
morphine and codeine were detected in the AM, but only morphine in the PM sample. It
is believed that in this case, codeine metabolized to concentrations below that of
detection. Morphine decreased as well, to a concentration that would be expected of a
drug that metabolized in a linear fashion.
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While it cannot be said for certain, the

differences in PMI (14 hours) may have made the difference in these two cases. If the
PMI of MOC 09 had been shorter or the PMI of MOC 11 had been longer, the results
may not have been the same.
Morphine/codeine 06 had an extended PMI of 48 hours. In this case, neither
morphine nor codeine was detected in the AM sample.

However, they were both

detected in the PM samples. This suggests that PMR was a factor here and the PMI may
have contributed to this. This was also seen in MOC 04 where only morphine was
detected in the AMBL, but both morphine and codeine were detected in the PM blood
samples (PMI = 34 hours).
Morphine/codeine 04 was also of interest because it illustrated the significant
concentration differences that can be present within different sourced PM blood samples.
In this case, a mixed heart sample had a 10 fold increase in morphine concentration over
the IVC BL sample. The mixed heart sample, which was blood collected from more than
one unspecified region of the heart, is susceptible to contamination from both the liver
and the lungs. The inferior vena cava blood is typically drawn from the lower abdominal
region of the body (52). While both samples are considered central sourced blood, their
anatomical location can result in very different drug concentrations.
Morphine/codeine 01 was of interest because the peripheral source blood (ILBL)
greatly exceeded the concentration of both the aorta and antemortem bloods. The reason
for this large increase cannot be definitively determined. Based on the other MOC cases
examined here, there is no reason to believe that the 20 hour PMI was sufficient to cause
such a great concentration inconsistency. While it is understood that drug concentrations
do not always respond in a predictable manner, it would seem that this case would be an
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exception to the rule.

An alternative explanation would suggest that the drug was

injected intravenously into the leg or foot region of the body. This would account for the
significantly higher morphine concentration found in the iliac vein blood.
An additional factor in blood concentration, regardless of half-life time intervals
would be the anatomic location of blood draws. In MOC 07, iliac vein blood was
submitted in both blood collection tubes. In situations like this, it is expected that blood
concentrations from either tube would be comparable to each other.

However, the

codeine concentration in the red-top tube was almost twice that of the gray-top. This
could have suggested that the blood drawn from both tubes were either collected from
different regions of the same iliac vein or collected from different iliac veins all together
(i.e. left and right leg veins). Either scenario is plausible, as the sample volume from the
iliac vein is relatively limited. Similarly, the HTBL sample submitted in both RT and GT
tubes for MOC 10 had a morphine concentration discrepancy. While the difference in the
drug concentration seen here was < 20%, it was greater than the significance limit (±
10%). This shows that even a relatively abundant source of blood (as compared to the
iliac vein) may not offer a homogenous sample. Conversely, since the morphine heart
blood concentrations for MOC 10 were statistically similar (± 9.1% by GC/MS) the
results were averaged. The data produced by these three cases indicates that while one
would like to believe that same source samples collected at the same time would render
statistically similar results, it is definitely not guaranteed.
And finally, a debatable issue in PM toxicology is whether or not peripheral blood
sources most closely resemble the blood drug concentration around the time of death.
Chart 3 displays the peripheral results for both morphine and codeine. Each chart also
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displays the calculated expected concentration range, denoted with the symbol “[” for
morphine and “]” for codeine.

In MOC 01, the morphine sample concentration

(2,185ng/mL) was not fully displayed, as it would have made it difficult to see the results
of the cases with the lower concentrations. Additionally, MOC 06 did not have an
expected range because morphine was not detected in the AM sample. Likewise, MOC
cases 14, 08 and 06 did not have expected codeine ranges, as codeine was not identified
in their respective AM samples. Also, MOC 07 has two codeine results displayed. This
was because codeine was detected in both RT and GT tubes; however, their
concentrations were not similar enough to be averaged into one. As a result, the data
from both tubes is represented.
Of the cases that had calculated expected ranges, only one (MOC 08) had its
morphine concentration within the expected range. The other cases, whether it be for
morphine or codeine, had peripheral concentrations that significantly exceeded their
expected values. This indicated that for morphine and codeine cases, peripheral blood
results are not likely to be reflective of perimortem blood concentrations.
One additional note of interest was how the central and peripheral blood
concentrations compared to each other. Chart 4 and Chart 5 show the central versus
peripheral data for morphine and codeine, respectively. Again, the peripheral morphine
concentration for MOC 01 was truncated so that the data from the other cases would be
visible. When examining the morphine data, only MOC 06 had central and peripheral
data that rendered statistically similar results. Of the five codeine cases, only MOC 08
and MOC 06 had statistically similar intra-case central and peripheral results. Among the
remaining dis-similar results, 66% of the morphine cases had higher central sourced
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Chart 3: Morphine and Codeine Peripheral Data
Morphine

Codeine

Codeine2
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100
50
0
MOC 14

MOC 08

MOC 09

MOC 06

MOC 01

Comparison of the peripheral concentrations to the expected
concentration range at the time of death
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MOC 07

Chart 4: Morphine Central versus Peripheral Data
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Chart 5: Codeine Central versus Peripheral Data
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MOC 06
MOC
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MOC 01
MOC
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concentrations, while 66% of codeine did as well. Based on this data, it would appear
that among statistically dis-similar data, peripheral blood results would likely offer drug
concentrations with fewer instances of increase. However, as indicated by Chart 3,
peripheral blood results still may not render drug concentrations that are indicative of
drug levels in the body at the time of death.
6.1.2 Methadone
Methadone, which is often used for the treatment of opioid addiction, is a
synthetic opioid whose plasma half-life ranges from 15 to 55 hours (42). It has an
apparent volume of distribution (Vd) of 4 -5 L/kg (42). In total, six cases were examined
in order to establish a drug concentration trend between antemortem and postmortem
samples. This section was divided into two parts, with both sections listing the cases in
order of increasing antemortem to death interval, as opposed to case number. The first
section encompasses those cases whose AM samples were collected within one
elimination half-life (Table 13). The second data set includes those cases where the AM
blood was collected longer than one elimination half-life before death (Table 14). As
discussed in section 1.4.3, half lives measure the amount of time needed for an ingested
substance to be removed from the system. With each half-life accounting for a 50%
decrease in concentration, it is estimated that at the end of five to six half-lives, the body
will rid itself of a drug in its entirety. Depending on the administered concentration and
the detection limits of an instrument, methadone taken within 4 half-lives (60 – 220 hrs)
of death, could still be present at detectable, if not quantifiable concentrations.
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Methadone analysis was conducted solely on GC/NPD.

All samples were

prepared as discussed in Section 4.3 Basic Drugs: Quantitative Blood Analysis by
GC/NPD. The controls, which were run thirty-one times, had two lot numbers. A oneway ANOVA (α = 0.05) was conducted on the two lots to determine if the data produced
within them was statistically similar. The summary results shown in Table 11 give the
breakdown information (including control averages and variances) for each lot. The
ANOVA results (Table 12) give an F-test value of 1.28 and an Fcrit of 4.18. Since F is
less than Fcrit, the two lots were determined to be statistically similar, resulting in the
methadone data being treated as one population. The percent error (CV) was calculated
to be 12.52%. Therefore, only drug concentrations that differ beyond that percentage
were considered significantly different.
Antemortem serum and postmortem iliac vein blood were received for MDN 04.
Initial laboratory analysis determined that the AM serum (collected 45 minutes before
death) was negative for methadone. Postmortem analysis conducted by the researcher
determined that methadone was present in the iliac vein blood samples. Iliac vein blood
received in both vacutainer and red-top polypropylene tubes were positive for methadone,
each with a concentration of 0.1 mg/L. Since the PM samples were of the same source,
their concentrations were averaged (average = 0.1 mg/L). In this case, the methadone
was self administered (as opposed to being given in the hospital). Based on the low PM
concentrations, it can be inferred that either a small dose of methadone was ingested
shortly before death (less than 48 hours) or a larger dose was taken more than 48 hours
before death. In either instance, the absence of methadone in the AM sample and
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Table 11: One-Way ANOVA Summary Results for Methadone Controls (0.50 mg/L)
n=31
Groups
Lot 1
Lot 2

Table 12: One-Way

Source of
Variation
Between Lots

Sum of
Squares
0.003

Count
14
17

Sum
6.80
8.60

Average Variance
0.48
0.003457
0.50
0.001563

ANOVA Results for Methadone Controls
95% Confidence Limit
df
1

Mean
Square
0.003

F-test
value
1.28

P-value

F crit

0.266

4.18

 If F > F critical, then results are significantly different
 If F < F critical, then results are similar
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quantifiable presence of it in the PM samples, suggested the presence of PMR (PMI=28.5
hours).
Methadone (MDN) case 01 was received with antemortem blood collected eight
hours before death and a postmortem interval (PMI) of 23 hours. The AM sample had a
methadone concentration of 0.26 mg/L. Postmortem specimens including central (mixed
heart) and peripheral (iliac vein) blood sources, had concentrations of 0.53 mg/L and
0.58mg/L, respectively. When using Equation 7, the expected concentration range at the
time of death would have been between 0.19 mg/L to 0.24 mg/L. However, the results
determined by PM analysis were more than twice that. A review of the medical records
for this case did not indicate any additional methadone dosing after the time of AM
collection to account for the increase in drug concentration detected in the PM samples.
An 8 hour AMD interval, as seen in MDN 01, is less than the minimum amount of
time needed for one elimination half-life (15 hours). However, metabolism was still
occurring. Therefore, the drug concentrations detected in the PM samples should have
been lower than the AMBL concentration. Instead, the PM concentrations showed a
substantial increase.

The increased PM blood concentrations suggested postmortem

release of methadone from the tissues that surrounded the blood collection sites at
autopsy. The ratio of mixed heart:AM was 2.0 and iliac vein:AM was 2.2. Additionally,
the mixed heart:iliac vein ratio was calculated to be 0.9.

Independent studies have

demonstrated (19)(20)(21) that central, rather than peripheral, blood sources are more
susceptible to PMR. Because of this, it is often believed that peripheral blood sources
offer more reliable data than central sources. However, in this case, less than 10%
separated the concentration of the two sources. The central (0.53 mg/L) and peripheral
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(0.58 mg/L) concentrations were statistically similar, indicating that both sources were
equally susceptible to the PM redistributive effect.
The decedent in MDN 05 died during a surgical procedure. Upon admission into
the hospital he acknowledged his use of cocaine and heroin. The hospital released the
AM blood collected prior to surgery to the Medical Examiner’s Department. Analyses
detected the presence of hospital administered medications (e.g. phenobarbital and
lidocaine), as well as non-hospital administered drugs such as cocaine, benzoylecgonine
(a major metabolite of cocaine), morphine (a metabolite of heroin, as well as a prescribed
pain medication) and hydromorphone. Unfortunately, by the end of this testing, there
was not enough AM blood remaining to test for the presence of methadone. Laboratory
testing did include a urine analysis (qualitative screen), which was positive for
methadone. Subsequent quantitative analysis by the laboratory was conducted on PM
blood in lieu of AM blood.
Routine laboratory analysis of the chest blood submitted for MDN 05 (PMI = 16
hours) detected 0.26 mg/L of methadone. Medical records indicated that methadone was
administered by the hospital 2.5 hours before death. One month after routine laboratory
testing, the researcher re-analyzed both postmortem chest blood tubes (red and gray).
Each had a concentration of 0.25 mg/L, since the PM samples were of the same source
their concentrations were averaged (0.25 mg/L). The lack of AM testing meant that this
case could not be evaluated for differences between AM and PM drug concentrations;
however it is an example of another goal of the project. While it is understood that one
sample is not a relevant population, the re-analysis suggested that when a preserved
methadone sample is stored in refrigeration for 30 days, degradation may not be a factor.
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Drug stability is an important variable to consider when trying interpreting the meaning
of toxicological data.
Methadone (MDN) 02 was submitted for laboratory testing with AM blood
collected 12 hours before death. The postmortem submission consisted of both aorta and
iliac vein bloods (PMI= 54 hours).

Routine analysis determined that the AM

concentration of methadone was 2.3 mg/L. Subsequent analysis of the PM samples
determined concentrations of 5.32 mg/L and 4.62 mg/L for the aorta (AOBL) and iliac
vein (ILBL) bloods, respectively. The linear range of methadone for this project was
from 0.1 – 1.0 mg/L. Therefore, the samples were diluted to bring their concentrations
within the appropriate range. The decedent had a history of opiate abuse (specifically,
heroin and morphine).

However, none of the records available to the researcher

suggested that the decedent was receiving methadone treatment to help alleviate the
withdrawal symptoms associated with opiate addiction. Typically people receiving such
treatment are given daily doses ranging from 100 – 200 mg (42). Studies have shown
that when following this dosing regimen, the average peak plasma concentration is
0.83mg/L (42). The concentrations encountered in MDN 02, well exceeded this level.
Based upon the AM concentration of 2.3 mg/L, the expected concentration range at the
time of death would have been between 1.38 – 2.05 mg/L. The calculated ratios of
AOBL:AM and ILBL:AM was 2.3 and 2.0, respectively. The central to peripheral ratio
of AOBL:ILBL equaled 1.1. All three of the ratio calculations were greater than 1.0,
suggesting that PMR occurred during the 54 hour PMI. However, while the aorta blood
appeared to receive a larger redistribution effect than the iliac vein blood, the differences
in their concentrations were not statistically significant. The significant range for the
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Table 13: Methadone Antemortem samples collected within one elimination half-life
t1/2 = 15 – 55 hours
Vd = 4 – 5 L/ kg
CV = 12.5%
Linear range: 0.1 – 1.0 mg/L

Case #

Source
(Whole blood)

Concentration
(mg/L)

AM
Concentration
(mg/L)

45 min

MDN 04

Iliac*

0.10

Not detected

8 hrs

MDN 01

Mixed heart
Iliac

0.53
0.58

0.26

12 hrs

MDN 05

Chest*

0.25

0.26

12 hrs

MDN 02

Aorta
Iliac

5.32
4.62

2.3

AMDeath

1

Quantity not sufficient for antemortem quantitation
*Average concentration
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Specimen
AM
Blood
AM
Blood
PM1
Blood
AM
Blood

PM:
AM

C: P

PMI
(hours)

Race/Sex

Age

-

-

28.5

WM

44

2.0
2.2

0.91

23

0.96

-

16

2.3
2.0

1.1

54

WM
WM
WM

33
38
68

AOBL was 4.65 – 5.98 mg/L, while ILBL was 4.04 – 5.20 mg/L. The critical ranges for
the two samples overlap, indicating that they are not statistically different.
When comparing these four cases, there were a few observations to note. First,
methadone concentrations were stable regardless of the collection tube. In MDN 05 chest
blood was collected in both tubes, while MDN 04 had iliac vein blood in both tubes.
Regardless of the anatomical source or collection tube, the blood drug concentration of
methadone was stable when stored under the same conditions.
Additionally by convention, toxicologists prefer to use peripheral blood for
quantitative analysis. Out of the four cases examined, two (MDN 01 and MDN 02) were
received with both central and peripheral blood. Both MDN 01 and 02 were affected by
PMR and their intra-sample results were statistically similar. This meant, that despite the
region of anatomical collection, the PM results returned analogous results. While there
are not enough cases available to make any absolute decisions, it would appear that
regardless of the PMI (MDN 01 = 23 hrs., MDN 02 = 54 hrs.), PMR of methadone can
affect central and peripheral blood sources similarly.
Finally, the overall data collected from these four cases illustrated that AM
methadone concentrations are consistently lower than their PM counterparts. This trend
was observed in all of the quantifiable data produced.
Included in the second part of this section are two methadone cases (Table 14).
One case had an AM collection of 72 hours before death. While this amount of time may
seem significant, in actuality it is within two elimination half-lives of methadone. As a
result, it is reasonable to believe that PM drug analysis could still be positive for
methadone. The second case had an AM collection of 20 hours after death. Blood
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samples can be collected after brain death for patients who are being maintained
artificially for the purpose of organ donation.
The decedent in MDN 03 was found unresponsive at home by a family member.
He had a history of heart disease and heroin addiction. He sought out treatment for his
addiction and was prescribed a methadone treatment regimen of 80 milligrams per day.
The hospital submitted AM Blood collected 72 hours prior to his death.

The AM

methadone concentration was 0.7 mg/L, resulting in an expected concentration range at
the time of death of 0.02 – 0.28 mg/L. Postmortem analysis (PMI = 24.5 hours) detected
methadone concentrations of 1.06 and 0.51 mg/L for aorta and inferior vena cava (IVC)
bloods, respectively. While both AOBL and IVC BL are commonly considered central
sourced bloods, the data they produced were statistically significantly different.

In

situations like this, it becomes increasingly important to identify the actual region of
collection for the IVC BL.
The inferior vena cava is the largest vein in the body. It begins at the joining of
the common iliac vein and continues to the right atrium, where it delivers deoxygenated
blood (53). Contamination of the IVC, depends greatly upon the region of collection.
Conversely, the aorta’s primary function is to distribute oxygenated blood away from the
heart and to the other tissues of the body. The aorta is comprised of three continuous
parts (ascending, arch and descending components), which based on its location can
receive direct contamination from both lungs, as well as the pulmonary artery. Upon
investigating the source of the IVC BL, it was explained that at the MDME Department,
IVC blood is collected from the lower abdominal region of the body (52). This means
that the IVC BL is peripherally located in comparison the AOBL. When examining the
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data, the AOBL:AM ratio equaled 1.5, while the IVC BL:AM ratio equaled 0.73.
According to this ratio data, no PMR was observed in the IVC BL sample. However, the
AOBL ratio of 1.5 was indicative of PMR. These results do follow the conventional idea
that more centrally located blood specimens are more susceptible to PMR.
The decedent in methadone 06 was an organ donor; whose AM sample was
collected 20 hours after brain death (refer to section 1.6.5). Upon analysis, the AM blood
was negative of methadone. The postmortem aorta and iliac vein bloods however had
methadone concentrations of 0.15 mg/L and 0.10 mg/L, respectively. With a methadone
CV of 12.52% the critical ranges for the AOBL and ILBL concentrations were 0.13 –
0.17 mg/L and 0.09 – 0.11 mg/L, respectively thereby making these concentrations
statistically dis-similar. The AOBL:ILBL ratio equaled 1.5. The ratio data suggested
that during the 31.5 hour postmortem interval, drug redistribution occurred.

This

redistribution effect was more pronounced in the aorta blood, rather than iliac vein blood.
The ratio data, along with the lack of drug detection in the AM sample, but its presence in
both PM samples indicated that PMR was a factor in this case.
When examining all six cases as a whole it became apparent that the methadone
data could have been grouped as it was (by increasing antemortem to death interval) or
based upon their blood collection sites. Three of the cases examined were submitted with
both peripheral and central blood, plus the addition of MDN 03, which had a more
peripherally located IVC BL and the more centrally located AOBL, as well. One case
came with central blood only. Typically blood collected from the central vessels is more
abundant than that available from the periphery. For that reason, it is not unusual to
receive more central only, rather than peripheral only cases. Of the three cases with both
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Table 14: Methadone Antemortem samples collected after one elimination half-life
t1/2 = 15 – 55 hours
Vd = 4 – 5 L/kg
CV = 12.5%
Linear range: 0.1 -1.0 mg/L

AM Death

Case #

Source
(whole blood)

Concentration
(mg/L)

Aorta
0.15
Iliac
0.10
Aorta
1.06
MDN
3 days
Inf. Vena
03
0.51
Cava
1
AFTER denotes collection time after brain death

20 hrs
AFTER1

MDN
06

AM
concentration
(mg/L)

Specimen

PM:AM

Not detected

AM
Blood

0.7

AM
Blood

1.5

100

0.7

C:P

PMI
(hours)

Age

Race/Sex

1.5

31.5

38

BM

-

24.5

60

WM

central and peripheral sources, all four had higher PM, rather than AM concentrations.
Among those PM concentrations the two cases whose AMD interval exceeded one
elimination half-life not only had intra-sample concentrations significantly different from
each other, but they also had higher central sourced blood concentrations.

Neither of

these factors was observed in the cases collected within one elimination half-life.
Those cases submitted with central only bloods (as well as the lone case of
peripheral only blood) had PM concentrations much higher than their AM counterparts.
The combined effect of all the data showed that regardless of the AMD interval or the
PM interval, PMR of methadone can occur. However, the data trend suggested that those
AM samples that were collected within one elimination half-life before death could have
had a PM redistributive effect that influenced two anatomically different PM sources
similarly.

This was reiterated by the lack of statistically different concentrations

obtained in those cases that had both central and peripheral blood collected. In most
instances PM concentrations can greatly exceed both the AM concentration and the
expected concentration range at the time of death, as long as the autopsy is conducted in
less than 54 hours, it may not matter which PM sample is used for quantitation.

6.2 Diphenhydramine
Diphenhydramine is classified as an antihistamine, but has a much wider array of
applications. It does relieve allergy related symptoms (e.g. itchy, irritated, watery eyes
and sneezing) (54) but is often also utilized for its sedative and antiemetic properties.
Over-the-counter formulations of diphenhydramine can range in concentration from 10 –
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50 mg doses and are obtained as elixirs, pills or creams (55). In high doses (≥ 300 mg) it
has been known to produce psychoactive delusions. This, in combination with its ease of
accessibility, has made this drug particularly appealing to adolescents (56).
During the course of this project, three separate diphenhydramine controls
(concentration = 0.5 mg/L; each with their own lot numbers) were made. The control
values produced for each lot were analyzed using a one-way ANOVA (α = 0.05) to
determine if a significant variation existed among the collected data. The summary data,
produced by Microsoft Excel, displayed in Table 15 shows the average concentrations, as
well as the amount of variance present within each lot. The ANOVA results in Table 16
gave an F-test value of 2.39 and a critical F (Fcrit) value of 3.24. Since F < Fcrit the data
produced by the 3 lots was considered statistically similar, which allowed the data was
treated as one population. Equation 5 was used to calculate the coefficient of variation
for the total population.

This value was determined to be 15%.

Therefore, any

quantitative diphenhydramine case data that fell within a ± 15% range was considered
similar. Data that exceeded these limits were considered dis-similar.
On average it takes diphenhydramine 3–14 hours for one elimination half-life to
occur. The twelve cases that are presented here were separated into two sections. The
first encompasses those cases whose antemortem bloods were collected within two
elimination half-lives before death (Table 17). While the second section, includes those
cases that exceed this limit (Table 18). In both sections, the cases were evaluated in the
order of increasing antemortem to death (AMD) interval, as opposed to numerical case
order. All samples were prepared as described in Section 4.3 Basic Drugs: Quantitative
Blood Analysis by GC/NPD (linear range 0.1 – 1.0 mg/L). While the sedative affects of
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diphenhydramine may have contributed to some of the deaths discussed here, it was
never listed as the sole cause of death.
Diphenhydramine (DPN) case 10 had antemortem blood collected 5 minutes
before death and had a diphenhydramine concentration of 0.11 mg/L. As a result, when
using Equation 7 the expected concentration range of diphenhydramine at the time of
death would have been between 0.10 – 0.11 mg/L. At autopsy, heart and mixed blood
samples were collected and submitted for analyses (PMI = 24 hours). Heart blood
(HTBL) had a concentration of 0.28 mg/L, while the mixed (MXBL) sample had a
concentration of 0.73 mg/L. Both PM concentrations exceeded the calculated range of
the expected concentration at the time of death. The PM:AM ratios for HTBL and
MXBL were 2.5 and 6.6, respectively. Statistical analysis of the two PM concentrations
determined that the HTBL and MXBL amounts were different. The term mixed blood is
a non-descript way of indicating a mixture of blood collected from various regions of the
body (potentially both central and peripheral). Trying to determine the significance of
the increased concentration obtained in the MXBL, as compared to the other two samples
cannot be accurately evaluated. Additionally, the C:P ratio calculation would not be
appropriate for this case. What can be shown was that regardless of the origin of the
source, both PM samples had concentrations that were higher than expected and they
each had PM:AM ratios greater than 1.0. This information suggested that PMR did take
place.
The antemortem blood for DPN 03 was collected 10 minutes before death. While
diphenhydramine was detected in the AM, the amount was below the LOQ. As a result,
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Table 15: One-Way ANOVA Summary Results for Diphenhydramine Controls
(0.5mg/L)
(n=41)
Groups
lot 1
lot 2
lot 3

Count
15
19
7

Sum
8.62
10.50
3.46

Average Variance
0.57
0.013
0.55
0.002
0.49
0.002

Table 16: One-Way ANOVA Results for Diphenhydramine Controls
95% Confidence Limit
Source of
Variation
Between lots

Sum of Squares

df

Mean Square

F-test value

F crit

0.03

2

0.015

2.39

3.24

 If F > F critical, then results are significantly different
 If F < F critical, then results are similar
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it would also be expected that the PM concentrations would be below the LOQ as well.
Iliac vein blood was submitted in both gray and red-top tubes.

Each had a

diphenhydramine concentration of 0.1 mg/L. While this value was just at the LLOQ, it
did show increased blood concentration after death.
The antemortem blood for DPN 08 was collected four hours before death and had
a concentration of 0.15 mg/L. As a result, the expected concentration at the time of death
would have been between 0.06 – 0.12 mg/L. Upon autopsy aorta and iliac vein bloods
were submitted for postmortem analyses. Aorta blood had a concentration of 0.48 mg/L,
while iliac vein blood had a concentration of 0.57 mg/L. Both PM samples exceeded the
expected concentration range.

In this case, the amount of diphenhydramine in the

peripheral blood exceeded that of the central sourced blood. However, the concentrations
for both PM sources fell within the acceptable limits of variation (± 15%) established for
diphenhydramine. As a result, the concentrations were considered to be statistically
similar.
Ratio calculations for DPN 08 rendered C: P results equaling 0.84, while PM: AM ratios
were 3.2 and 3.8 for AOBL and ILBL, respectively. The C:P ratio indicated a lack of
PMR, while both PM:AM ratios suggested the presence of PMR.

An obvious

discrepancy between the ratio calculations existed. However, the combination of the
PM:AM data as well as the fact that both PM sources had concentrations that were at
least four times higher than the expected concentration range, was used by the researcher
to determine that PMR was a factor.
Nine and a half hours passed between the AM sample collection and death in case
DPN 01. Diphenhydramine was detected in the antemortem, but was at an amount below
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Table 17: Diphenhydramine antemortem samples collected within two elimination half-lives
t1/2 = 3-14 hours
Vd = 3 – 4 L/kg
CV = 15.0 %
Linear range: 0.1 – 1.0 mg/L

AMDeath

5 min
10 min
4
hours
9.5
hours
10
hours
11
hours
14
hours
14
hours

Case #

DPN
10
DPN
03
DPN
08
DPN
01
DPN
05
DPN
06
DPN
04
DPN
07

AM
Concentration
(mg/L)

Specimen

PM:
AM

C: P

PMI
(hours)

Race/Sex

Age

0.11

AMBL

2.5
6.6

-

24

WM

61

0.1

<LOQ

AMBL

-

-

28.5

WM

44

Aorta
Iliac

0.48
0.57

0.15

AMBL

0.84

19

WF

49

Mix*

0.12

<LOQ

AMBL

-

23

BM

57

Iliac
Iliac
Heart
Iliac
Mix
Iliac
Heart
Iliac

0.20
0.14
2.96
0.71
0.12
0.11
0.53
0.57

0.18

AMBL

-

11

BM

43

<LOQ

AMBL

4.17

25

BM

36

0.10

AMBL

-

19

WF

49

0.27

AMBL

0.93

17

WF

65

Source
(Whole Blood)

Concentration
(mg/L)

Heart
Mix

0.28
0.73

Iliac

1

Pulmonary Artery
* Average concentration
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3.2
3.8
1.1
0.78
1.2
1.1
2.0
2.1

the LOQ (0.1 mg/L). Postmortem mixed blood was collected in both the red and graytop tubes. The red-top MXBL sample had 0.11 mg/L of diphenhydramine and the graytop MXBL had 0.13 mg/L. As would be expected for PM samples of the same source,
their concentrations were determined to be statistically similar. Additionally, since they
were of the same source and of similar concentrations, their results were averaged
(0.12mg/L). While the exact amount in the AM sample is unknown, it would be expected
that during the 9.5 hours between AM sample collection and death, that the amount of
diphenhydramine would have continued to decrease, rendering the PM concentration
below the LOQ as well. However, that was not the case. Instead, during the 23 hour
PMI, the amount of diphenhydramine increased to just within the quantifiable limits of
the assay. The apparent increase of drug in the PM sample was indicative of PMR.
Antemortem blood for diphenhydramine 05 was collected ten hours before death
and had a concentration of 0.18 mg/L. The expected concentration range at the time of
death would have been between 0.02 – 0.11 mg/L.

Iliac vein blood was submitted for

PM analyses in both red and gray-top sampling tubes (PMI = 11 hours). The red-top tube
had a concentration of 0.20 mg/L and the gray-top tube had 0.14 mg/L. These values
resulted in PM: AM ratios of 1.1 and 0.78 for the RT and GT, respectively. While one
PM sample indicated an increase in drug concentration (relative to the antemortem
sample), the other PM specimen did not. Statistical evaluation of the PM samples
determined that their concentrations were statistically dis-similar. While it is expected
that samples collected from the same source would have virtually identical
concentrations, this is not always the case. Since the amount of iliac blood is relatively
limited, it would not be uncommon for the iliac blood to have been collected from more
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than one site along the vein, or from both veins. In either instance, a concentration
discrepancy between tubes can arise. Despite the overall dis-similarity between the
tubes, both iliac blood concentrations exceeded the expected concentration range at the
time of death. Therefore, it is likely that a small amount of PMR occurred in this case.
In diphenhydramine case 06, the antemortem was collected 11 hours before death.
The antemortem sample had a diphenhydramine concentration below the LOQ. After
autopsy, heart and iliac vein bloods were submitted (PMI = 25 hours). Heart blood had a
concentration of 2.96 mg/L, while iliac vein blood had a concentration of 0.71 mg/L.
While both the central and peripheral blood sources showed increased concentrations
over the AMBL, the central sourced blood was more than four times greater than both the
peripheral and antemortem bloods when considering the LOQ. The resulting C:P ratio
was 4.17. The increased PM blood concentrations and the high central to peripheral ratio
indicated that PMR was a factor in this case. Additionally, the largely elevated heart
blood concentration signifies that, diphenhydramine was largely stored in the tissues of
the chest cavity and/ or liver and subsequently released during the 25 hour PMI.
The antemortem blood for DPN case 04 had a concentration of 0.10 mg/L and
was collected 14 hours before death. The low concentration and the relatively long AMD
interval caused the expected diphenhydramine concentration range (0.003 – 0.05 mg/L)
to be less than the LOQ. Upon autopsy, mixed and iliac vein bloods were submitted for
postmortem analyses. The mixed blood had 0.12 mg/L of diphenhydramine, while the
iliac vein blood had 0.11 mg/L. Postmortem: antemortem ratios equaled 1.2 and 1.1 for
MXBL and ILBL, respectively. Both postmortem samples were at least double the upper
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limit of the expected concentration range. This was indicative of diphenhydramine being
released and redistributed postmortem, during the 19 hour PMI.
Antemortem for DPN 07 was collected 14 hours before death. The AM sample
had 0.27 mg/L of diphenhydramine. Heart and iliac vein bloods were collected during
autopsy.

Heart blood had a concentration of 0.53 mg/L and iliac vein blood had

0.57mg/L. The expected concentration range at the time of death was between 0.01 and
0.13mg/L. Both PM samples had amounts that exceeded this range, resulting in PM:AM
ratios of 1.96 and 2.11 for HTBL and ILBL, respectively. These values were indicative
of PMR. However, the peripheral blood sample exceeded the concentration of the central
blood sample, resulting in a C:P ratio of 0.93, which would indicate a lack of PMR.
While the ILBL did have a higher concentration than the HTBL, the difference between
the two values was not statistically significant. The PM:AM ratios, as well as the
increased levels of diphenhydramine in the PM samples lead the researcher to conclude
that PMR did occur.
Seventy-four percent of cases whose AM was collected within two elimination
half-lives before death had postmortem concentrations that were statistically greater than
their respective AM concentrations.

One-hundred percent of the data had PM

concentrations greater than their respective calculated concentration range at the time of
death. As a result, the overwhelming majority of the first half of the diphenhydramine
data returned results that were consistent with PMR.

The average Vd for

diphenhydramine is 3.5 L/kg (range = 3- 4 L/kg). Any apparent volume of distribution
greater than 1 L/kg is said to be reflective of a drugs ability to redistribute. In the case of
diphenhydramine (who’s apparent Vd ranges from 3 to 4 times greater than the critical
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limit) the propensity for redistribution is great. A few of the cases had mixed blood
submitted as a PM sample. While the exact location of the sample procurement cannot
be resolved, these samples give a generalized view of what is occurring within the body
after death. Changes in drug concentrations can be identified in mixed samples, just as
they are in ‘pure’ samples. In the absence of the latter, a comparison between a mixed
and AM sample can still give important information about the tendency of a drug.
As demonstrated in other chapters of this manuscript, PM:AM ratios and C:P
ratios calculated for the same case do not always agree. This was exhibited here in DPN
08 and 07, where both PM:AM ratios were greater than 1.0, but their C:P values were
less than 1.0.

In the absence of an AM sample, it would have been incorrectly

determined that PMR was not present. Perhaps it would be best to view the C:P ratio as
proof of PMR occurring as predicted (e.g. more extensively in the central cavity), rather
than actual evidence of PMR existing at all.
Also observed within these cases was a discrepancy between two postmortem
samples of the same source. Diphenhydramine case 05 had a relatively short PMI of 11
hours. Upon collection, iliac vein blood was stored in both the red and gray-top sample
tubes. However, the diphenhydramine drug concentration varied significantly between
the two tubes. This case serves as a reminder that assumptions made about sample
homogeneity may not always be appropriate.
The second half of this section focuses on the diphenhydramine cases that had
antemortem samples collected beyond two elimination half-lives (Table 18) before death.
Only two cases fell into this category. While two cases may not be enough data to draw
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any formal conclusions, the addition of these cases to the totality of the diphenhydramine
data can be used to reinforce some ideals discussed in the earlier part of this chapter.
Diphenhydramine case 02 had antemortem blood collected 48 hours before death.
The AM blood had a concentration of 0.33 mg/L. Aorta and iliac vein bloods were
submitted for postmortem analyses.

The PM concentrations were 0.56 mg/L and

0.40mg/L for AOBL and ILBL, respectively. After 48 hours (approximately four halflives), the expected concentration range would have been 5.0 x 10-6 to 0.03 mg/L.
Instead, the amount of drug in both PM samples exceeded that of the AM blood and its
expected range. The AOBL:AM ratio equaled 1.70, while the ILBL:AM ratio was equal
to 1.21. Additionally, the C:P ratio equaled 1.4. A review of the medical records
reported the administration of multiple medications during the 48 hour hospitalization,
some of which included naloxone (an opioid antagonist), epinephrine and atropine;
however, diphenhydramine administration was not reported.

Therefore, there was

nothing to suggest that the concentration of the drug would have increased as a result of
additional dosing or incomplete distribution. Consequently, it appears that the drug was
released and redistributed during the 13 hour PMI.
Statistical analyses of the data collected on DPN 02 showed that the aorta blood sample
concentration was significantly different from that of the iliac vein blood. Additionally,
when comparing the PM to the AM concentrations, the aorta blood was also significantly
different from the antemortem blood concentration.

Conversely, the concentration

obtained for the iliac vein blood was determined to be similar to the antemortem sample.
The comparisons of the PM and AM samples seemed to indicate that while both PM
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Table 18: Diphenhydramine antemortem samples collected after two elimination half-lives
t1/2 = 3-14 hours
Vd = 3 – 4 L/kg
CV = 15.0 %
Linear range: 0.1 – 1.0 mg/L

AM –
Death
(hours)

20
48

Case #

DPN
09
DPN
02

Source
(whole blood)

Concentration
(mg/L)

AM
concentration
(mg/L)

Specimen

PM: AM

C: P

PMI
(hours)

Race/ Sex

Age

Mixed* Heart

0.96

<LOQ

AMBL

-

-

21

BF

65

Aorta
Iliac

0.56
0.40

0.33

AMBL

1.7
1.2

1.4

13

WF

59

* Average concentration
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specimens were influenced by redistribution, the aorta blood was affected more
extensively.
Diphenhydramine case 09 had an antemortem concentration lower than the LOQ
of the assay. Mixed heart blood was submitted in both red-top and gray-top tubes. The
RT MXHT blood had a concentration of 0.97 mg/L, while the GT had 0.96 mg/L. Since
the PM samples were of the same source and had statistically similar concentrations, the
PM results were averaged to equal 0.96 mg/L. The AMBL concentration was below the
LOQ; therefore, it can be inferred that the PM concentration was at least 90% higher than
the AM. In this case the AM blood was collected approximately 20 hours before death.
There was no indication in the medical records that re-administration was a factor. As a
result, it appears as though during the 21 hour PMI, PMR likely occurred.
When reviewing all of the cases as a whole, it became apparent that postmortem
redistribution was a real factor when trying to interpret PM blood drug concentrations of
diphenhydramine. The data discussed here seemed to suggest that on average at least a
50% increase in PM concentrations (when compared to AM results) could be expected.
While it is generally accepted that blood concentrations obtained from the central cavity
have higher concentrations (because of increased sources of possible contamination), this
is not necessarily the case for diphenhydramine.
Of all the cases discussed, only four were submitted with both central and
peripheral blood for comparison (Chart 6). Two out of the four had statistically higher
central concentrations than peripheral. The other two cases (DPN 08 and 07) had central
and peripheral data that gave statistically similar results. Admittedly, the amount of
central vs. peripheral data was limited. However, it did seem to reinforce the idea that

113

redistribution may not always follow the expected pattern, which assumes that
quantitative values obtained from peripheral sourced blood are more accurate than central
blood. To the contrary, this data would seem to indicate that central and peripheral
concentrations may not differ that significantly from each other. Again, reiterating the
idea that using the C:P ratio as an indicator for PMR may not be the most reliable
predictor.
Diphenhydramine 02 had one of the shortest PMI (13 hours) of the cases
presented. Despite this, it not only produced data that was indicative of PMR, but it also
demonstrated that central and peripheral results could vary significantly in a short amount
of time. This would suggest that PMR may begin rather quickly after death.
Finally, for each case discussed, the expected drug concentration range at the time
of death was calculated (Equation 7).

Chart 7 displays the peripheral blood

concentrations as they compare to that of the expected range, denoted by the symbol “[.”
Diphenhydramine cases 03 and 06 had AM concentrations that were below the LOQ;
therefore a quantitative range could not be determined. However if PMR did not occur,
the PM concentrations would have been expected to be below the LOQ as well.
Diphenhydramine 05 was submitted with two peripheral sources, the results of
both tubes are displayed. When examining the Chart 7 data as a whole, 100% of the
cases exceeded their calculated ranges. Therefore, while a peripheral sourced blood may
be the preferred postmortem specimen for quantitative analyses, in the case of
diphenhydramine, it likely will not be reflective of the blood drug concentration around
the time of death.
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Chart 6: Diphenhydramine Central versus Peripheral Data
Error rate: 15%
Central

Peripheral

4
3.5

Concentration (mg/L)

3
2.5
2
1.5
1
0.5
0
DPN 08

DPN 07
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DPN 06

DPN 02

Chart 7: Diphenhydramine Peripheral Source Data
Peripheral

Peripheral

0.9

Concentration (mg/L)

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
DPN 03

DPN 08

DPN 05

DPN 06

DPN 04

DPN 07

Comparison of diphenhydramine peripheral source blood to its
expected drug concentration at the time of death
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DPN 02

6.3 Benzodiazepines
Benzodiazepines are a class of drugs with a wide array of uses, including muscle
relaxation, sedation and anxiety relief. The broad application of benzodiazepines has
helped to make them among the most widely prescribed medications in the world. This
study examined diazepam, nordiazepam, alprazolam, midazolam, clonazepam and 7aminoclonazepam specimens in whole blood and serum. As described in section 2.2, the
samples were analyzed by GC/ECD (linear range: 0.01–0.2 mg/L), HPLC/MS/MS (linear
range: 0.01–1.0 mg/L) or by HPLC/DAD (linear range: 0.1–10 mg/L). Identification of
the instrumental analysis is addressed in each of the following sections on a case-by-case
basis.

6.3.1 Alprazolam
Alprazolam analyses were conducted on two instruments. All data collected as
part of routine laboratory analyses were performed on a gas chromatograph/ electron
capture detector (GC/ECD). This same instrument was used for research purposes until
March 2008. Since that time, the quantitative benzodiazepine research was analyzed by
high performance liquid chromatography/ tandem mass spectrometry (HPLC/MS/MS)
(refer to section 4.2.2 (b)). The switch from GC/ECD to HPLC/MS/MS allowed for an
extended linear concentration range. In addition, the HPLC/MS/MS method monitored
seven analytes, while the GC/ECD only quantified three.
The control data produced by both the GC/ECD and the HPLC/MS were
statistically analyzed by using a two-way ANOVA (α = 0.05). The purpose of the two-
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way ANOVA was to determine if the control data collected from the two systems
significantly varied. The F-test result for that comparison was 0.33, while the Fcrit value
equaled 4.4. Since F < Fcrit the ANOVA results determined that no significant variation
was observed between the two instruments (Table 19). Additionally, the amounts of day
to day variability, as well as the interaction between the sources of variation, were not
considered significantly different either. Since it was determined that the GC/ECD and
LC/MS control data were statistically similar, the data generated from both systems were
treated as one population.

The coefficient of variation for the population equaled

18.73%. Intra-case drug concentrations that were included within the ± 18.73% range
were considered similar.
Alprazolam is a benzodiazepine with an average elimination half-life (t1/2) of 11
hours (ranging from 6 – 27 hours (57)). It has an apparent volume of distribution (Vd) of
0.9 – 1.3 L/ kg (57). For this study, 14 cases were evaluated. The data is presented in
order of increasing antemortem to death intervals. Those cases whose AM blood was
collected within two AMD intervals were included within the first section.

Two

additional donor cases whose blood was collected within hours of brain death were also
included here (Table 20).

The second section covers those cases that exceed two

elimination half-lives between AM sample collection and death (Table 21). Additionally,
one donor case, whose AM blood was collected seven days after death was also included
in the second section.
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Table 19: Two-Way Analysis of Variation for Alprazolam Comparison of GC/ECD
versus HPLC/MS/MS Controls
Source of
Variation
Day to Day
GC/ECD vs.
LC/MS
Interaction

Sum of
Squares
0.001191

8

Mean
Square
1.49E-04

F-test
value
1.76

2.84E-05

1

2.84E-05

0.33

4.41

0.000744

8

9.3E-05

1.10

2.51

df

F crit
2.51

Antemortem blood for Alprazolam (Alp) 09 was collected 13 minutes before
death. The AM concentration was 0.09 mg/L. Such a short AM to death time interval
would suggest that in the absence of PMR, the postmortem blood concentrations would
be similar to that of the AM (ranging from 0.088 – 0.089 mg/L). The postmortem
samples submitted in both the red-top (RT) and gray-top (GT) tubes were iliac vein blood
samples with a PMI of 21 hours. The RT concentration equaled 0.080 mg/L, with the GT
equaling 0.089 mg/L. While, the red-top did render a slightly higher concentration
(~11.5% higher), the difference between the two tubes was less than the 18.73% needed
to make the difference statistically significant. Since the PM concentrations were similar
and of the same source, their concentrations were averaged to 0.084 mg/L. When using
the average, the PM:AM ratio was calculated to equal 0.89. Additionally, when applying
the CV percentage, it was determined that the PM and AM concentrations were
statistically similar. The combination of the ratio results, as well as the CV results
indicated that PMR did not occur in this case.
Alprazolam 02 AM samples were collected 20 minutes before death and had AM
alprazolam concentration of 0.01 mg/L. The expected alprazolam concentration at the
time of death would have been between 0.01 – 0.01 mg/L (raw data = 0.0096 –
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Table 20: Alprazolam antemortem samples collected within two elimination half-lives
t1/2 = (6 – 27 hours)
Vd = 0.9 – 1.3 L/kg
CV population = 18.73%
AM Death

Case #

Source
(whole blood)

Concentration
(mg/L)

AM
concentration
(mg/L)

Specimen

PM: AM

C:P

PMI
(hours)

Race/Sex

Age

13 min

Alp
091

Iliac*

0.084

0.09

AMBL

0.9

-

21

WM

21

20 min

Alp
021

Aorta

0.02

Iliac

0.04

0.01

AMBL

0.5

45.5

WM

26

40 min

Alp
142

Chest

0.04

Iliac

0.03

0.02

AMBL

1.3

52

WM

52

1.5 hrs

Alp
061

Chest

<LOQ

Chest

<LOQ

<LOQ

AMBL

-

19

WM

40

11 hrs

Alp
031

Heart

NDD

Iliac

NDD

0.01

AM S

-

19

WM

50

12 hrs

Alp
111

Aorta
Iliac

0.48
0.43

>LOQ

AM S

1.1

54

WM

68

15 hrs

Alp
041

Heart

0.04

Iliac

0.05

0.03

AMBL

0.8

32.5

WM

41

30 min
AFTER

Alp
052

Heart

<LOQ

Iliac

<LOQ

0.01

AMBL

-

89

WM

45
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2.0

4.0
2.0

1.5
-

-

-

1.3

1.7
-

-

AM Death

Case #

6 hrs
AFTER

Alp
011

Source
(whole blood)

Concentration
(mg/L)

Heart

NDD

Iliac

NDD

AM
concentration
(mg/L)

Specimen

0.01

AMBL

GC/ECD data; linear range = 0.01 – 0.2 mg/L
LC/MS/MS data; linear range = 0.01 – 1.0 mg/L
* Average concentration
NDD = No Drugs Detected
1
2

Table 20, continued

121

PM: AM
-

-

C:P

PMI
(hours)

Race/Sex

Age

-

14

WM

21

0.0099mg/L). The postmortem aorta and iliac vein blood samples had a PMI of 45.5
hours and concentrations of 0.02 and 0.04 mg/L, respectively. These concentrations
significantly exceeded their expected concentration range (CV ± 18.73%). The central to
peripheral ratio equaled 0.5, while the aorta blood:AM blood ratio equaled 2.0 and the
iliac vein blood: AM blood equaled 4.0.

Historically it is believed that when

central:peripheral and/ or PM:AM ratios are greater than or equal to 1.0, PMR likely
occurred. However, in this case the C:P < 1.0, but both PM: AM ratios were > 1.0.
When viewing the Alp 02 data as a whole, both PM samples were determined to be
statistically different from their AM concentrations.

This in combination with the

PM:AM ratio data has caused the researcher to determine that PMR was a factor in this
case.

Additionally, the aorta and iliac vein blood samples were determined to be

statistically dis-similar to each other. This was of particular interest because the iliac
vein blood concentration was greater than the aorta blood concentration (hence C:P <
1.0). While it is generally accepted that PMR is more pronounced in centrally located
blood sources, this case would be an exception to that rule.
The deceased in Alp 14 was the victim of a homicide. He was transported to the
hospital and had his blood collected 40 minutes before death (AM concentration =
0.02mg/L), making his expected alprazolam concentration at the time of death range
between 0.018 – 0.019 mg/L. Postmortem submission included a sample obtained from
the left chest cavity (0.04 mg/L) and the iliac vein (0.03 mg/L). Both PM samples had
concentrations higher than the AM. However, only the left chest cavity blood was
determined to be statistically higher than the AM sample. The CHBL:AM ratio equaled
2.0, while the ILBL:AM ratio equaled 1.5. Additionally, while the CHBL:ILBL ratio
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equaled 1.3 their concentration variation was within the ± 18.73% range. All of the ratio
data indicated that postmortem redistribution occurred during the 52 hour postmortem
interval, despite the statistical similarities among most of the data. The researcher was
not able to find any literature comparing ratio data to statistical significance. Therefore,
it may be possible that the two are mutually exclusive. An alternative explanation for the
AM and PM concentration differences could be that the victim was still absorbing
alprazolam at the time of death. If this were the case, the expected concentration at the
time of death would have been slightly higher than the AM concentration, causing PM
levels to be higher, which may not have been deemed statistically different than the AM
concentration (as was the case with the ILBL).
The decedent in Alp 06 was a victim of homicide. His AM blood was collected
1.5 hours before death, but had an alprazolam concentration below the LOQ (GC/ECD
limit of quantitation = 0.01 mg/L). The postmortem chest blood samples (collected in
both a red-top polypropylene and gray-top vacutainer tubes) had a PMI of 19 hours. Both
PM samples contained alprazolam at concentrations below the LOQ. While these results
were not quantitative, they were still important. The AM blood had alprazolam detected,
but at levels below quantitation.

Therefore, there was some potential for PMR.

However, none could be identified during the 19 hour PMI. This was an example of how
a short antemortem to death interval and a relatively short PMI can result in a lack of
significant change in concentration between AM and PM samples.
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Equation 8: Alprazolam’s blood to plasma ratio

For Alp 03, AM blood was collected in a serum separator tube. As a result, the
specimen available for analysis was serum, not whole blood. However, as indicated in
Baselt (57), alprazolam’s blood to plasma ratio equals 0.8. Consequently, the result of a
given serum concentration multiplied by 0.8 would be approximately equal to that of a
whole blood concentration (Equation 8). For this case, the AM blood was collected 11
hours before death and had a concentration of 0.01 mg/L. When applying this result to
Equation 8 the equivalent blood concentration would be 0.008 mg/L. When rounded the
equivalent blood concentration would equal 0.01 mg/L. With an antemortem to death
interval of 11 hours, the expected concentration range at the time of death would be 0.003
– 0.007 mg/L. Analysis of the postmortem samples (PMI = 19 hours) did not detect the
presence of alprazolam. This sample was analyzed by GC/ECD which had a limit of
detection of 0.002 mg/L. Although the expected concentration range was low, it would
have fallen within the detectable limits of the assay. With no PM concentrations to
consider, it can be concluded that PMR was not a factor in this case.
In Alp 11, antemortem serum, as opposed to blood, was collected 12 hours before
death. The serum was determined to have an AM concentration greater than the upper
limit of quantitation (ULOQ) (0.2 mg/L; analyzed by GC/ECD). The volume of the
sample was not sufficient for subsequent dilution and re-analysis.

The original

paperwork documented the concentration, although exceeding the validated linear range,
at 0.30 mg/L. Postmortem submission (PMI = 54 hours) included aorta and iliac vein

124

bloods. Since the AM concentration exceeded the linear range, the PM samples were
diluted prior to analysis to ensure that their concentrations would fall within the validated
range. The aorta and iliac vein blood concentrations were determined to be 0.48 mg/L
and 0.43 mg/L, respectively.

Assuming instrument linearity up to 0.30 mg/L, the

expected concentration at the time of death would have been between 0.07 – 0.22 mg/L.
When calculating the AOBL:AM, ILBL:AM, as well as the AOBL:ILBL ratios the
values were determined to be 1.6, 1.4 and 1.1, respectively. All three ratio values
indicated that PMR did occur. Alternatively, it should be considered that with such a
large amount of drug in the system, it is possible that the body was still in the absorptive
stage of the pharmacokinetic process, during the 12 hours between collection and death.
This would have resulted in an increase of drug concentration that could have been
detected in the PM sample. Unfortunately, based on the information given there is no
way of knowing the exact cause of the increased concentration.
Alprazolam 04 was collected 15 hours before death and had a concentration of
0.03 mg/L. As a result, the expected concentration at the time of death would have
ranged between 0.005 – 0.02 mg/L. The postmortem heart blood concentration was
0.04mg/L and postmortem iliac vein blood concentration equaled 0.05 mg/L. Both PM
samples (PMI of 32.5 hours) had concentrations higher than that of the AM blood,
although only the difference between the iliac blood and AM were determined to be
statistically dis-similar.

The HTBL:AM and ILBL:AM ratios were 1.3 and 1.7,

respectively. Both of these calculations suggested the presence of PMR. Conversely, the
heart: iliac vein ratio, which equaled 0.8, did not. The discrepancy observed in the ratio
calculations were of concern as both C:P and PM:AM ratios are supposed to be indicative
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of PMR. Upon reviewing the data, even though the HTBL concentrations were not
statistically different from the AM concentration, both PM concentrations greatly
exceeded the expected concentration range. Therefore, it was determined that PMR was
a factor here.
Alprazolam 05 was the case of an organ donor. His AM samples submitted for
testing were drawn 30 minutes after brain death (refer to section 1.6.5). The calculated
concentration of alprazolam was at the limit of quantitation (LOQ) (0.01 mg/L). The
decedent in this case was maintained on life support for three days while awaiting organ
procurement. Based on the official time of brain death, his PMI would have been 89
hours. However, he was receiving fluids and had functioning organs for an additional
three days. Therefore, for the purposes of this experiment, his actual PMI (time between
organ procurement and autopsy) was less than 24 hours, which would make his AM to
death interval closer to 72 hours. A 72 hour AM to death interval for alprazolam would
result in anywhere from three to twelve elimination half-lives. It would be expected that
the concentration at the time of death would be very low, if detectable at all. Analysis of
the PM heart and iliac vein blood samples were each below the LOQ of the assay. This
indicated that no PMR occurred between the 24 hours of organ procurement and autopsy.
Alprazolam 01 was a 21 year old white male who suffered from both depression
and anxiety.

He would self medicate by obtaining alprazolam (dosage unknown)

whenever he felt it necessary. The decedent ultimately committed suicide and became an
organ donor upon family approval. His AM blood, collected six hours after brain death,
had an alprazolam concentration of 0.01 mg/L. His postmortem samples (heart and iliac
vein bloods) were both negative for alprazolam (GC/ECD limit of detection =
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0.002mg/L). The PMI was 14 hours, the shortest time of all 14 cases tested. Organ
donors often have postmortem blood negative of any drug not given in preparation of
surgery. This is a direct result of the amount of fluids infused through the body just prior
to surgery (in this case at least 6 hours of fluid).

Infusions often dilute drugs of

toxicological importance to concentrations well below quantitation limits. The detection
of alprazolam in the AM and its subsequent absence in the PM suggested that PMR was
not a factor in this case.
The majority of the above mentioned cases had AM collection times within two
elimination half-lives before death. There were two exceptions, Alp 05 and Alp 01,
which were both organ donors. It is well known that drugs of toxicological importance
can be lost during the preparatory procedure of organ procurement. However, this brings
to light the importance of accurate date and time information concerning AM collection,
brain death and organ removal. On the surface, it appeared that the AM collection time
was ideal for Alp 05. However, with further investigation it was revealed that the date of
the AM was actually collected about three days before procurement. This would indicate
that the patient received infusions for an additional 72 hours after blood collection. Even
though the presence of alprazolam was not critical in this case, this type of information
could influence the interpretation of results from other cases. For example, ALP 01 was
also an organ donor. The decedent had a history of psychological issues and intermittent
alprazolam usage. His AM was collected six hours after he was declared brain dead.
From a postmortem toxicological standpoint, that means AM collection was not until 6
hours after fluid infusion. Although alprazolam did not contribute to the death of either
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individual, in other situations accurate timeline information could be a crucial factor in
accurately assessing a cause of death.
When the cases are organized in order of increasing AM to death interval, the first
four cases (Alprazolam 09, 02, 14 and 06) were of particular interest. Each case had AM
blood collected ≤ 1.5 hours before death. Alprazolam 09 and 06 had the shortest and
longest AM to death interval (of the first four), respectively. They each had relatively
short PMI ≤( 21 hours) and both were determined to not be affe cted by PMR.
Alprazolam 02 and 14 had AM blood collected within 40 minutes of death. Alprazolam
02 had a PMI of 45.5 hours, while Alp 14 had a PMI of 52 hours. Both of these cases
were potentially affected by redistribution. While four cases are not sufficient to make
any definitive decisions, it would appear that the PMI can greatly affect PM drug
concentrations even when the AM to death collection intervals are relatively short.
Additionally seven cases were submitted with both central and peripheral sources.
Of those, four had quantitative data for both sources (Alp 02, 04, 11 and 14). Only Alp
02 had PM source data that was statistically different, all other cases gave similar results.
This was of particular interest because toxicologists commonly believe that central
sourced blood is more susceptible to redistribution. While two of the four cases did show
higher central sourced concentrations; overall, they were not statistically different. The
one case that showed the dis-similarity had a higher peripheral blood concentration,
indicating that the peripheral sample was more subject to PMR in that case. Therefore,
the belief that quantitative data collected from the peripheral source is less likely to be
contaminated appears to be questionable.
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In most situations observed in the alprazolam data both C:P, as well as PM:AM
ratios were in agreement as to whether or not PMR occurred. However, Alp 02 and 04
both had PM: AM ratios≥ 1.0 and C:P ratio < 1.0. Both cases were determined to be
affected by PMR; however, because their PM concentrations exceeded their expected
concentration ranges. In addition discrepancies between statistical significance levels
and ratio calculations also arose. This was demonstrated in alprazolam cases 04 and 14,
which were both determined to be potentially affected by PMR. The statistical analysis
of Alp 04 and the ILBL of Alp 14 showed concentration similarities between PM and
AM results. Since the relationship between statistical significance and PMR is not well
understood, all of the data and calculations produced for each case had to be considered
in its entirety.

Only then could a determination be made as to whether or not

redistribution influenced the results.
The remaining alprazolam cases all had antemortem collection times that
exceeded two elimination half-lives (Table 21). The first of those was alprazolam 10.
The antemortem blood received in the laboratory for Alp 10 was dated one day before
death but did not specify a time. When calculating the time between hospital arrival and
death, no more than 38.5 hours could have passed between AM collection and death.
Routine laboratory testing of the AM sample resulted in a concentration of 0.13 mg/L for
alprazolam. Sometime after the blood draw, the patient was declared brain dead and
became an organ donor.

Organ procurement began five hours after brain death.

Postmortem aorta blood concentrations (submitted in both red and gray tubes) were 0.01
mg/L each.

As a result, the PM aorta blood concentrations were averaged.

subsequent calculations will be based on the average value of 0.01 mg/L.
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All

If the AM blood for Alp 10 was in fact collected 38.5 hours before death, then the
expected drug concentration range at the time of death would have been between 0.001 –
0.06 mg/L. The actual PM concentration was within the expected range. This indicates
that the infusion of fluids (given in preparation of organ procurement) did not negatively
affect the PM drug concentration. Additionally, the aorta:AM ratios equaled 0.08. The
data collected for this case did not indicate that PMR occurred.
Alprazolam 08 had an AM concentration of 0.04 mg/L from a sample collected 45
hours before death. The expected concentration at the time of death ranged from 2.2 x
10-4 – 0.01 mg/L. The PM iliac vein and heart blood samples had a PMI of 28.5 hours
and concentrations of 0.01 mg/L each. The central:peripheral ratio equaled 1.0, while the
heart blood:AM, as well as the ILBL:AM ratios each equaled 0.25. While the C:P ratios
indicated the possibility of PMR, the PM:AM ratios did not. It has been determined by
the researcher that since the PM concentrations fell within the expected range that PMR
did not occur.
In Alp 13, the AM blood sample was collected three days before death. The
decedent was transported to the hospital as a result of an intentional drug overdose. The
AM alprazolam concentration was 0.26 mg/L, well above therapeutic levels (0.02 –
0.06mg/L (57)). The expected concentration at the time of death ranged from 6.3 x 10-5 –
0.04 mg/L. The aorta and iliac vein blood samples, collected 24 hours after death, had
statistically similar concentrations of 0.1 mg/L and 0.08 mg/L, respectively. Hospital
records indicated that the decedent presented with overdose symptoms caused by the
ingestion of oxycodone and alprazolam. While both PM concentrations exceeded their
expected range, the aorta: AM and iliac vein:AM ratios equaled 0.31 and 0.42,
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Table 21: Alprazolam antemortem samples collected after two elimination half-lives
t1/2 = (6 – 27 hours)
Vd = 0.9 – 1.3 L/kg
CV = 18.73%
AM Death
38.5 hrs

45 hrs
3 days
5 days
7 days
AFTER

Case #

Alp
102
Alp
081
Alp
132
Alp
071
Alp
122

Source
(whole blood)

AM
Concentration
concentration Specimen
(mg/L)
(mg/L)

Aorta*

0.01

Heart
Iliac
Aorta
Iliac

0.01
0.01
0.08
0.11

IVC
Aorta
Iliac

PM:AM

0.08
0.08
0.25
0.25
0.31
0.42

C: P

PMI
(hours)

Race/Sex

Age

-

43

WM

29

1.0

28.5

WF

0.72

24

WM

53

0.13

AMBL

0.04

AMBL

0.26

AMBL

<LOQ

0.02

AMBL

-

-

16

WM

45

0.30
0.17

0.9

AMBL3

0.33
0.19

1.8

36

WM

71

GC/ECD data; linear range = 0.01 – 0.2 mg/L
LC/MS/MS data; linear range = 0.01 – 1.0 mg/L
3
Not collected during the terminal event
* Average concentration
1
2
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respectively. Additionally, the central:peripheral ratio equaled 0.73. All of the ratio data
indicated a lack of PMR; however, the PM concentrations exceeded their expected range.
At the time of death, the body’s ability to metabolize and eliminate drugs from the system
could have been compromised because of the overdose. As a result, although (based on
the concentrations) it looks as if PMR occurred, the role of the overdose cannot be
overlooked. Consequently, it cannot be determined if PMR was a factor.
The antemortem blood for Alp 07 was collected 5 days before death and had a
concentration of 0.02 mg/L. Medical records did not indicate the administration of
alprazolam during the decedent’s five day hospitalization, which would suggest that the
drug was ingested before his admittance.

The combination of the low AM blood

concentration and the five day AMD interval resulted in an expected concentration range
at the time of death being at levels below both the LOD and the LOQ (expected range =
1.9 x 10-8 – 9.2 x 10-4 mg/L). An autopsy was conducted 16 hours after death, and
inferior vena cava (IVC) blood was submitted for toxicological analyses. Alprazolam
was detected in the IVC BL but at a concentration below the LOQ (0.01 mg/L). The PM
blood concentration was below that of the AM, indicating that metabolism did occur.
However the fact that alprazolam was detected in the PM sample, suggests that its
concentration greatly exceeded the expected concentration range.
The decedent in Alp 12 intentionally overdosed on his alprazolam prescription
and phoned family members to make them aware. He was transported by emergency
services to the hospital, treated and survived. However, he remained an inpatient for
approximately 3.5 weeks. The patient exhibited anxious and aggressive behavior and as
a result was prescribed 0.5 mg tablets of alprazolam twice daily and an additional 1 mg
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tablet at bed time. On the date of his death, he phoned family members to inform them
that he had taken 40 alprazolam tablets, while still an in-patient. He was treated, but
ultimately died approximately 2.5 hours later.
The AM blood submitted for analysis was dated the day of his hospital admission
(approximately 3.5 weeks before death). This sample had a concentration of 0.9 mg/L,
which would be indicative of an overdose. However, he was treated and stabilized after
this blood draw. Any AM blood samples that may have been collected during the
terminal event were not submitted with the original AM sample to the MDME
Department.

Thirty-six hours after death, aorta and iliac vein blood samples were

collected. Upon analysis, the aorta blood concentration was 0.30 mg/L, while the iliac
blood was almost half that at 0.17 mg/L. Since the AM sample analyzed did not correlate
with the terminal event, its concentration cannot be further considered. However, when
examining the postmortem samples, the AOBL:ILBL ratio equaled 1.8. Additionally, the
aorta and iliac vein blood sample concentrations were determined to be statistically dissimilar. In the absence of the appropriate AM sample, it cannot be determined if PMR
was a factor for this case. In all likelihood, a relevant AM sample would have been
collected during the absorptive phase. As a result any discrepancy between AM and PM
concentrations could have been a result of incomplete distribution, as opposed to PMR.
The alprazolam cases discussed in the second half of this section bring to light
some important considerations.

When AM samples are collected more than two

elimination half-lives before death, it becomes increasingly important to have accurate
and reliable records (including both social and medical histories), which include a
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timeline leading up to the terminal event. Increased time intervals may, at times, equate
to increased confounding circumstances, as was the case in Alp 12.
Alprazolam 12 was an example of how important it is to view all of the
information as a whole. If the AM sample had been the only sample tested, then the
cause of death would have been due to drug toxicity. While ultimately, that would have
been accurate, that particular AM sample was not directly related to the actual terminal
event. Had the decedent not overdosed the second time and died from causes unrelated to
alprazolam, the cause of death would have been inaccurately assigned. This is why social
and medical histories, in combination with toxicological findings can all impact the death
investigative process.
Alprazolam cases 08, 10 and 13 were useful as well. Alprazolam 08 and 10 were
examples of how a drug can be present and not have an influence on the cause of death.
In contrast, in cases of overdose the overwhelming presence of a drug may hinder the
body’s ability to eliminate the drug. Alprazolam 13 is an example of the fact that a
person can live for three days after an overdose and still maintain a level of drug that
exceeds therapeutic levels. In their entirety, the alprazolam cases show that depending on
any one factor (or piece of information) to determine the cause of death can lead to
inaccuracies. Therefore it is important to consider all the facts before drawing any formal
conclusions.
Finally, it was also important to combine the two alprazolam sections and
examine the intra-case dynamics.

The relationship between central and peripheral

results, as well as how well peripheral concentrations compare to their expected
concentration ranges was examined. Of the fourteen cases discussed, ten were submitted
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with both central and peripheral sourced blood (Chart 8). Out of those ten cases, six had
quantifiable postmortem results. Through statistical analyses, it was determined that in
83% of the cases no significant difference existed between the two sources. Although
peripheral blood is the preferred source for postmortem analyses, this data suggested that
in the majority of instances no measurable difference existed between the two anatomical
locations. The peripheral data was further evaluated in Chart 9.

In

order

to

better

interpret the meaning of the postmortem results, each case that had quantifiable AM
values was subjected to Equation 7 to determine the expected concentration range at the
time of death. This range was an important factor used throughout the chapter to help
determine which cases were affected by PMR. In Chart 9 the peripheral results were
compared to the expected concentration ranges for each case. The symbol “[” was used
to denote the concentration range. At times, the rounded results of the upper and lower
ends of the range were equal. For those cases the symbol “-” was used. Alprazolam case
03 had quantifiable amounts of the drug in the AM sample (0.01 mg/L); however it was
not detected in the PM sample.

Consequently, the case was represented with the

expected range symbol “[”, despite the absence of a peripheral result. In 50% of the
alprazolam cases, the peripheral blood concentrations were higher than what would have
been expected at the time of death. Twenty-five percent of the data was below the
expected range, and the remaining 25% was within range. The data produced here
seemed to indicate that it would not be likely that PM peripheral blood results would
accurately reflect the blood drug concentration of a person around the time of death.
Furthermore, when reviewing all 14 cases, regardless of anatomical location, only
21% of them had data consistent with PMR. Fifty percent of the cases showed a lack of
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Chart 8: Alprazolam Central versus Peripheral Data
Error rate = 19%
Central

Peripheral

0.6
0.5
0.4
0.3
0.2
0.1
0
Alp 02

Alp 14

Alp 11
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Alp 04

Alp 08

Alp 13

Chart 9: Peripheral Alprazolam Results
Error rate = 19%

Peripheral

Concentration (mg/L)

0.5
0.4
0.3
0.2
0.1
0
Alp 09 Alp 02 Alp 14 Alp 03 Alp 11 Alp 04 Alp 08 Alp 13

Peripheral alprazolam data as it compares to the expected
concentration range at the time of death
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PMR, while the remaining 29% could not be definitively qualified either way. The
collected data seemed to indicate that PMR was not an overwhelming factor for
alprazolam. This was consistent with the apparent volume of distribution of the drug (0.9
– 1.3 L/kg), which suggested the potential for redistribution, but not necessarily a
propensity for it.

6.3.2 Diazepam
Diazepam (Valium®), introduced in the 1960’s, is a long-acting benzodiazepine.
Its ability to treat anxiety, muscle spasms and alcohol withdrawal symptoms, help to
make it one of the most popular benzodiazepines prescribed. Acceptable therapeutic
doses can vary from 2 to 40 mg daily (79). This section will evaluate diazepam and its
demethylated metabolite nordiazepam.

Elimination half-lives for diazepam and

nordiazepam range from 21 – 37 hours and 50 – 99 hours, respectively (79). The
apparent volume of distribution (Vd) for diazepam ranges between 0.7 – 2.6 L/kg (79).
Typically a Vd above 1.0 L/kg can be indicative of postmortem redistribution and it is
possible that diazepam may exhibit some redistributive tendencies. The cases presented
here all had antemortem blood collected within one elimination half-life before death.
The data is displayed in Table 24.
Miami-Dade County Medical Examiner Department’s Toxicology laboratory
conducted nordiazepam and diazepam quantitative testing on a Perkin Elmer HPLC/DAD
(section 4.2.2 (b)).

While none of the postmortem results were taken from this

instrument, due to a finite amount of antemortem sample submitted, some of the cases
discussed here did not have sufficient volume for retesting for the purposes of this
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project. As a result, the AM data collected as part of routine laboratory work was
included in this section.
Postmortem analysis of nordiazepam and diazepam however, for the purposes of
this

project,

were conducted

solely on

Thermo-Finnigan’s

LCQ Advantage

HPLC/MS/MS system. In an effort to show that the results obtained from the two
methods would not significantly differ from each other a two-way ANOVA (95%
confidence limit) was conducted on the control data collected from both instruments.
The nordiazepam ANOVA results (Table 22) which compared the two instruments gave
an F-test result of 3.77 and an Fcrit of 4.35. Additionally, Table 23 displays the diazepam
ANOVA results in which the F-test and Fcrit values for comparing the two instruments
were 1.63 and 4.35, respectively. Both nordiazepam and diazepam had F-test values less
than their Fcrit values. Therefore, ANOVA determined that no significant difference
existed between the two systems. Additionally, the amounts of day to day variability, as
well as the interaction between the sources of variation, were not considered significantly
different.
Since it was proven that the data obtained on both instruments were comparable,
the intra-nordiazepam data as well as the intra-diazepam data were each treated as one
population. When using Equation 5 the CV for nordiazepam and diazepam was 14% and
and 17%, respectively. For each drug, any concentrations that fell within the ± CV range
were considered similar. Any concentration that exceeded the limits of the range was
considered statistically different.
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Table 22: Two-Way Analysis of Variation for Nordiazepam Comparison of
HPLC/MS/MS to HPLC/UV Control Data
Source of Variation
Day to Day
LC/MS vs. LC/UV
Interaction

Sum of
Squares
0.043
0.044
0.072

df

Mean Square

F-test Value

F crit

9
1
9

0.005
0.044
0.008

0.42
3.77
0.69

2.39
4.35
2.39

Table 23: Two-Way Analysis of Variation for Diazepam Comparison of
HPLC/MS/MS to HPLC/UV Control Data
Source of Variation
Day to Day
LC/MS vs. LC/UV
Interaction

Sum of
Squares
0.13
0.03
0.14

df

Mean Square

F-test value

F crit

9
1
9

0.01
0.03
0.07

0.83
1.63
0.85

2.39
4.35
2.39
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The antemortem blood for diazepam (DZM) case 06 was collected 1.5 hours
before death. Nordiazepam and diazepam were detected at concentrations of 0.01 mg/L
each. The expected concentration range at the time of death for nordiazepam was 0.01 –
0.01 mg/L (raw data: 0.0098 – 0.0099 mg/L), while diazepam’s was 0.01 – 0.01 mg/L
(raw data: 0.0095 – 0.0097 mg/L). Upon autopsy, heart and iliac vein bloods were
submitted. Heart blood had concentrations of 0.03 mg/L for nordiazepam and 0.02 mg/L
for diazepam. The iliac vein sample had concentrations of 0.02 mg/L and 0.02 mg/L for
both nordiazepam and diazepam, respectively (Table 24).

Both postmortem blood

samples had concentrations of nordiazepam and diazepam that were at least twice the
amount detected in the antemortem sample. As a result, the heart blood:AM ratios
equaled 3.0 and 2.0 for nordiazepam and diazepam, respectively.

The iliac vein

blood:AM ratios each equaled 2.0 for nordiazepam and diazepam. Additionally, the
central to peripheral ratio equaled 1.5 for nordiazepam and 1.0 for diazepam. Even
though the PMI was only 6.5 hours, based on the ratio data and the increased PM
concentrations, it would appear that PMR did occur.
In addition, the concentration of nordiazepam in DZM 06 was higher in the HTBL
than the ILBL. However, statistical analyses determined that the concentrations were not
significantly different. The acceptable range of variability for nordiazepam in the HTBL
sample was 0.02 – 0.03 mg/L, while its range in the ILBL sample was 0.02 – 0.02 mg/L
(raw data 0.017 – 0.023 mg/L).

Since the ranges overlapped, the data had to be

considered similar.
Antemortem blood for DZM 07 was collected 1.5 hours before death. The blood
had a concentration of 0.01 mg/L for both nordiazepam and diazepam. Heart and iliac
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vein bloods were submitted for PM analysis.

The heart blood had 0.01 mg/L of

nordiazepam, as well as 0.01 mg/L of diazepam. The iliac vein blood had concentrations
of 0.01 mg/L for both nordiazepam and diazepam. As a result, all PM:AM ratios equaled
1.0, as did the C:P ratios.
The blood samples (AM and PM) for DZM 07 were all analyzed on the same day
on the LC/MS instrument. Since the results obtained were all quantitatively equal, there
were no statistical differences among the values. Even though all of the calculated ratios
equaled 1.0, the lack of distinctly different data made it not possible to identify the
presence of PMR.
Antemortem blood for DZM 05 was collected 4.5 hours before death. The AM
sample had 0.29 mg/L of nordiazepam and 0.38 mg/L of diazepam. The expected
concentration ranges for nordiazepam and diazepam were 0.27 – 0.28 mg/L and 0.33 –
0.35 mg/L, respectively. Mixed heart and iliac vein bloods were submitted for PM
analysis. The mixed heart sample had 0.14 mg/L of nordiazepam and 0.09 mg/L of
diazepam. The iliac vein blood sample had nordiazepam and diazepam concentrations of
0.07 mg/L and 0.04 mg/L, respectively. The PM concentrations were below the expected
concentration range. Nordiazepam had PM: AM ratios of 0.48 and 0.24 for the MXHT
blood and ILBL samples, respectively. Diazepam had PM:AM ratios of 0.24 and 0.10 for
MXHT blood and ILBL, respectively. However, the C:P ratios were 2.0 and 2.2 for
MXHT and ILBL, respectively.
The AM sample for DZM 05 was analyzed by HLPC/DAD two years prior to the
PM analysis by LC/MS. Unfortunately, there was not sufficient quantity of AM sample
to submit for re-analysis. As a result, it is likely that during this two year time period the

142

PM drug concentrations degraded. Therefore, the comparison of the PM:AM results are
probably skewed. However, both PM samples were stored under the same conditions for
that two year period. Consequently, the degradation of those two samples should have
occurred in a similar fashion. While it cannot be determined for sure that PMR occurred,
at the very least the PM results demonstrated that before collection from the body, the
mixed heart sample was exposed to more contamination than the iliac vein sample.
Antemortem blood for DZM 04 was collected five hours before death. Diazepam
was identified but at levels below the LOQ (0.01 mg/L by HPLC/MS). Following
autopsy (PMI = 31 hours), postmortem heart and iliac vein bloods were submitted for
analyses. Diazepam was also detected in the heart blood, but at concentrations below the
LOQ. The iliac vein sample had 0.01 mg/L of diazepam. While the concentrations
detected in these samples were low, it would appear that some amount of PMR was
present in the periphery.
The antemortem blood for DZM 01 had 0.42 mg/L of nordiazepam and 0.02 mg/L of
diazepam. There were 15 hours between AM collection and death. As a result, the
expected concentration ranges at the time of death for nordiazepam would have been
0.34– 0.37 mg/L, while diazepam would have been 0.01 – 0.02 mg/L. Upon autopsy,
heart and iliac vein bloods were submitted for analyses. The heart blood sample had 0.19
mg/L of nordiazepam and 0.02 mg/L of diazepam. The iliac vein blood had 0.17 mg/L of
nordiazepam and 0.02 mg/L of diazepam.

The PM nordiazepam concentrations

decreased more rapidly than predicted by the calculated results. The resulting PM:AM
ratios for nordiazepam were 0.45 and 0.40 for heart blood and iliac vein blood samples,
respectively. None of the data produced by nordiazepam was reflective of PMR.
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Table 24: Diazepam and Nordiazepam antemortem samples collected within one elimination half-life
Diazepam t1/2 = 27-37 hours Vd = 0.7 – 2.6 L/kg
Nordiazepam t1/2 = 50-99 hours
CV= ± 14%
AM
Source
Concentration
PMI
Case #
Concentration
Analyte
PM: AM C: P
Race/Sex
(mg/L)
(hours)
(Whole blood)
(mg/L)

1.5
hours

DZM 06

1.5
hours

DZM 07

4.5
hours

DZM 05

5
hours

DZM 04

15
hours

DZM 01

48
hours

DZM 03

66
hours
1

DZM 02

Heart
Iliac
Heart
Iliac
Mixed Heart
Iliac
Heart
Iliac
Heart
Iliac
Iliac
Heart
Iliac

0.03 nordiaz
0.02 diaz
0.02 nordiaz
0.02 diaz
0.01 nordiaz
0.01 diaz
0.01 nordiaz
0.01 diaz
0.14 nordiaz,
0.09 diaz
0.07 nordiaz,
0.04 diaz
NDD nordiaz
<LOQ diaz
NDD nordiaz
0.01 diaz
0.19 nordiaz
0.02 diaz
0.17 nordiaz
0.02 diaz

0.01 nordiaz1
0.01 diaz1

Nordiaz
Diaz

0.01nordiaz1
0.01 diaz1

Nordiaz
Diaz

0.29 nordiaz2
0.38 diaz2

Nordiaz
Diaz

NDD nordiaz1
<LOQ diaz1

Nordiaz
Diaz

0.42 nordiaz1
0.02 diaz1

Nordiaz
Diaz

0.55 nordiaz

0.16 nordiaz1

Nordiaz

0.04 nordiaz,
0.02 diaz
0.02 nordiaz,
0.02 diaz

0.02 nordiaz1
0.01 diaz1

Nordiaz
Diaz

LC/MS/MS analysis (linear range 0.01 – 1.0 mg/L)

2

3.0
2.0
2.0
2.0
1.0
1.0
1.0
1.0

1.5
1.0

6.5

WM

50

1.0
1.0

24

WM

25

2.0
2.2

19

WF

51

-

31

WM

50

1.1
1.0

63

WF

53

3.4

-

26

WF

46

2.0
2.0
2.0
2.0

2.0
1.0

24

BM

55

0.48
0.24
0.45
1.0
0.40
1.0

LC/UV analysis (linear range 0.1 – 10 mg/L)
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Age

The diazepam data for DZM 01 had PM concentrations just within the upper limit
of the expected range. The PM:AM ratios for diazepam were 1.0 and 1.0 for heart blood
and iliac vein bloods, respectively. While it is believed that ratios with values≥ 1.0 can
exhibit PMR, the cumulative diazepam data did not suggest PMR was a factor. What is
of particular interest in this case was that both the central and peripheral source blood
samples returned concentration data that were similar to each other. This would indicate
that the overall change in drug concentration in the body progressed consistently and in
the same direction, regardless of the anatomical collection site.

This was further

reinforced by the C:P ratios of nordiazepam and diazepam equaling 1.1 and 1.0,
respectively.
Diazepam case 03 had AM blood collected 48 hours before death. The sample
had 0.16 mg/L of nordiazepam, however diazepam was not detected. While the AMD
interval seemed long, it was actually less than the elimination half-life range for
nordiazepam (50- 99 hours). Postmortem iliac vein blood was submitted in a gray-top
tube and had a nordiazepam concentration of 0.55 mg/L. Diazepam was not detected in
the PM sample. The expected concentration of nordiazepam at the time of death would
have been between 0.08 – 0.11 mg/L. The PM concentration well exceeded this range,
resulting in a PM:AM ratio of 3.4. The data produced by the ILBL would suggest that
PMR occurred during the 26 hour PMI.
Antemortem blood for DZM 02 was collected 66 hours before death. Analysis of
the AM blood sample determined that 0.02 mg/L of nordiazepam and 0.01 mg/L of
diazepam were present. The expected concentration range for nordiazepam was between
0.01 – 0.01 mg/L, while the expected range for diazepam was below the LOQ. Heart and
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iliac vein bloods were submitted for postmortem analysis. The heart blood sample had
0.04 mg/L of nordiazepam and 0.02 mg/L of diazepam. The ILBL sample had 0.02 mg/L
of both nordiazepam and diazepam. The PM:AM ratios for both sources and both drugs
equaled 2.0 each. The HTBL concentration for nordiazepam was twice that of the ILBL
concentration (C:P = 2.0). However, diazepam was equal in both sources (C:P = 1.0).
The PM data collected for DZM 02 exceeded the expected concentration ranges for both
nordiazepam and diazepam. Additionally, the ratio data in its entirety returned values
that were ≥ 1.0. The data as a whole supports the idea that PMR occurred for both
diazepam and nordiazepam.
The discrepancies between the AM and PM data seen in DZM 05 were likely due
to the time elapse between AM and PM testing. In any situation, it would be optimal to
analyze all the relevant samples for one case within the first few months of collection.
However, that did not occur here. Diazepam 05 was still included in this project because
it is a reflection of a real world scenario. It is not entirely uncommon for toxicology
testing requests to be submitted over a year after a sample has been collected. In these
situations, the MDME laboratory complies with the request and will conduct the testing.
However, as demonstrated in this case, the analytical results obtained may not be an
accurate reflection of the drug concentrations present at the time of sample collection.
Postmortem redistribution was believed to be a factor in diazepam cases 06, 03
and 02. All three had PM concentrations at least twice that of their respective AM
concentrations, which resulted in PM:AM ratios≥ 2.0. However, their antemortem to
death intervals ranged between 1.5 to 66 hours and their postmortem intervals ranged
from 6.5– 63hours. The large range of the intervals made it difficult to identify a clear
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trend for what factors may contribute to PMR of cases containing diazepam and
nordiazepam.

It was interesting among these cases that the overall change in

concentrations between the two drugs, typically moved in parallel to each other. This is
in contradiction to the data produced in the morphine codeine (MOC) cases. The MOC
data showed that cases which contained both morphine and codeine could have opposing
shifts in concentration, meaning that one drug could decrease in concentration, while the
other increased.

In diazepam and nordiazepam cases, if one drug increased in

concentration, then they both did.
The cumulative diazepam data identified many issues of interest. Firstly, six out
of the seven cases analyzed were collected with both central and peripheral sourced
postmortem specimens (Chart 10). In 83% of those cases, the intra-case diazepam data
had concentrations that were statistically similar regardless of the source of anatomic
collection. Likewise, nordiazepam had 67% of its intra-case data return statistically
similar results regardless of collection site. In the majority of cases researched, the
quantitative results would appear to be similar regardless of the PM specimen analyzed.
As previously mentioned, the time intervals (AMD and PM) were too broad to
definitively identify the reason(s) for concentration discrepancies.

While in most

instances specimen choice would not matter, for the few instances in which it would, it
would be best to use peripheral blood for all quantitative analyses. In addition, also
displayed on Chart 10 is DZM 04. Since the AM concentration was below the LOQ, an
expected range could not be calculated. However, it would be expected that the PM
results would not exceed the AM. The peripheral source had a quantifiable level and that
level was included in the chart.
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Chart 10: Diazepam and Nordiazepam Central versus Peripheral Data
Error rate: 14% Diazepam, 17% Nordiazepam
Central diazepam

Peripheral diazepam

Central nordiaz

Peripheral nordiaz

Concentration (mg/L)

0.25
0.2
0.15
0.1
0.05
0
DZM 06

DZM 07

DZM 04
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DZM 08

DZM 09

DZM 10

Chart 11: Diazepam and Nordiazepam Peripheral Data
Error rate: 14% Diazepam, 17% Nordiazepam

Peripheral Diazepam

Peripheral Nordiazepam

0.4

Concentration (mg/L)

0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
DZM 06 DZM 07 DZM 04 DZM 08 DZM 03 DZM 09 DZM 10

Comparison of diazepam and nordiazepam peripheral data
to the expected concentration range at the time of death
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Chart 11 examined the diazepam and nordiazepam peripheral sourced data only.
The results of the peripheral data were compared to the calculated expected concentration
ranges for each case. The expected ranges are denoted with the symbol “[” for diazepam
and “]” for nordiazepam. In some instances the rounded concentrations for the upper and
lower levels of the range were equal. For those cases, the symbol “-” was used for either
drug. The data in Chart 11 shows that 50% of the diazepam PM results were above their
expected concentration range, while 17% was below. The remaining 33% of the cases
produced PM data that was within the expected concentration range at the time of death.
Similarly to the diazepam data, the nordiazepam results had 50% of its PM data above the
expected concentration range. In addition, 33% were below the expected range and 17%
were within range. Based on these results, PM quantitative results for both diazepam and
nordiazepam are not likely to be reflective of the drug concentration present in the system
at the time of death. To the contrary, it would appear as though peripheral blood data for
both drugs are more likely to return results with elevated concentrations.

6.3.3 Midazolam
Midazolam is a short-acting benzodiazepine derivative often sold under the trade
name Versed®. The injection of midazolam into the body is known to rapidly induce
sedation. As a result, in the United States, it is often administered by hospitals just prior
to surgery. In addition, midazolam (along with other benzodiazepines) triggers smooth
muscle relaxation. Consequently, it is often given by paramedics just prior to tracheal
intubation of a distressed person. In this situation, the use of midazolam relaxes the
gastrointestinal tract muscles, thereby helping to prevent aspiration during intubation
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(80). According to Baselt (81), midazolam has an elimination half-life of 1 – 4 hours and
an apparent volume of distribution of 1.0 – 2.5 L/kg.
For this study, midazolam was quantitated using only Thermo Finnigan’s LCQ
Advantage HPLC/MS/MS system.

While midazolam can be qualitatively identified

during the process of routine laboratory work, it is a drug that is not quantitated at the
MDME Department’s toxicology laboratory. The reason for this is that midazolam is
almost exclusively given in a hospital setting and generally not prescribed in the United
States. For that reason, its potential for abuse is extremely low. However, since one of
the criteria for this study was the need of antemortem blood (which could only be drawn
in a hospital setting) midazolam was one of the most commonly encountered drugs in the
project. As a result, the researcher decided to collect quantitative data (linear range 0.01
– 1.0 mg/L). Only one control lot, and one instrument, was used during the analysis
process. Therefore, ANOVA processing was not needed. However, the CV of the
population was determined to be 18% (Table 25). All drug concentrations that fell within
a ± 18% range were determined to be statistically similar. The cases presented can be
found in Table 26, listed in order of increasing antemortem to death interval.
Table 25: Midazolam Control Data (0.1 mg/L) Statistics
Concentration Mean
Standard Deviation
CV

0.145571 mg/L
0.026144
± 18%

Midazolam (MDZ) 01 had antemortem blood collected 16 minutes before death.
The AM sample had a midazolam concentration of 0.29 mg/L.
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The expected

concentration at the time of death would have ranged between 0.24 – 0.28 mg/L. Upon
autopsy, heart and iliac vein blood samples were collected and submitted for analyses
(PMI = 26 hours). The heart blood sample had a concentration of 0.05 mg/L, while the
iliac vein blood had 0.06 mg/L of midazolam. The PM to AM ratio equaled 0.16 for the
HTBL and 0.20 for the ILBL. Additionally, the central to peripheral ratio equaled 0.79.
When examining the quantitative data, it was apparent that the ILBL concentration was
higher than the HTBL concentration. This would lead one to believe that in the case of
PMR, the peripheral blood was more greatly affected. However, statistical analysis
determined that the HTBL and ILBL concentrations were, in fact, similar.

The

concentration effects were similar regardless of anatomical collection site.
The overall data produced in MDZ 01 reflected a lack of PMR. This was further
demonstrated by the ratio data, in which all ratios had values < 1.0. Additionally, the PM
concentrations were not only less than the AM concentration, but they were significantly
below the expected concentration range at the time of death.
The antemortem blood for MDZ 04 was collected two hours before death and had
0.16 mg/L of midazolam present. The expected drug concentration at the time of death
ranged between 0.04 to 0.11 mg/L. Heart and iliac vein blood samples were collected at
autopsy. Postmortem blood concentrations equaled 0.02 mg/L and 0.01 mg/L for heart
and iliac vein samples, respectively. The central to peripheral ratio equaled 1.6, while the
HTBL:AM and ILBL:AM ratios equaled 0.14 and 0.09, respectively. The C:P ratio
results were indicative of PMR, however both PM: AM ratios combated this. The
researcher determined that since the PM concentrations obtained were significantly less
than expected, PMR did not occur during the 23 hour PMI.
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Table 26: Midazolam Cases listed in order of increasing AM to death intervals
t1/2 = 1 - 4 hours
Vd = 1.0 – 2.5 L/kg
Linear range: 0.01 – 1.0 mg/L
CV = ± 18%

AMDeath
16 min
2 hrs
3.5 hrs
6 hrs
6.5 hrs
30 hrs
2 days
unknown

Case #
MDZ
01
MDZ
04
MDZ
08
MDZ
03
MDZ
07
MDZ
06
MDZ
02
MDZ
05

AM
Source
Concentration
Concentration
(mg/L)
(Whole Blood)
(mg/L)
Heart
0.05
0.29
Iliac
0.06
Heart
0.02
0.16
Iliac
0.01
Mixed
<LOQ
0.02
Iliac
<LOQ
Mixed
<LOQ
0.01
Aorta
<LOQ
Aorta
<LOQ
0.01
Iliac
<LOQ
Mixed
<LOQ
0.06
Aorta
<LOQ

Analyte
AMBL
AMBL
AMBL
AMBL
AMBL
AMBL

PM: AM
0.16
0.20
0.14
0.09
1.0
1.0

C: P

PMI
(hours)

Race/Sex

Age

0.79

26

BF

44

1.6

23

BM

37

-

17

WF

50

-

10

BM

25

-

33.5

BM

38

-

37

WM

39

Heart*

<LOQ

0.06

AMBL

-

-

32

WM

83

Aorta

0.32

0.05

AMBL

6.4

-

43

WM

29

* Average concentration
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Antemortem blood from MDZ 08 was collected 3.5 hours before death and had a
concentration of 0.02 mg/L. The expected concentration range at the time of death was
between 1.8 x 10-3 – 0.01 mg/L. A mixed blood sample, as well as an iliac vein blood
sample was submitted for PM analyses. Both PM samples had blood concentrations less
than the LOQ. This was consistent with the calculated expected concentration range, as
only the upper range value was within the LOQ and it was determined that PMR was not
present in this case.
Antemortem blood for MDZ 03 had a concentration of 0.01 mg/L. Since the
AMBL was collected 6 hours before death, it had an expected concentration range of 3.8
x 10-8 – 4.4 x 10-4 mg/L, well below the LOD (0.002 mg/L). Mixed and aorta bloods
were submitted post autopsy. Midazolam was detected in both samples, but at levels
below the LOQ. The fact that midazolam was detected, indicated that the concentration
was higher than the calculated expected range. However, the PM concentrations were
still below the AM concentration. As a result, it was determined that PMR was not a
factor.
A concentration of 0.01 mg/L was detected in the AM blood collected 6.5 hours
before death in midazolam case 07. The low AM concentration in combination with the
amount of time that passed during the antemortem to death interval caused the expected
concentration range at the time of death (1.1 x 10-4 – 3.2 x 10-3 mg/L) to be below the
LOD. Aorta and iliac vein bloods were analyzed and returned concentrations below the
LOQ. Therefore PMR did not occur.
In midazolam 06, the AM blood was collected 30 hours before death and had an
AM concentration of 0.06 mg/L. If no additional midazolam was administered during the
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AMD interval, the expected concentration range at the time of death would have been
between 5.6 x 10-11 – 3.3 x 10-4 mg/L. There was a 37 hour PMI in this case. After
which, mixed and aorta bloods were collected and submitted for testing. Both PM
specimens had blood drug concentrations that were less than the limit of quantitation.
This was consistent with the expected concentration range.
Antemortem blood for MDZ 02 had a concentration of 0.06 mg/L and was
collected 2 days before death. The expected midazolam concentration at the time of
death was between 5.6 x 10-11 – 3.5 x 10-4 mg/L.

Analysis of the heart blood sample

submitted post autopsy was positive for midazolam, however at a level below that of
quantitation. The expected concentration range was below the LOD. While it would
appear that the PM concentration was higher than expected, it was still at least 6 times
below that of the AM sample. As a result, it was determined that PMR did not occur.
The AM blood for midazolam 05 was submitted with only a collection time on it,
not a date. Upon checking the hospital records, the decedent was a patient there for
approximately 48 hours. Based on the time written on the tube, the AM sample was
either collected 32 hours or 8 hours before death. Since the exact date of collection
cannot be resolved, an expected concentration range was not calculated. The AM sample
however, did have a midazolam concentration of 0.05 mg/L. As a result, it would be
expected that the PM concentrations would be below this value.

Aorta blood was

submitted in both the red-top and gray-top blood collection tubes post autopsy. The
midazolam concentration was 0.31 mg/L and 0.34 mg/L for red-top and gray-top tubes,
respectively. Since the tubes were of the same anatomical source and the concentrations
were statistically similar, the overall midazolam concentration was averaged to
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0.32mg/L. The increased PM concentration (relative to the AM concentration) resulted
in a PM:AM ratio of 6.4.

A review of the medical records only indicated one

administration of midazolam. Therefore, the increase in the postmortem sample cannot
be explained by re-administration. In the absence of any contradictory information, it
would appear as though PMR occurred during the 43 hour PMI. If so, this would be the
only midazolam case researched that exhibited this phenomena.
Although the apparent volume of distribution for midazolam (1.0 – 2.5 L/kg) does
suggest that the drug could have some redistributive effects, with the exception of MDZ
05, the data collected indicated otherwise. Eighty-eight percent of the cases examined
showed no signs of PMR.

Although there were a few instances where the PM

concentrations were higher than their expected calculated ranges (MDZ 08, 03, 07 and
02), those concentrations were still below their respective antemortem concentrations.
Only MDZ 05 had a PM concentration that exceeded its AM level. The uncertainty of
the actual AMD interval for that case makes it difficult to compare to the others. Its PMI,
however, was noted as being 43 hours, which would make it the longest PMI examined.
If the true AMD interval equaled eight hours (as opposed to 32 hours) then this case
would have a relatively short AMD coupled with a long PMI. This was a combination
believed to influence PMR of alprazolam. Further studies of midazolam cases would be
needed before any formal conclusions could be drawn.
Additionally, midazolam cases 01 (PMI = 26 hours) and 13 (PMI = 23 hours)
were the only two case that returned quantifiable data for both central and peripheral
sourced samples. In MDZ 01, the concentrations of midazolam obtained in both sources
were statistically similar to each other, indicating that concentration changes between the
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two regions of the body were not significantly different. In that case, however, the AMD
interval was only 16 minutes.

In MDZ 04, the AMD interval was slightly more

pronounced at two hours. The PM results obtained in that case did indicate statistically
different results depending on the anatomical region of collection. As would be expected
based on conventional theory, the central sourced blood had a higher amount of
midazolam (two times greater) than the peripheral blood. While neither case rendered
results indicative of PMR, the two cases did show that under certain circumstances, PM
concentrations may still have a tendency to differ in concentration based on anatomical
location.
Sixty-three percent of the PM data collected was qualitative. Since this research
was primarily based on quantitative data, the usefulness of qualitative data may not be
readily apparent. In the instance of midazolam, PM data that was below the limit of
quantitation, although within the limit of detection was reflective of an overall decrease
in midazolam blood concentrations after antemortem sample collection.

Based on the

results of this study, generally midazolam did not appear to store itself within the tissues
of the body. This was primarily of interest because the range of the apparent volume of
distribution suggested otherwise.

6.3.4 Clonazepam and 7-aminoclonazepam
Clonazepam is a long acting nitrobenzodiazepine (t1/2 = 19 – 60 hours) (61) often
used to treat epilepsy, anxiety and sleep disorders.

7-aminoclonazepam is the

pharmacologically inactive major metabolite of clonazepam, which is produced by a
reduction reaction (62). Nitrobenzodiazepines (including clonazepam) have been known
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to reduce to their 7-amino analogs in storage, even when preserved (21)(33)(63). This
fact makes the interpretation of these drugs more difficult than other benzodiazepines
discussed in this manuscript. The elimination half-life of 7-aminoclonazepam could not
be found in the literature prior to the writing of this section. It is possible that since the
drug is not believed to be active, its rate of elimination has not been extensively studied.
Equation 7 was used to calculate the expected concentration range of clonazepam only,
not 7-aminoclonazepam. Quantitative analyses of both drugs however, were conducted
on both the GC/ECD and HPLC/MS.

A two-way ANOVA (95% confidence) was

conducted on the control data collected from both instruments to determine if the data
was similar enough to be treated as one population.
The results obtained from the two-way ANOVA indicated that the data collected
on the two instruments were dis-similar. This is illustrated in Table 27 (clonazepam) and
Table 28 (7-aminoclonazepam). The clonazepam data had an F-test value of 26.8 and an
Fcrit of 4.3 when comparing the two instruments. Likewise, 7-aminoclonazepam had an
F-test value of 8.8 and an Fcrit value of 4.3. Anytime an F-test value is greater than its
Fcrit, the null hypothesis (that is, there is no difference between the two) is rejected, as
was the case here. In an effort to verify the F-test results, Tukey’s post hoc analysis was
conducted as described in section 5.0 Calculations.

Tukey’s critical value for

clonazepam was 0.012, with a mean difference of 0.030. 7-aminoclonazepam’s critical
value was 0.004 and had a mean difference of 0.007. For both clonazepam and 7aminoclonazepam, Tukey’s critical value was less than the mean difference, indicating
that a difference between the instruments did in fact exist. Therefore, it was determined
that the ANOVA calculations were accurate. As a result, the data produced on each
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Table 27: Two-Way Analysis of Variation for Clonazepam Comparison of GC/ECD
to LC/MS/MS control Data
Source of
Variation

Sum of
Squares

df

Mean
Square

F-test
value

F crit

Day to Day
GC/ECD
vs. LC/MS
Interaction

0.001

9

0.0002

0.42

2.39

0.011

1

0.0107

26.86

4.35

0.002

9

0.0002

0.50

2.39

Tukey’s
critical
value

Mean
Difference

0.012

0.030

Table 28: Two-Way Analysis of Variation for 7-aminoclonazepam Comparison
GC/ECD to LC/MS/MS control Data

Source of
Variation

Sum of
Squares

df

Mean
Square

F-test
value

F crit

Day to Day
GC/ECD vs.
LC/MS
Interaction

0.0002

9

2.34E-05

0.57

2.39

0.0004

1

0.0004

8.83

4.35

0.0009

9

0.0001

2.58

2.39
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Tukey’s
critical
value

Mean
Difference

0.004

0.007

instrument was treated separately. Clonazepam cases analyzed by GC/ECD had a CV of
15%, while 7-aminoclonazepam had a CV of 17%.

The clonazepam and 7-

aminoclonazepm data collected by LC/MS had CV’s of 15% and 21%, respectively (refer
to Table 29).

Table 29: Coefficient of Variation for Clonazepam and 7-aminoclonazepam
Analyte
Clonazepam
7-aminoclonazepam

Instrument
GC/ECD
LC/MS
GC/ECD
LC/MS

CV
15%
15%
17%
21%

The data from the clonazepam (CNP) cases used in this study can be seen in
Table 30. The cases are presented in order of increasing antemortem to death (AMD)
interval. Whenever sample quantity allowed, AM samples were re-analyzed at or around
the same time as the PM analyses. On occasion the sample volume was not sufficient for
this and the concentration obtained as a part of routine analysis was used.

The results

obtained from re-analyzed AM samples are discussed on a case-by-case basis.
Clonazepam (CNP) case 04 had AM blood collected 10 minutes before death.
The sample had 0.03 mg/L of clonazepam and 0.13 mg/L of 7-aminoclonazepam. The
expected concentration range for clonazepam at the time of death would have been
between 0.03 – 0.03 mg/L (raw data: 0.0298 – 0.0299 mg/L). Postmortem iliac vein
blood was submitted in both the gray and red-top collection tubes (PMI = 28.5 hours).
The red-top ILBL had concentrations of 0.02 mg/L and 0.15 mg/L for clonazepam and 7aminoclonazepam, respectively. The gray-top ILBL had 0.02 mg/L of clonazepam and
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0.23 mg/L of 7-aminoclonazepam. Although the PM sources were the same, the 7aminoclonazepam concentrations were statistically different from each other (± 17% by
GC/ECD). Therefore the concentrations from both tubes could not be averaged. The 7aminoclonazepam concentration discrepancy in the PM specimens was of interest
because as reported by Drummer (21) and Steentoft (64), 7-aminoclonazepam can be
formed PM even in preserved blood. It is possible that the GT ILBL had more 7aminoclonazepam production than the RT ILBL.
When comparing the PM data to that of the AM, all of the concentrations, with
the exception of the RT ILBL 7-aminoclonazepam concentration, were determined to be
statistically dis-similar to the AM. The PM:AM ratios for the RT ILBL were 0.67 and
1.1 for clonazepam and 7-aminoclonazepam, respectively. The GT ILBL had PM:AM
ratios of 0.67 and 1.8 for clonazepam and 7-aminoclonazepam, respectively.

By

convention, it is believed that ratio results that are greater than or equal to 1.0 are
reflective of PMR. Therefore, despite the discrepancy between the actual values obtained
in the PM samples, both tubes seem to be in agreement that some amount of
redistribution affected 7-aminoclonazepam, while none influenced clonazepam. The fact
that for both sources clonazepam decreased below its expected range and 7aminoclonazepam increased caused the researcher to determine that despite the ratio data,
PMR did not influence either drug in this case. Instead, the results were indicative of
chemical conversion between the two drugs.
The AM blood for CNP 07 was collected one hour before death and was analyzed
as a part of routine analysis by GC/ECD.

The sample was determined to have

concentrations of 0.03 mg/L and 0.02 mg/L for clonazepam and 7-aminoclonazepam,
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Table 30: Clonazepam antemortem samples collected within two elimination half-lives
AM –
Death
(hours)

Case
#

10 min

CNP
041

1 hour
1.5
hours
6 hours

CNP
072
CNP
062
CNP
021

12
hours

CNP
051

14
hours

CNP
031

15
hours

CNP
082

66
hours

CNP
092

Source
(whole
blood)
Iliac RT
Iliac GT
Heart
Iliac
Heart
Iliac
Heart*
Aorta
Iliac
Mixed
Iliac
Heart
Iliac
Heart
Iliac

Clonazepam: Vd = 1.5 – 4.4 L/kg; t1/2 = 19 – 60 hours
7-aminoclonazepam: Vd and t1/2 = unknown
AM
Concentration
concentration Specimen
PM: AM
C: P
(mg/L)
(mg/L)
0.02 clonaz,
0.67 clonaz
0.15 (7amino)
1.1 (7amino)
0.03 clonaz
AMBL
0.13 (7amino)
0.02 clonaz,
0.67 clonaz
0.23 (7amino)
1.8 (7amino)
0.05 (7amino)
2.5 (7amino)
0.03 clonaz
0.83
AMBL
0.02 (7amino)
0.06 (7amino)
3.0 (7amino) (7amino)
0.04 (7amino)
1.0 (7amino)
1.0
0.04 (7amino)
AMBL
0.04 (7amino)
1.0 (7amino) (7amino)
0.03 clonaz
0.08 clonaz,
0.04 (7amino)
0.02 clonaz,
0.47 (7amino)
NDD
NDD
0.02 clonaz,
0.17 (7amino)
0.02 clonaz,
0.10 (7amino)
0.04 (7amino)
0.04 (7amino)

0.01 clonaz

AMBL

<LOQ clonaz
0.17 (7amino)

AMBL

0.01 clonaz

AMBL

0.15 clonaz
0.05 (7amino)

AMBL

0.04 (7amino)

AMBL

1

GC/ECD (linear range: 0.01 – 0.2 mg/L)
LC/MS (linear range: 0.01 – 1.0 mg/L)
* Average concentration
2
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PMI
(hours)

Race/Sex

Age

28.5

WM

44

24

WM

25

6.5

WM

50

3.0 clonaz

-

70.5

WF

22

0.23
(7amino)

4.0
clonaz
0.08
(7amino)

54

WM

68

-

19

WF

49

63

WF

53

24

BM

55

2.8 (7amino)
0.13 clonaz
3.4 (7amino)
0.13 clonaz
2.0 (7amino)
1.0 (7amino)
1.0 (7amino)

1.0
clonaz
1.7
(7amino)
1.0
(7amino)

respectively. The expected concentration of clonazepam at the time of death would have
been between 0.03 – 0.03 mg/L (raw data: 0.0289 – 0.0296 mg/L). However, there was
sufficient quantity of the AM blood sample to be re-tested for research purposes.
Four months after the original analysis of CNP 07, AM blood as well as PM heart
and iliac vein bloods (PMI = 24 hours) were analyzed (as part of one batch) by LC/MS.
At that time the AM blood concentration for 7-aminoclonazepam was 0.05 mg/L, while
clonazepam was not detected (LOD by LC/MS = 0.002 mg/L). The heart blood sample
had 0.05 mg/L of 7-aminoclonazepam and the iliac vein blood had 0.06 mg/L of 7aminoclonazepam. The central to peripheral ratio equaled 0.83. Clonazepam was not
detected in either PM sample.
In, and of itself, the absence of clonazepam in the re-test of the AM sample would
be indicative of drug instability of the drug in the AM tube during the 4 month storage
period. However, the decrease of clonazepam was coupled with a 50% increase in 7aminoclonazepam. It is more likely that drug reduction in the AM sample occurred.
Also of interest was that the PM samples rendered concentrations that were statistically
similar to each other, as well as being similar to the re-tested AM values. The data
produced for this case was not indicative of PMR, rather the apparent conversion of
clonazepam into 7-aminoclonazepam caused this concentration discrepancy.
The AM and PM samples for CNP 06 were analyzed on the same day as part of
one batch on the HPLC/MS system.

The AM sample had 0.04 mg/L of 7-

aminoclonazepam while clonazepam was not detected. Since the elimination half-life for
7-aminoclonazepam is not known, an AMD interval could not be calculated. However,
the AMD interval was only 1.5 hours, suggesting that the expected concentration range at
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the time of death would not have deviated significantly from the AM. Heart and iliac
vein bloods were submitted post autopsy (PMI = 6 hours). Both PM samples had
concentrations of 0.04 mg/L for 7-aminoclonazepam. Similarly to the AM, neither PM
blood detected the presence of clonazepam. The C:P ratio as well as both PM: AM ratios
were equal to 1.0, leading one to believe that PMR occurred. However, the short AMD
interval combined with the short PMI (6 hours) may not have been sufficient time to
observe a significant decrease in drug concentration. The amount of 7-aminoclonazepam
in the PM samples was likely within its expected concentration range at the time of death,
suggesting a lack of PMR.
Antemortem blood for CNP 02 had 0.01 mg/L of clonazepam detected. The
sample was collected six hours before death, and had an expected concentration range of
8.3 x 10-3 – 9.3 x 10-3 mg/L (GC/ECD limit of detection = 0.001 mg/L). Heart blood was
submitted in both gray and red-top collection tubes. Both tubes rendered clonazepam
concentrations of 0.03 mg/L.

As a result, the PM concentrations were averaged

(0.03mg/L). The increase of clonazepam in addition to a PM: AM ratio equaling 3.0,
resulted in the determination that PMR occurred in this case.
Antemortem blood for CNP 05 was collected 12 hours before death. In this
sample, 7-aminoclonazepam had a concentration of 0.17 mg/L and clonazepam was
detected, but at limits below the level of quantitation for the GC/ECD (0.01 mg/L). Aorta
and iliac vein bloods were submitted post autopsy (PMI = 54 hours) for analyses. Aorta
blood had 0.08 mg/L of clonazepam and 0.04 mg/L of 7-aminoclonzepam. The ILBL
had 0.02 mg/L and 0.47 mg/L of clonazepam and 7-aminoclonazepam, respectively.
Both PM samples had increased levels of clonazepam with respect to the AM sample.
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However, for 7-aminoclonazepam, only the ILBL had a higher level than the AM blood.
The PM:AM ratios for 7-aminocloanzepam were 0.23 and 2.8 for the AOBL and ILBL,
respectively. Central to peripheral ratios of clonazepam and 7-aminoclonazepam equaled
4.0 and 0.08, respectively.
The samples analyzed for CNP 05 were all tested on the same day. The PM data
showed a clear increase in the concentration of clonazepam with respect to the AM
sample.

This would suggest that PMR did occur for this drug.

However, other

observations were made as well. The AOBL returned results that showed an increase in
clonazepam and a decrease in 7-aminoclonazepam. So while clonazepam was affected
by PMR during the 54 hour PMI, 7-aminoclonazepam levels were reduced as a result of
metabolism (AMD interval = 12 hours). Conversely, there was an increase in both
clonazepam and 7-aminoclonzepam concentrations in the iliac vein. This was indicative
of PMR influencing both drugs.
The antemortem blood for CNP 03 was collected fourteen hours before death.
Clonazepam was detected at a concentration of 0.01 mg/L, while 7-aminoclonazepam
was not detected. The expected clonazepam concentration range at the time of death
would have been between 0.01 – 0.01 mg/L (raw data: 0.006 – 0.008 mg/L). Postmortem
mixed and iliac vein bloods were submitted as well (PMI = 19 hours). Neither PM
sample had detectable levels of clonazepam or 7-aminoclonazepam (LC/MS LOD =
0.002 mg/L).

This would suggest that during the AMD interval clonazepam was

effectively eliminated from the body. As a result, PMR was not a factor for this case.
The original analysis of the AM blood for CNP 08 had 0.15 mg/L of clonazepam
and 0.05 mg/L of 7-aminoclonazepam detected (AMD interval = 15 hours). The sample
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was re-tested four months later in a batch which included the cases postmortem (HTBL
and ILBL) specimens. The reanalyzed AM blood saw a decrease in clonazepam (0.09
mg/L) and an increase in 7-aminoclonazepam (0.17 mg/L), which is likely indicative of
clonazepam reduction reaction. When using the data from the re-analysis the expected
clonazepam concentration at the time of death ranged between 0.05 – 0.07 mg/L. The
heart blood sample had 0.02 mg/L of clonazepam and 0.17 mg/L of 7-aminoclonazepam.
The iliac vein blood had 0.02 mg/L of clonazepam and 0.10 mg/L of 7-aminoclonazepam
(PMI = 63 hours). The PM:AM ratios for clonazepam were 0.22 for both the HTBL and
ILBL samples, with a C:P ratio of 1.0. While the PM:AM ratios for 7-aminoclonazepam
were 1.0 for HTBL and 0.59 for ILBL, with a C:P ratio of 1.7.
Clonazepam case 08 had conflicting ratio data. Both PM: AM samples suggested
a lack of redistribution, while the C:P indicated its presence. With a 15 hour AMD
interval, one could expect to see a decrease in both drugs. However, only clonazepam
levels decreased in the HTBL, which the 7-aminoclonazepam concentration was
maintained. Alternatively, this data could be an example of clonazepam reduction. It is
not likely that 7-aminoclonazepam would have maintained its concentration under these
circumstances.

The

possibility

of

clonazepam

converting

causing

the

7-

aminoclonazepam results to appear unchanged cannot be overlooked. Conversely, the
iliac vein data was consistent with metabolism reducing the concentration of both drugs.
Therefore, PMR was not a factor for either drug.
The AM and PM samples for clonazepam case 09 were analyzed on the same day
as part of a single batch analysis by HPLC/MS. The AM blood, which was collected 66
hours before death, had a 7-aminoclonazepam concentration of 0.04 mg/L. Clonazepam
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was not detected within this sample. Heart and iliac vein bloods were submitted after a
24 hour postmortem interval.

Both heart and iliac vein blood samples had 7-

aminoclonazepam concentrations of 0.04 mg/L. As a result, the PM to AM ratios, as well
as the C:P ratio equaled 1.0. All of the ratio data suggested that this case was affected by
PMR. With such a long AMD interval, it would be expected that the concentration of 7aminoclonzepam would have decreased, not remained steady. Therefore, it does seem
that PMR affected the results of this case.
When reviewing the clonazepam data as a whole, it was hard to identify a pattern
for when (and if) redistribution would influence the results.

For other drugs (e.g.

morphine and codeine) reviewed in this manuscript, it was helpful to re-arrange the cases
in order of increasing PMI (as opposed to increasing AMD interval). Therefore, the
clonazepam data displayed in Table 30 was reorganized to show the cases in order of
increasing PMI (Table 31). Six out of the eight cases reviewed had clonazepam present.
Of those, only two cases (CNP 02 and 05, 33.3%) showed signs of postmortem
redistribution. This contradicts the apparent Vd 1.5 – 4.4 L/kg which is indicative of a
moderate level of redistribution. Intertwined within those two cases were CNP 04 and 08
(ordered as 04, 05, 08 and 02). Clonazepam cases 04 and 08 had data consistent with
chemical reduction of clonazepam into 7-aminoclonazepam. If one were to only look at
case 05 and 02 (both with antemortem to death interval ≤ 12 hours and PMI ≥ 54 hours) it
would appear that longer PMI may correlate to increased incidences of clonazepam PMR.
When focusing specifically on those last 4 cases (PMI
≥ 28.5 hours, AMD intervals
between 10 minutes – 15 hours) it became evident that the role of chemical conversion
cannot be overlooked.

167

Table 31: Clonazepam cases listed in order of increasing postmortem interval
PMI
(hours)

AM –Death
(hours)

Case #

6.5

1.5 hours

CNP 062

19

14 hours

CNP 031

24

1 hour

CNP 072

24

66 hours

CNP 092

28.5

10 min

CNP 041

54

12 hours

CNP 05

2

2

Source
(whole blood)

Concentration
(mg/L)

Heart
Iliac
Mixed
Iliac
Heart
Iliac
Heart
Iliac

0.04 (7amino)
0.04 (7amino)
NDD
NDD
0.05 (7amino)
0.06 (7amino)
0.04 (7amino)
0.04 (7amino)
0.02 clonaz
0.15 (7amino)
0.02 clonaz
0.23 (7amino)
0.08 clonaz
0.04 (7amino)
0.02 clonaz
0.47 (7amino)
0.02 clonaz
0.17 (7amino)
0.02 clonaz
0.10 (7amino)
0.03 clonaz
0.03 clonaz

Iliac
Iliac
Aorta
Iliac

63

15 hours

CNP 08

70.5

6 hours

CNP 021

Heart
Iliac
Heart
Heart

NDD = No Drug Detected
± Possible PMR
√ = PMR occurred
- = no PMR
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AM
concentration
(mg/L)

Specimen

PMR
Clonaz

PMR
7-amino

0.04 (7amino)

AMBL

NDD

±

0.01 clonaz

AMBL

-

NDD

NDD clonaz 0.05
(7amino)

AMBL

-

-

0.04 (7amino)

AMBL

NDD

√

0.03 clonaz 0.13
(7amino)

AMBL

-

-

<LOQ clonaz
0.17 (7amino)

AMBL

√

√ (ILBL)

0.09 clonaz 0.17
(7amino)

AMBL

-

-

0.01 clonaz

AMBL

√

NDD

Six out of the eight cases tested had 7-aminocloanzepam present. Of those six,
1.5 cases (25%) had data consistent with the redistribution of 7-aminoclonazepam. The
half percent accounted for CNP 05, where only the ILBL results were consistent with
PMR. Not included within the 25% was case 06, which was possibly influenced by
redistribution, but data could not be definitively qualified. Of the cases that exhibited
redistribution, case 05 had AMD interval of 12 hours and a PMI of 54 hours, while case
09 had an AMD of 66 hours with a PMI of 24 hours. With such a broad range for both
intervals, it was not possible to correlate PMR with either one. Additionally, neither of
the remaining two clonazepam cases (CNP 07 and 08) were influenced by PMR either.
Instead, chemical conversion affected their results.
Both CNP 07 and 08 had their AM blood analyzed twice. In both instances, the
result was four months from the original test date. The re-test results showed AM
conversion of clonazepam to 7-aminoclonazepam for both cases. However in CNP 07
the PM results maintained the same concentration as the AM results, which could be
expected here, as the AMD was only one hour. As for CNP 08, the ILBL results were
actually reflective of metabolism and elimination occurring during the 15 hour AMD
interval. The HTBL sample had results consistent with clonazepam reduction.
Additionally, an interpretive issue arose. Clonazepam cases 06 and 09 each had
AM and PM data (both central and peripheral) return concentrations of 0.4 mg/L. While
on the surface it would appear that those two cases should have similar conclusions, it
was the AMD intervals, as well as the PM intervals that made the distinction.
Clonazepam case 06 had an AMD of 1.5 hours and a PMI of 6.5 hours. Neither interval
appeared to be a sufficient amount of time to allow redistribution to occur. It was more
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likely that a slight reduction in drug concentration occurred after the AM collection and
the short PMI was not enough time to allow for the release and distribution of the drug
postmortem. Conversely, CNP 09 had an AMD interval of 66 hours, which according to
the elimination half-life (19 – 60 hours) would have been enough time to see a 50%
decrease in drug concentration. Instead of a decrease, the PM samples appeared to
maintain their drug concentrations. It is likely that during the 24 hour PMI, the drug was
released and redistributed.
In all, clonazepam is a drug that may not be easily interpreted postmortem. The
effects of pharmacokinetics, PMR and time intervals could not be clearly defined. The
data collected here was a stark contradiction to what would be expected when
considering the apparent volume of distribution of the drug. In fact, more cases were
influenced by chemical conversion than redistribution. As a result, anytime clonazepam
needs to be measured, it would be advisable to monitor the levels of 7-aminoclonazepam
as well. Quantitative results for both drugs may be helpful when trying to determine the
meaning of the PM results. If AM blood is available, it should be tested immediately, as
chemical conversion can affect the results of that specimen as well.

6.4 Microbial Study
The main purpose of the microbial study was to determine if microbial growth
could contribute to changes in drug concentration. This was assessed in two ways. First,
it was important to know if microbes could use drugs as a food source. Second, but of
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equal importance, was to determine if the addition of sodium fluoride (anti-microbial
agent) to the blood samples was a sufficient means of halting bacterial growth.

6.4.1 Codeine and Hydrocodone as a Food Source for Bacteria
A 96-well MT plate (Figure 5) was set-up as described in section 4.5.4 Assessing
the Usefulness of Codeine and Hydrocodone as a Food Source for Bacteria. On day 0
the initial reading was taken. At that time the cells were inoculated with the bacteria, as
well as the drug standards at concentrations of 100, 200 and 600 ng/mL. The amount of
growth was monitored for 6 consecutive days thereafter.
The codeine data is displayed in Chart 12. On average the Pseudomonas growth
patterns exceeded those of E. coli by three times or more. The Pseudomonas bacteria
mixed with the 100 ng/mL standard saw the most growth, while the 600 ng/mL standard
saw the least. Conversely, the opposite was true for E. coli as the 600 ng/mL grew the
best, with the 100 ng/mL growing the least. Despite the growth discrepancy observed
among the inter-bacterial data, statistical analysis proved that the intra-bacteria growth
patterns were not significantly different throughout the observation period.
Chart 13 displays the results of the hydrocodone containing cells. The growth
pattern observed among this data set was similar to that of the codeine results. Again,
Pseudomonas had at least three times the growth of E. coli. However, throughout the
seven day period, it was E. coli that had the least amount of variation. The best growth
was observed when Pseudomonas was combined with the 200 ng/mL standard.
Conversely, E. coli grew the best when mixed with the 100 ng/mL standard.
data sets, the 600 ng/mL standards saw the least amount of growth.
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For both

Overall, the drug standards that contained Pseudomonas outgrew the cells containing E.
coli. A subsequent photometer reading of the microbial solutions used to inoculate the
plates was taken. The results determined that the density of Pseudomonas (1.5) was
approximately 87% higher than that of E. coli (0.23). As a result it would be expected
that Pseudomonas would outperform E. coli.

Also working to the advantage of

Pseudomonas is that it is amenable to a multitude of environments. While it is known to
grow in locations such as skin and soil, it is not a microbe commonly associated with the
human decomposition process.

It was included in this study more as a gauge to

determine if it would be possible for bacteria to use the carbon structures of drugs as a
source of food.

Conversely, Escherichia coli are known to be present within the

intestines. As tissues breakdown, the bacteria can release and spread throughout the
body. Therefore, the way E. coli responded to the project was of special interest. So
while, Pseudomonas responded better to the growth conditions, both Pseudomonas and
E. coli proved this was possible for bacteria to be sustained by nothing more than the
carbon structure of drugs.
6.4.2 Aerobic and Anaerobic Study
In order to assess the ability of sodium fluoride to halt microbial growth upon
sample collection, antemortem and postmortem bloods containing the agent were
inoculated onto nutrient agar plates. The AMBL was collected and stored in a GT tube
until the time of testing. The PM blood (collected in both red-top and gray-top tubes)
came from a single decomposing cadaver. The liquefied blood from both tubes, as well
as the dried blood accumulating around the lid of the RT, was inoculated. The plates
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Chart 12: Pseudomonas and E. coli Growth Patterns When Using Codeine as a Food Source
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Chart 13: Pseudomonas and E. coli Growth Patterns When Using Hydrocodone as a Food Source
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were prepared in duplicate, with one set stored under aerobic conditions and another in an
anaerobic environment. Both sets were maintained for 11 days at 17 ºC. The results for
the aerobic and anaerobic studies can be seen in Table 32 and Table 33, respectively.
The initial results of the aerobic study saw growth on one of the RT chest blood
replicates, but not the other. As a result, the blood from that tube was retested in
duplicate. The re-analysis did not show any growth on either plate. While the agar and
the plastic loops (used for both the original and re-test experiments) were sterile, the
pipette tips (used to spike the 75 µL of blood onto the plates) were not. In all likelihood,
the non-sterile tip, used to spike the original plate that showed growth, was contaminated.
The AM and PM red-top, as well as the PM gray-top, showed no signs of growth when
stored in an anaerobic environment. However, both replicates of the dried RT blood did.
Since both replicates grew, this was not believed to be a contamination issue. In order to
determine what type of anaerobe was growing, the plates were sent for microbial
identification at the International Forensic Research Institute’s DNA profiling laboratory
on the campus of Florida International University. The identification results are still
pending.
Overall, it was determined that under aerobic conditions sodium fluoride is a
suitable additive for the prevention of microbial growth.

When properly prepared,

neither AM or PM samples saw any growth. This is of the utmost importance, as once
the blood is collected it is maintained in an aerobic environment. Conversely, growth
was detected in the anaerobic experiment. The anaerobic experiment, however, was not
without flaws, as the blood used had already been exposed to oxygen for several

175

Table 32: Growth Activity of Preserved Blood Stored in an Aerobic Environment
Sample Type

Source

Tube

Growth

Action

AM

AMBL

GT

X

N/A

PM

CHBL

RT

√1

Re-streaked

PM

CHBL

GT

X

N/A

PM

CHBL

RT dried blood

X

N/A

Table 33: Growth Activity of Preserved Blood Stored in an Anaerobic Environment
Sample Type

Source

Tube

Growth

Action

AM

AMBL

GT

X

N/A

PM

CHBL

RT

X

N/A

PM

CHBL

GT

X

N/A

PM

CHBL

RT dried blood

√

sent for identification

X = no growth
√ = growth
1
√ = growth on one replicate only
N/A = not applicable
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months prior to testing. This would result in the death of the strict anaerobes, but the
possible survival of the facultative anaerobes (those that can survive in either oxygen-rich
or oxygen-depleted environments). Bearing that in mind, the only growth detected was
on the dried blood sample. Out of the samples tested, it was the only one with an obvious
depletion of oxygen. Therefore, any organism that could survive those conditions would
likely thrive in an oxygen-free environment.
This portion of the experiment showed that under the current storage conditions,
continued growth of bacteria in the collected blood samples is not a concern. However,
the effect of bacterial growth in the body prior to sample collection may impact drug
concentrations.

6.4.3 Cumulative Microbial Results
The combination of the MT plate and agar plate experiments rendered some
results of interest. Drugs can in fact be used as a food source for bacteria. However, as
shown in the agar plate experiment, once the blood is collected and preserved (in an
aerobic environment) bacteria, including E. coli, were no longer viable. On the other
hand, under anaerobic conditions some bacteria (potentially facultative anaerobes) did
grow. This was not deemed a problem for two reasons. First, once collected, all of the
samples are stored aerobically, not anaerobically. Second, the only growth seen in the
anaerobic study came from a dried blood sample.

When drug identification and

quantitation are performed, fluid blood, not dried blood, is used. The results of the
anaerobic study showed no growth on any of the fluid blood samples. The presence of
those bacteria should not negatively influence the results.
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6.5 Stability Study
Hydrocodone and codeine standards, prepared in dilute phosphate buffered saline
solution, were spiked in whole blood to give a final concentration of 200 ng/mL.
Analytical analysis conducted by GC/MS/MS quantitatively monitored codeine and its
metabolite morphine, while hydrocodone and its metabolite hydromorphone were
analyzed by GC/ SIM-MS.

The initial analysis of both drugs was conducted by

GC/MS/MS; however, an interference causing the ion suppression of the hydrocodone-d3
ion (288) resulted in the inability to detect the internal standard ion. It was decided that
the Opiate II quantitative method (4.4.2 (b) Opiate II by GC/MS (SIM)) could be used
alternatively. In that method, hydrocodone-d3 was still the internal standard; however,
the 331 ion was monitored instead. For both methods, the metabolites of the parent drugs
were also monitored, as it was imperative to determine if any concentration changes
could be attributed to chemical conversion. Initial analysis of codeine was conducted on
the same day of the spike. As a result of the interferent, hydrocodone’s initial analysis
was delayed by three days. For both drugs however, re-analyses were performed 30 and
60 days later. In between testing dates, the blood samples were refrigerated at 2 ºC. The
results are displayed in Table 34.
Codeine, a drug evaluated in section 6.1.1 Heroin, Morphine and Codeine, had an
error rate (established during research testing) of 10%. Hydrocodone was not assessed in
any other part of this study. Therefore, in order to determine the amount of error
associated with the drug, the standard deviation (2.988) and concentration mean
(22ng/mL) of the controls collected as part of routine analysis were calculated. When
using Equation 5 the CV was determined to be 13%. Any concentrations which fell
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within the established limits of error were considered statistically similar, while those that
exceeded the limits were not.
Codeine had an initial reading of 191 ng/mL in the RT and 197 ng/mL in the GT.
Both concentrations were similar to each other, as well as being similar to the 200 ng/mL
spiked concentration.

At the second reading, concentration discrepancies began to

emerge in the RT tube. Its blood concentration decreased to 179 ng/mL. While this level
was statistically similar to the previous concentration reading, it exceeded the limits of
the CV (± 10%), thereby making it significantly different from the originally spiked
concentration. Conversely, the amount of drug in the GT tube (183 ng/mL) was similar
to both the spiked and the initial concentrations. The third and final reading again
showed a decrease in codeine concentrations. This time, both RT and GT (166 ng/mL
each) levels were statistically lower than both the spiked amount and the initial reading.

Table 34: Results of the 60 Day Drug Stability Study of Refrigerated Blood
Analyte

Spiked
Tube
Concentration

Codeine

200 ng/mL

Morphine
(metabolite)

N/A

Hydrocodone

200 ng/mL

Hydromorphone
(metabolite)

N/A

RT
GT
RT
GT
RT
GT
RT
GT

Initial
Reading
(ng/mL)
191
197
not detected
not detected
131
126
not detected
not detected

Red-top tube = RT
Gray-top tube = GT
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30 Day
Reading
(ng/mL)
179
183
not detected
not detected
131
127
not detected
not detected

60 Day
Reading
(ng/mL)
166
166
not detected
not detected
130
126
not detected
not detected

The steady decline in the codeine concentration for both tubes indicated that
under the current storage conditions, codeine may not be stable. The lack of morphine
detection would suggest that while chemical conversion did not seem to be a factor, drug
degradation should still be considered. This conclusion was in direct contrast to the
results found in both the Holmgren (45) and Peters (44) studies. They each determined
that codeine was stable in storage for a period of at least one year. Their blood samples
were frozen at temperatures of -20 ºC and -18 ºC, respectively.

Based on this

information, it would appear that drug preservation of codeine is much more reliable
when the sample is frozen, not refrigerated.
After the collection of the hydrocodone data, the results were determined to be
skewed. As previously mentioned, hydrocodone had to be analyzed by GC/SIM-MS as a
result of an internal standard interference observed in the GC/MS/MS data. Upon initial
analysis (using the SIM method) a prominent internal standard peak was detected and the
instrument switch was made. The initial reading saw a concentration decrease of 65% in
the RT (131 ng/mL) and 63% in the GT (126 ng/mL) tubes. At the time, the reason for
the significant concentration decrease was not known. The analyses continued 30 days
(RT= 131 ng/mL; GT = 127 ng/mL) and 60 days (RT = 130 ng/mL; GT = 126 ng/mL)
later.

Although significantly decreased from the spiked amount (200 ng/mL), the

monthly readings were consistent to each other, regardless of sample tube.
After careful review of the hydrocodone standard preparation procedure and the
resultant analytical findings, it was determined that the internal standard was again
causing a problem. While the MS/MS method saw ion suppression of the internal
standard, the SIM method saw ion enhancement. The internal standard for the sample
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produced area responses that ranged from 11 – 18% higher than the calibrators on any
given run. The increased internal standard resulted in decreased sample concentration, as
concentrations are calculated based on an area response ratio between the sample and
internal standard. In theory, if the problem had been caught in the beginning the SIM
method still could have been used. However, the sample should have been extracted
using the method of standard additions.
The method of standard additions is used to resolve problems associated with
matrix effects (e.g. ion suppression or enhancement). To account for this problem, the
sample itself should have been spiked with known drug concentrations to produce a
calibration curve. The sample concentration could then have been calculated against that
curve. While this would have fixed the miscalculation, in actuality the volume of the
sample available for testing would not have been sufficient to allow for three separate
methods of addition calculations. Each batch, which consisted of a blank, a five-point
calibration curve, four controls (low and high concentrations in duplicate) and sample
extraction in duplicate, would have required a minimum of 12 mL of sample. The graytop tubes used hold 10 mL each (2 tubes total) and there was 30 mL in the red-top. In
addition, sample blood for the GC/MS/MS method was needed as well.
In the absence of the standard addition data, the internal standard responses were
corrected for in each batch. While this is a practice never used at the MDME- toxicology
laboratory, using a corrective calculation in this instance is the resource available to the
researcher in the absence of additional blood. It was important to use this particular
blood sample because it was the same blood used in the microbial study. Therefore, the
results could be better compared.
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In order to correct for the internal standard bias, the average internal standard
response was calculated for the 5-point curve. The internal standard response for the RT
and GT tubes were then averaged based on their respective collection tube, followed by
an average calculation for the sample (RT and GT) tubes.

The percent difference

between the calibration curve and sample internal standard responses were calculated.
For example, in one batch the red-top and gray-top internal standard responses exceeded
the curve response by 11% and 16%, respectively. The internal standard response of the
case was decreased by its appropriate percentage based on the sample tube. After this,
the hydrocodone concentrations were recalculated using the adjusted internal standard
responses. Applying this correction, resulted in sample concentrations ranging from 151
to 164 ng/mL. When comparing these results to the method CV (13%), all of the
recalculated values remained statistically similar to each other regardless of sample tube.
Although the concentrations were still significantly lower than the spiked concentration,
the adjusted concentrations were between 18 – 25% lower. This was a vast improvement
over the non-adjusted calculations which resulted in discrepancies ranging from 63 –
65% lower.
In all, this experiment showed that refrigerated storage may not be the best option
for analyte preservation of some drugs (specifically codeine). However, since the graytop tubes are made of glass, freezing them may not be a wise alternative either. In lieu of
changing the type of collection tube used, it would be in the best interest of the analyst(s)
to conduct quantitative analyses relatively quickly, as concentration levels may change in
storage. This instability may not affect all drugs, as was seen here with hydrocodone.

182

While hydrocodone levels were consistently lower than the spiked amount, the
concentration remained constant over the three month testing period. In addition, while
this study was not intended to account for the difficulties that matrix effects can present,
their influence on this drug was evident. This is an issue that can present itself at
anytime.

It is especially important to consider when testing postmortem biological

samples. In this instance, the sample was from a decomposing cadaver. In such a
situation, multiple biological processes are occurring and interferences may result. This
issue did not present itself in other samples used for this study. However, none of the
other samples were taken from a cadaver in such a state of decomposition. Regardless, in
real-life instances the role of matrix effects should be considered when reviewing the
analytical data.
7.0 Conclusions:
The goals of this project were to 1) evaluate the differences in drug concentrations
between antemortem and postmortem specimens, 2) determine how the presence of
microbes influence drug concentrations, 3) determine the stability of drugs in whole
blood and 4) define an interpretive framework to aid in the interpretation of postmortem
drug concentrations in whole blood. In Chapter 6: Results and Discussion, the first three
goals were discussed in great detail.

7.1 Microbes and Stability: Potential Influences on Postmortem Concentrations
In all, it was determined that in the absence of a preservative, both Escherichia
coli and Pseudomonas aeruginosa can use drugs (specifically codeine and hydrocodone)
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as a carbon source for food. It is however important to keep in mind that the drugs
analyzed for this study were preserved in tubes that contained the anti-microbial agent
sodium fluoride. After inoculating preserved blood samples, it was determined that under
the current storage conditions, sodium fluoride effectively eliminated microbial activity.
The same PM blood and drug standards used for the microbial experiment were
also used for the stability study. Aliquots of the blood (stored in both gray-top vacutainer
and red-top polypropylene tubes) were spiked with both codeine and hydrocodone to give
a final concentration of 200 ng/mL each. The blood was analyzed by GC/SIM-MS and
the GC/MS/MS monthly for a period of 60 days. Included in the analytical method were
morphine and hydromorphone, the metabolites of codeine and hydrocodone, respectively.
By monitoring both parent and metabolite concentrations the role of chemical conversion
could be considered.

The results indicated the refrigerated storage can effectively

maintain hydrocodone concentrations. Unfortunately, the same was not true for codeine,
which steadily declined in concentration throughout the study.

However, when

combining the microbial and stability results it was determined that instances of
concentration instability were not a result of microbial degradation. In addition, at least
for these two drugs, chemical conversion did not contribute either. For a future study, the
role of storage temperature and photo-degradation should be considered, as those two
factors may have influenced the codeine results.
The data generated from the microbial and stability experiments played a
fundamental role in achieving the first goal of the experiment, which was to evaluate the
differences in drug concentrations observed in antemortem and postmortem samples.
When differences were identified, it was important to determine the cause of the
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discrepancy. Some drugs (e.g. diphenhydramine, morphine and codeine) produced data
that was overwhelmingly consistent with being influenced by postmortem redistribution.
This was apparent when the postmortem results were consistently greater than the drug
levels in their respective antemortem samples. In contrast, other drugs like midazolam
were efficiently metabolized and eliminated from the body. Unfortunately, not all of the
data collected was as straight forward.
7.2 Interpretive Guidelines
The combined information gained from the first three goals was used to achieve
the fourth goal, which was to develop an interpretative framework for the postmortem
results. Upon examining the data, it quickly became apparent that strict interpretative
rules would not work.

Just as decomposition is a dynamic process that can vary

drastically based on a number of different factors, the interpretation of postmortem
results can too. Even analytes within the same drug class do not necessarily behave
similarly.

In lieu of developing strict guidelines, a list of important interpretative

considerations was developed.
According to its apparent volume of distribution (3 – 4 L/kg), diphenhydramine is
a drug that has a propensity for postmortem redistribution.

The experimental data

collected for this study was in agreement with that. The study results indicated that PMR
can begin as quickly as 11 hours after death. The results consistently indicated that PM
diphenhydramine levels will likely be significantly higher than their AM counterparts. In
addition, while it is often believed that peripheral blood concentrations most closely
resemble drug levels at the time of death, the data generated here contradicted that,
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indicating that there was no direct correlation between PM peripheral and AM blood
concentrations. In actuality, PM diphenhydramine concentrations (whether central or
peripheral) typically will greatly exceed both their AM and expected concentrations
levels at the time of death. As a result, when reviewing diphenhydramine postmortem
results, it would be advisable to bear in mind that the concentrations obtained are likely
elevated.
The benzodiazepines alprazolam, midazolam, diazepam and clonazepam are a
class of drugs known for their central nervous system depressant and muscle relaxant
properties. Although pharmacologically related, it should not be assumed that they all
respond similarly in a postmortem environment. Alprazolam data suggested that the drug
was subject to PMR when the combination of a short antemortem to death interval
(≤40min) was coupled with a long postmortem interval (≥ 45.5 hours). The results
obtained in this study determined that any other variation of those two intervals likely
would not result in redistribution. These results were reasonable, as its apparent volume
of distribution (Vd = 0.9 – 1.3 L/kg) did not reflect a strong tendency for redistribution.
In addition, when comparing postmortem central to peripheral concentrations, 71% of the
cases showed no significant difference between the two sources. In most instances,
quantitative analysis could be conducted on either PM specimen. That is not to say that
the PM results would be equivalent to the expected concentration range at the time of
death. In fact only 25% of the PM data collected fell within its expected range at the time
of death. The remaining 75% were either above or below the calculated expectation. In
all, although alprazolam is not likely to redistribute, a skew of the PM results may still
exist.
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Midazolam is a benzodiazepine which rapidly metabolizes from the body (t1/2 = 14 hours). While its apparent volume of distribution (1.0 – 2.5 L/kg) was indicative of a
drug that could effectively undergo postmortem redistribution, the data collected refuted
this. In 100% of the cases no signs of redistribution could be identified, regardless of
AMD (range: 16 min – 48 hours) or PM (10 – 37 hours) intervals. In all instances, it
appeared as though metabolism and elimination effectively decreased (and in many
instances removed) the drug from the body prior to death.
The benzodiazepine diazepam was monitored along with its pharmacologically
active metabolite nordiazepam. With elimination half-lives of 21 – 37 hours and 50 – 99
hours for diazepam and nordiazepam, respectively, both drugs are considered to have a
long-lasting effect.

When comparing their postmortem concentrations to their

antemortem’s, there was an expectation that signs of chemical conversion between the
two would be evident.

However, that was not the case.

In most instances when

comparing PM to AM concentrations, both parent and metabolite would move in parallel
to each other, meaning they would both either increase or decrease within the same case.
This could be reflective of diazepam’s stability in storage, as drug instability may have
led to more instances of opposing concentrations shifts between the parent and
metabolite. Their similar concentration shifts did not negate the influence of PMR on
either drug, as 50% of the data (for both drugs) was indicative of PMR. The remaining
50% of the cases had PM concentrations either within or below their expected
concentrations at the time of death. When comparing central to peripheral data in most
instances either specimen could be used to quantify diazepam, however peripheral
nordiazepam concentrations were typically lower. Since diazepam and nordiazepam are
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monitored together in most labs, peripheral blood would be the preferred source for
quantitative analyses. However, for both drugs, it should not be expected that peripheral
results are reflective of drug concentrations at the time of death, as only 17% of diazepam
and 0% of nordiazepam results were within their calculated concentration ranges.
Clonazepam was a drug that presented many challenges. It is classified as a longacting benzodiazepine (t1/2 = 19- 60 hours), but a prolonged effect in a living person, did
not equate to drug stability in a postmortem specimen. Clonazepam, monitored here with
its pharmacologically inactive metabolite, 7-aminoclonazepam, was largely susceptible to
chemical reduction in storage. As a result, the levels of clonazepam would reduce, while
7-aminoclonazepam levels would increase.

This was of particular interest because

clonazepam’s apparent volume of distribution (1.5 – 4.4 L/kg) suggested that the drug
was prone to PMR. The results of this study determined that only 37% of the cases were
susceptible to redistribution. When examining the results, it became rather difficult to
identify a predictable pattern for when and how drug concentrations would change. As a
result, in instances of quantitative analysis, interpretation should be done with caution. In
an effort to reduce these PM concentration concerns, it may seem like a good idea to only
analyze the AM blood for this particular drug. However, the reanalysis of antemortem
blood samples (n= 2) determined that clonazepam concentrations can decrease as early as
four months in storage (2 ºC). Although two samples do not equate to a significant
populations size, the data did suggest that when clonazepam levels are a concern, the
samples should be analyzed as close to collection as possible.
aminoclonazepam concentration should be monitored as well.
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In addition the 7-

The synthetically derived opioid methadone, as well as the naturally occurring
opiates morphine and codeine were also examined for this study. In keeping with its
apparent volume of distribution (4 – 5 L/kg), methadone consistently produced data that
was influenced by PMR, with the impact being greater on the central sourced blood. The
postmortem results (regardless of source) were routinely greater than both the expected
concentration ranges at the time of death, as well as the AM concentrations. The data
indicated that PMR would occur for this drug regardless of AMD (45 min – 72 hours) or
PM intervals (16 – 54 hours), as their ranges varied greatly. When interpreting PM
methadone levels, it would be advisable to consider the drug concentrations elevated.
Because of the pharmacological similarities, morphine and codeine are two drugs
that are not commonly prescribed together. However, they are often detected together, as
morphine is a major metabolite of codeine. In addition morphine (as a metabolite) and
codeine (as a by-product) are also produced as a result of heroin metabolism. It was only
logical to review their results together.

In keeping with their apparent volumes of

distribution, both morphine (Vd = 2 -5 L/kg) and codeine (Vd = 3.5 L/kg) exhibited a
strong predisposition for PMR.

By re-arranging the data in order of increasing

postmortem interval, it became very clear that both drugs exhibited increased incidences
of redistribution with longer PM intervals. Conversely, the influence of the antemortem
to death interval (range: 9 minutes – 24 hours) was negligible.
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7.3 Additional Considerations
The role of chemical conversion between codeine and morphine was a minor
issue, as only 15% of the cases were affected.

When comparing PM central and

peripheral results, it became apparent that in most instances the extent of PMR was site
dependent, with the central source seeing a greater affect. However, factors such as the
location of intravenous injection (in the case of heroin abuse) should not be overlooked as
this can alter the redistribution effect. Overall the peripheral sourced blood had lower
drug concentrations, only 1 morphine case had a level within its expected concentration
range at the time of death.

The interpretation of both morphine and codeine in

postmortem specimens should be done with caution.
Finally, throughout the data collection process, central: peripheral, as well as
postmortem: antemortem ratio results were being collected and compared. The ratio
results conflicted in 54% of the cases.

When comparing both ratios, to the final

determinations made by the researcher, it was the PM: AM ratio that was most often in
agreement. As a result, it was determined that while the C:P ratio could be a great tool in
determining whether or not redistribution occurred in a predicted fashion (e.g.
redistribution was more pronounced in the central sourced blood), it may not be the most
reliable way of evaluating whether or not PMR actually happened.

7.4 Final Thoughts and Future Work
Overall, the goals for this project were met. While in some instances definitive
conclusions could not be drawn, the body of work in its entirety is an examination of the
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various issues that plague a postmortem toxicologist. A drug concentration alone carries
no weight. The understanding of what it means, its application and whether or not its
presence influenced the death of someone is of the utmost importance. This study
investigated theories and ideas common to toxicological professionals. While some
concepts were reinforced, others were not. It would be advisable that future experiments
continue to examine the importance of ratio data (e.g. central:peripheral and
postmortem:antemortem), as well as the affect clonazepam stability has on postmortem
interpretations. Additionally, further studies concerning the impact of microbial activity
on drug concentrations prior to sample collection are needed. By examining factors such
as temperature, the addition of biological carbon sources (mixed with drug carbon
sources) and environment (e.g. aerobic or anaerobic), the true impact bacteria have on
toxicological findings may be better identified.
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